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C-001
SINGLE-PORT LAPAROSCOPIC 
CHOLECYSTECTOMY: COMPARATIVE 
STUDY IN THE CONSECUTIVE INITIAL 
206 CASES
Y. K. You, H. J. Choi, G. H. Na, T. H. Hong, S. K. Lee, J. 
H. Park, Y. C. Yoon and D. G. Kim
Department of Surgery, Division of HBP Liver 
Transplantation, Seoul St. Mary’s Hospital, The Catholic 
University of Korea, Seoul, Korea
Introduction: Laparoscopic cholecystectomy has been the 
standard of care for gallbladder diseases since the late 1980s. 
Many surgeons have rapidly adopted single-port laparo-
scopic cholecystectomy for gallbladder pathologies. The aim 
of present study was to analyze clinical outcome in initial 
single-port laparoscopic cholecystectomy.
Materials and Methods: Data from 206 consecutive sin-
gle-port laparoscopic cholecystectomies between May 2008 
and Jun 2012 were analyzed retrospectively. We divided the 
patient into four groups – group I (n = 56), II (n = 50), III 
(n = 50) and group IV (n = 50) consecutively. During each 
procedure only one longitudinal transumbilical incision, 1.5 
to 2.0 cm in length, was made to access the abdominal cavity. 
One of the various single-port trocars was used for proce-
dure. Standard laparoscopic instruments were used for the 
performance of cholecystectomy.
Results: Patient’s demographics did not differ among the 
groups. Of the fourteen cases that were converted to conven-
tional laparoscopic surgery, seven were part of group I, one 
of II, fi ve of III and one of group IV. Mean operation time 
for single-port laparoscopic cholecystectomy in each group 
was 71.6, 58.2, 69.1 and 53.3 minute in groups in order. 
There were two operative complications in the group I, 
which were successfully managed with laparoscopic surgery. 
There was no statistical difference in hospital stay among the 
groups.
Conclusion: Single-port laparoscopic cholecystectomy can 
be safely performed for various gallbladder lesions in 
selected cases, and the operation time improved with accu-
mulation of cases.
C-002
NOTES AND GB SURGERY
G. V. Rao
Abstract not available at time of publication.
C-003
APPROACHES TO THE DIFFICULT GALL 
BLADDER (DIFFICULT LAPAROSCOPIC 
CHOLECYSTECTOMY)
A. N. Supe
Seth G S Medical College and K E M Hospital, Mumbai, 
India
Laparoscopic cholecystectomy is now being performed for 
wider indications such as acute cholecystitis and other dif-
fi cult situations. Factors that predict overall operative diffi -
culty are – Clinical factors – Acute cholecystitis, Previous 
abdominal surgery, Cirrhosis, Age >65, Male and patients 
with BMI >27.2 kg/m2 and Sonographic factors – GB wall 
>4 mm, Contracted GB, Pericholecystic collection, and 
Stone impaction in Hartman’s pouch. Using these risk 
factors, it was possible to divide patients into high-risk 
(Conversion Rate 15.3%) and low-risk groups (Conversion 
Rate 1.3%).
Laparoscopic Cholecystectomy comprises four clear steps
1. Creation of pneumoperitoneum and insertion of all trocars: 
this may be diffi cult in patients with obesity, previous 
abdominal surgery.
2. Separation of all adhesions to the GB – A) Diffi culty in 
retraction of GB. B) Diffi cult dissection around GB. 
Bleeding from dissected area can be troublesome espe-
cially in infl amed GB.
3. Dissection and skeletonization of the cystic duct and cystic 
artery. The cystic duct may be either short & wide, or 
adherent due to infl ammation.
4. Excision and extraction of the GB is diffi cult if GB is 
friable, infl amed or has impacted large calculus.
Prediction of diffi culty should not be considered to be contra-
indication but surgeon must be better prepared. Improved 
optics, better instrumentations, special maneuvers & tech-
niques and ‘tips and tricks’ learned from experience has 
allowed us to improve safety and reduce conversion rates 
even in these “diffi cult” cases. The presentation will cover 
techniques found useful in managing these cases at each step.
C-004
STRATEGY AND SKILLS ON 
PREVENTION OF BILE DUCT INJURY 
DURING LAPAROSCOPIC 
CHOLECYSTECTOMY
Q. Wang
Abstract not available at time of publication.
C-005
MANAGING GALLSTONE 
DURING PREGNANCY
T. J. M. Lalisang
Digestive Surgery Division, Cipto Mangunkusumo 
Hospital, Faculty of Medicine, University of Indonesia, 
Jakarta
Introduction: Surgery during pregnancy entails the obvious 
added risk of morbidity for two – mother and fetus. Delay 
in defi nitive treatment of biliary disease during pregnancy 
increases acute biliary pancreatitis which impact on preterm 
delivery until fetus lost. Premature contractions became fre-
quent and necessitating tocolytic and corticoid therapy used. 
Transient changes in the biliary system during pregnancy, 
including gallbladder stasis and the secretion of bile with 
increased amount of cholesterol and decreased amounts of 
chenodeoxycholic acid, increased the risk of gallbladder 
disease. Nonoperative management of symptomatic choleli-
thiasis increases the risk of complications of biliary lithiasis, 
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such as cholecystitis and empyema, while obstructing 
common bile duct stones with or without cholangitis and 
biliary pancreatitis raise maternal mortality.
Methods: Retrograde case report.
Result: One case of gallbladder stone during second trimes-
ter pregnancy was successfully treated with laparoscopic 
cholecystectomy in our institution.
Conclusion: Laparoscopic cholecystectomy during preg-
nancy has advantages for the mother in that it speeds up her 
recovery, giving her less pain and facilitated natural birth 
without a cesarean section. On the fetus side is always save, 
not induced preterm delivery or abortion.
Identifi cation of gallbladder stone during pregnancy 
warrant a preventive laparoscopic cholecystectomy or endo-
scopic CBD exploration which promising a good outcome.
C-006
MANAGEMENT OF ASYMPTOMATIC 
GALL STONES
S. P. Haribhakti, H. N. Soni and A. P. Nagpal
Department of GI & Laparoscopic Surgery, Haribhakti 
Surgical Hospital & Sterling Hospital, Ahmedabad, India
Introduction: Gallstone disease is one of the most common 
of all digestive diseases. The routine use of ultrasonography 
for the evaluation of abdominal pain, pelvic disease, and 
abnormal liver function tests has led to the identifi cation of 
incidental gallstones in many patients. The majority of these 
patients have no symptoms attributable to the gallstones; 
however, approximately 20 percent will become symptom-
atic at up to 15 years of follow-up.
Method: Data reviewed from the review of published 
medical literature related to epidemiology, natural history, 
treatment and outcome related to treatment for gall stone 
diseases.
Results: Role of prophylactic laparoscopic cholecystec-
tomy or incidental cholecystectomy at the time of other 
abdominal surgery is acceptable in high risk patients who are 
prone to develop gallbladder carcinoma or gall stone com-
plications. Patients with diabetes mellitus may have an 
increased risk of complications, the magnitude of the risk 
does not warrant prophylactic cholecystectomy.
Conclusion: Prophylactic cholecystectomy in most patients 
with asymptomatic gallstones is not advisable. (Grade 1B). 
But during this laparoscopic era, young patients with asymp-
tomatic gall stones and prolong life expectancy against risk 
of gall stone complication study is still awaited.
C-007
CHOLECYSTECTOMY IN THE 
CIRRHOTIC PATIENT
R. Bryant
Royal Brisbane Hospital, Queensland, Australia
Cholelithiasis occurs with an increased incidence in cirrhotic 
patients. Laparoscopic cholecystectomy is technically more 
diffi cult in cirrhotic patients, due to a stiff immobile liver and 
increased bleeding with portal hypertension and coagulopa-
thy. The patients are at increased risk of postoperative com-
plications, particularly hepatic insuffi ciency. Laparoscopic 
cholecystectomy can be considered in cirrhotic patients with 
symptomatic cholelithiasis. Particulars of the surgical tech-
nique include maneuvers to improve exposure, meticulous 
hemostasis with strategies to deal with bleeding varices, and 
the prudent use of variations such as a fundus fi rst technique 
or sub-total cholecystectomy where required. The literature 
demonstrates that patients with Childs A or B cirrhosis can 
safely undergo laparoscopic cholecystectomy, but that patients 
with Childs C cirrhosis have an elevated mortality and alterna-
tives to laparoscopic cholecystectomy should be considered.
C-008
CHOLECYSTOSTOMY IN ACUTE 
CHOLECYSTITIS
P. Evans
Alfred Hospital, Melbourne, Australia
Percutaneous Cholecystostomy (PC) tube placement is 
an established treatment option for acute cholecystitis. 
Procedure-related morbidity and mortality are low, but mean 
mortality from all causes is about 16% (range 0–48%) across 
most published series. Technical success rates for PC are 
high and in most cases there is resolution of acute cholecys-
titis within 1–3 days. Whilst transhepatic PC tube placement 
is preferred to direct puncture of the Gallbladder, there is 
demonstrable difference in outcomes. PC tube blockage or 
dislodgement occurs in about 20% of cases, and recurrent 
cholecystitis occurs in approximately 10% of cases. In most 
series, half of all patients treated by PC eventually proceed 
to cholecystectomy. In the majority of cases this can be 
performed laparoscopically.
There are no universally-accepted indications for PC and 
multiple criteria have been suggested. It is generally reserved 
for those patients with high-risk for cholecystectomy (ASA 
>3, age >80 years, severe sepsis or ICU admission) or for 
patients with potentially reversible comorbidities. PC tube 
placement has been advocated for critically ill ICU patients 
with sepsis of unknown origin. There are no randomized 
controlled trials comparing PC to emergent cholecystectomy, 
and there is a need for such a trial. Any attempts to compare 
the two procedures based on published series is inappropriate 
due to selection bias.
C-009
ADVANCES IN DIAGNOSIS AND 
STAGING FOR HEPATOCELLULAR 
CARCINOMA
L. McCormack
Hospital Aleman of Buenos Aires, Argentina
Diagnosis: Probably the best non-invasive approach to 
diagnosis of HCC was outlined by the AASLD. Because of 
the limitations of serum AFP measurements, other serum 
markers of HCC used alone or in combination with AFP have 
been evaluated for diagnosis or prognosis in patients with 
HCC. Although these other markers are not used in routine 
clinical practice, they continue to be a topic of investigation. 
When the studies are inconclusive, follow-up imaging may 
clarify the diagnosis. Molecular genetic studies have shown 
promise in identifying a molecular signature that can dif-
ferentiate dysplastic nodules from HCC, but more studies are 
needed. Percutaneous biopsy should only be performed when 
imaging results are uncertain, and when the result would 
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directly impact on management. Unfortunately, remains a 
challenge to properly differentiate a tumor-related from a 
cirrhosis-related benign portal vein thrombosis in a patient 
with HCC occurring in a cirrhotic liver.
Staging Systems: Many systems have been proposed to 
predict the prognosis for HCC, none of which has been 
universally adopted. These schemas variably incorporate: the 
severity of underlying liver disease, the size of the tumor, 
local tumor extension and the presence of metastases. A 2010 
consensus conference from the AHPA proposed that the 
staging of the AJCC/IUCC should be used to predict outcome 
following resection or liver transplantation. The BCLC 
scheme is appropriate in patients with advanced HCC not 
candidate for surgery. However, there is no universal agree-
ment as to which staging system is best in predicting the 
survival of patients with HCC.
C-010
MOLECULAR MARKERS OF HCC – 
A GUIDE TO TREATMENT OPTIONS 
AND PROGNOSIS
R. T-P. Poon
Abstract not available at time of publication.
C-011
BIOPSY SHOULD BE PERFORMED 
BEFORE RESECTION OR TRANSPLANT 
FOR HCC
(for the ‘No’ side of the debate)
K. Madhavan
National University Health System, Singapore
In this debate regarding the biopsy of suspected HCC before 
liver resection or transplantation, I will be fi rst laying out the 
reasons for even considering a biopsy prior to what is con-
sidered and hoped to be curative treatment of HCC.
Evidence will be looked at on which are based the advice 
to biopsy suspected lesions in the liver prior to surgical treat-
ment. Most of these perceived benefi ts are based on not 
sound data and are far out weighted by the risks from a 
biopsy – both as regards complications and long term onco-
logical disadvantages. Also, available evidence does not 
allow us to deny any patient transplantation or resection 
based on biopsy fi ndings. The various techniques of biopsy 
employed now a days will be analyzed and their success rate 
and failure rate will be compared including the consequences 
of each. Finally a critical look at the benefi ts of a pre op 
biopsy and its “value” in the current surgical treatment of 
chronic liver disease will be undertaken.
C-012
DEBATE: BIOPSY SHOULD BE 
PERFORMED BEFORE RESECTION 
OR TRANSPLANT FOR HCC (FOR THE 
‘YES’ SIDE)
M. C. Wu
Abstract not available at time of publication.
C-013
RESECTION STRATEGIES IN 
HEPATOCELLULAR CARCINOMA (HCC)
N. Kokudo, S. Tamura, K. Hasegawa, M. Takahashi, Y. 
Inoue, J. Kaneko, Y. Sakamoto, T. Aoki and Y. Sugawara
Hepato-Biliary-Pancreatic Surgery Division, Department 
of Surgery Graduate School of Medicine, University of 
Tokyo, Tokyo, Japan
According to Japanese guidelines for HCC, liver resection is 
recommended for HCC patients with 3 or less tumors regard-
less of tumor size, provided liver damage (Child – Pugh 
classifi cation) is A or B. For more appropriate patient selec-
tion, precise evaluation of hepatic functional reserve and 
extent of liver resection is essential. Liver surgeons in Japan 
routinely measure the indocyanine green (ICG) 15-minute 
retention rate for more precise evaluation. An ICG integrated 
algorithm to decide which extent of liver resection tolerable 
for each patient is widely used in Japan [Makuuchi M 1993 
Semin Surg Oncol 9: 298].
HCCs often invade portal venous system or Glisssonian 
sheath, and therefore, surgery for these tumors should involve 
the resection of tumor-bearing portal venous branches or 
Glissonian pedicles. Anatomic resection, ultrasonically 
guided segmentectomy, is a method developed to overcome 
the dilemma between the benefi ts and risks of surgical pro-
cedures. Oncological advantage of anatomic resection has 
been shown by a number of cohort studies. Recent advance 
in 3-D computer simulation has enabled liver surgeons more 
precise and safe operative planning.
C-014
TECHNIQUES OF VASCULAR CONTROL 
DURING LIVER RESECTION
W. Zhou
Abstract not available at time of publication.
C-015
SALVAGE SURGERY AFTER 
DOWNSTAGING FOR HCC
H.-J. Kim
Yeungnam University Hospital, Korea
Surgical resection remains the best treatment for HCC, and 
small HCC resection has markedly improved the outcome 
after resection. Resection of large HCC may still provide an 
opportunity of long-term survival, but the outcome of 
patients with unresectable HCC is extremely poor. In clinical 
practice, large unresectable HCC still dominates in patients, 
for whom downstaging-resection is a new approach to 
surgery. Downstaging followed by resection (downstaging-
resection, cytoreduction and sequential resection) plays a 
role in improving prognosis of patients with unresectable 
HCC.
We have experienced 20 downstaging resection patients 
until 2010. Approaches for downstaging included transarte-
rial chemoembolization (TACE), hepatic intra-arterial infu-
sion chemotherapy, portal vein embolization and radiotherapy 
with mono- or combined therapy. Our regimen for hepatic 
arterial infusion chemotherapy (HAIC) is low dose 5 FU plus 
cisplatin. Overall and recurrence-free survival rates at 1, 3 
years were 81%, 61%, and 64%, 53%, respectively.
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We will introduce our strategies for downsatging resection 
for unresectable HCC.
In conclusion, hepatic resection after downstaging is a 
viable option for patients with unresectable HCC. However, 
due to the high rate of recurrence, hepatic resection after 
downstaging should be used with caution.
C-016
SURGERY FOR RECURRENT 
HEPATOCELLULAR CARCINOMA
Z.-Y. Huang, B.-Y. Liang and X.-P. Chen
Department of Surgery, Tongji Hospital, Tongji Medical 
College, Huazhong University of Science and Technology, 
Wuhan, China
Hepatic resection is a major effective treatment for patients 
with HCC, however, 75%–85% of patients develop tumor 
intrahepatic recurrence within 5 years after resection. The 
treatment for intrahepatic recurrence after hepatic resection 
is of vital importance for prolonging overall survival of the 
patients. The treatment for recurrent HCC includes surgical 
treatment (repeat hepatic resection and salvage liver trans-
plantation) and nonsurgical treatment (ablation therapy, 
percutaneous ethanol injection, transcatheter arterial chem-
oembolization and medical treatment). Nonsurgical treat-
ment is usually applied to recurrent HCC unsuitable for 
second operation, either because of advanced nature of 
recurrent HCC or insuffi cient preserved liver function. 
Radiofrequency ablation is usually recommended for patients 
with a limited number of small recurrent tumors, only with 
5-year overall survivals of 18%∼51.6%. Transcatheter arte-
rial chemoembolization is another widely accepted nonsurgi-
cal treatment for multinodular recurrent HCC, the 5-year 
survival only ranges from 0 to 27%. Molecular targeted 
therapies (such as sorafenib) are recommended for patients 
with advanced recurrent HCC, with limited benefi t. Surgical 
removal is still believed to be the most effective treatment 
for recurrent HCC. The 5-year survivals of 23%–69% after 
repeat resection were reported. Our cohort study showed the 
1-, 3- and 5-year overall survivals after repeat hepatic resec-
tion in 81 patients with recurrent HCC were 70.9%, 40.8% 
and 22.4%, respectively. Salvage liver transplantation is 
another treatment choice for recurrent HCC fulfi lling the 
Milan criteria. Studies have indicated that salvage liver trans-
plantation for recurrent HCC fulfi lling the Milan criteria 
could achieve similar long-term survival as primary liver 
transplantation. Our cohort study showed that the 1-, 3- and 
5-year overall survivals of salvage liver transplantation in 11 
patients with unresectable recurrent HCC (8 of 11 patients 
with recurrent HCC beyond the Milan criteria) were 90.9%, 
46.8% and 46.8%, respectively. Collectively, surgical treat-
ment, either salvage liver transplantation or repeat hepatic 
resection, provides the best survival benefi t in selected 
patients with recurrent HCC.
C-017
THERAPEUTIC INTERVENTIONS 
INFLUENCING MORTALITY IN ACUTE 
PANCREATITIS
R. Jarmin
Department of Surgery, Faculty of Medicine, Universiti 
Kebangsaan Malaysia, Kuala Lumpur, Malaysia
Introduction: The incidence of acute pancreatitis appears 
to be increasing worldwide. However the mortality has been 
reduced to less than 5%. The downward trend has also been 
seen in the incidence of severe pancreatitis. The reduction of 
mortality has been attributed to several factors which include 
better understanding in the pathophysiology of pancreatitis, 
improvement in the management and ICU care, nutrition, 
pharmacological therapy and the advancement of the thera-
peutic interventions.
Methods: The advancement of medical technologies like 
imaging, endoscopic facilities as well as minimal access 
surgery has signifi cantly infl uenced the current management 
of pancreatitis. Although the surgical management in early 
years had demonstrated higher mortality rate in the manage-
ment of severe pancreatitis, the present evidence had showed 
some signifi cant contribution of therapeutic interventions in 
improving the mortality rate of acute pancreatitis.
Results: The presentation will focus on the infl uence of 
therapeutic intervention towards the management of acute 
pancreatitis. The important key points will be highlighted in 
terms of intervention modalities, timing of the intervention 
and the outcome of the procedures. It will also include the 
rationale of certain therapeutic procedures based on the 
available evidence in literatures.
Conclusions: Although the quality of care for acute pancre-
atitis has improved over the years, better understanding of 
the disease process, optimum management plan and appro-
priate therapeutic interventions would defi nitely improving 
the mortality rate of acute pancreatitis.
C-018
APPROACH TO RECURRENT 
IDIOPATHIC PANCREATITIS
P. Wagle, P. Bhalla and R. Gowda
Lilavati Hospital & Research Centre, Mumbai, India
Recurrent idiopathic pancreatitis is a common clinical yet 
potentially life threatening condition that may pose a dilemma 
both in diagnosis & eventual therapy. Common causes in our 
practice include biliary microlithiasis/sludge, pancreas 
divisum, obstructive ductal disorders like a small neoplasm, 
autoimmune pancreatitis, groove pancreatitis & lastly genetic 
mutations.
Serum investigations include Triglycerides, IgG4, & PTH. 
Genetic testing of CFTR, SPINK1 & PRSS1 though valuable 
may not be easily available.
We propose MRCP as the fi rst imaging modality as it is 
non invasive & easily available. EUS is a better tool for 
diagnosis of microlithiasis & early chronic pancreatitis but 
remains operator dependent & sparsely available. The role 
of ERCP has reduced with the advent of the above modalities 
but is needed in manometry for SOD & for subsequent 
sphincterotomy.
Inspite of a detailed diagnostic algorithm, at least 20% of 
patients remain undiagnosed as to the etiology of recurrent 
pancreatitis.
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C-019
PANCREATITIS AND 
PANCREAS DIVISUM
S. Pongprasobchai
Siriraj Hospital, Bangkok, Thailand
Pancreas divisum (PD) is the most common congenital 
anomaly of the pancreas, which accounts for 8% of normal 
population. It is controversial whether the relatively obstruc-
tive outfl ow of Santorini duct in PD can lead to recurrent 
acute pancreatitis (RAP), chronic pancreatitis (CP), or just 
an innocent bystander of idiopathic CP.
Critical reviews showed that the prevalence of PD in 
patients with RAP or CP is probably similar to patients 
without pancreatitis. Isolated dorsal pancreatitis which is the 
hallmark and suggests that PD is a culprit of RAP or CP is 
not always present (30–88%). CFTR and SPINK1 mutations 
have been found commonly in patients with PD and RAP or 
CP (22% and 42%, respectively). There are many case series 
but there is only 1 small RCT on the effi cacy of endoscopic 
therapy for PD in RAP and none exists for CP. The proper 
endoscopic technique is not yet established. Results of the 
treatment also varied but are better in RAP (81%) than CP 
(69%).
Eventually, careful patient selection for the treatment is 
essential. Suitable patients are likely patients who present 
with RAP (not CP or pancreatic pain only), have isolated 
dorsal pancreatitis (by pancreatogram or EUS), dilated 
Santorini duct, Santorinicele or in the presence of CFTR or 
SPINK1 mutations.
C-020
TECHNIQUES AND TIMING OF 
SURGICAL INTERVENTION IN ACUTE 
PANCREATITIS
R. Carter
Abstract not available at time of publication. 
C-021
MANAGEMENT OF HEMORRHAGIC 
COMPLICATIONS IN SEVERE 
ACUTE PANCREATITIS
K. Wada
Teikyo University School of Medicine, Tokyo, Japan
Massive hemorrhagic complications may occur in the course 
of severe acute pancreatitis (SAP) either in early or late 
period. The incidence of hemorrhagic complication in acute 
pancreatitis is reported with a wide range (from 1% to 15%) 
in the literature. Once hemorrhagic complications happen in 
patients with SAP mortality is considerably high. Hemorrhagic 
complications in SAP may include various types of source 
such as gastrointestinal (e.g. peptic ulcers, gastrointestinal 
varix), intraabdominal, retroperitoneal, surgical site, or 
abscess cavity.
Among gastrointestinal bleeding, left-sided portal hyper-
tension (cause for gastrointestinal varices) due to isolated 
obstruction of splenic vein is frequently seen in SAP. Much 
more attention should be paid for patients with necrosis and/
or pseudocyst who have higher incidence of splenic vein 
obstruction. First management of choice for hemorrhage 
from gastrointestinal varices is endoscopic treatment, but in 
cases with refractory bleeding surgical management with 
splenectomy should be considered.
Bleeding from local major vessels (artery and vein) is 
major cause of death of SAP. Pathophysiology of disruption 
of major vessel is various as follows; 1) devastation due to 
severe infl ammation and pancreatic necrosis which is usually 
seen in the early period. 2) pancreatic or peripancreatic 
abscess which is more often observed in weeks to months 
after the onset. 3) pseudocyst formation which makes 
erosion, persistent compression, ischemia combined with 
enzymatic action. Management of hemorrhage from major 
vessel should be selected according to the site of bleeding. 
In bleeding from arteries interventional radiology (angio-
graphic embolization) should be attempted as early as pos-
sible, keeping in mind that if it is fails then only surgical 
treatment gives the patient a chance to survive. On the other 
hand, venous bleeding is more frequently required surgical 
management such as packing or emergency proximal or 
distal pancreatectomy.
Hemorrhagic complications is fatal event in the course of 
SAP, awareness is needed especially for patients at high-risk 
such as necrotizing pancreatitis, abscess, pseudocyst or 
patients after necrosectomy. Management should be selected 
in each case according to the site of bleeding, while the entire 
management for SAP. Of note when hemorrhagic complica-
tion occurred surgical management is sometimes still only 
chance to survive for patients with SAP.
C-022
ENDOSCOPIC THERAPEUTIC 
TECHNIQUES IN ACUTE AND 
CHRONIC PANCREATITIS
G. C. Vitale
Professor of Surgery, Department of Surgery, University of 
Louisville School of Medicine, Louisville, USA
ERCP has continued to have a role in management of acute 
and chronic pancreatitis. Endoscopic treatments serve as an 
adjunct to surgical treatment in many cases. The endoscopic 
treatments may provide defi nitive care without surgery.
ERCP is used in gallstone pancreatitis for patients with 
associated cholangitis and rising bilirubin. In other cases of 
gallstone pancreatitis, laparoscopic cholecystectomy with 
cholangiogram is the mainstay of treatment with ERCP 
reserved for failed laparoscopic stone extraction. Endoscopic 
management of chronic pancreatitis with stenting of stric-
tures and drainage of pseudocysts has become standard fi rst 
line of treatment. Techniques for transgastric drainage and 
debridement of pancreatic abscess and necrosis are also 
increasingly successful.
Prospective trials demonstrate improved outcome with 
decreased morbidity, mortality and hospital stay for patients 
with gallstone pancreatitis and associated cholangitis, if 
ERCP is done within 72 hours. Endoscopic stenting for 
chronic pancreatitis is successful in the medium term for 
approximately two-thirds of patients. Surgery remains the 
defi nitive treatment for endoscopic stenting failure, but with 
higher morbidity. Pancreatic pseudocysts can be drained 
endoscopically with expected 90% long-term success rate. 
Pancreatic abscess and infected necrosis can be approached 
in selected cases via an endoscopic transgastric route with 
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excellent results. In early studies, approximately two-thirds 
of patients treated with this approach can be successfully 
managed entirely endoscopically. The endoscopic approach 
does not seem to complicate surgery when it is used in an 
adjunctive fashion.
In summary, advances in endoscopic management of pan-
creatic disease are notable in the treatment of pancreatic 
stricture and pseudocyst/abscess. Successful endoscopic 
treatment has reduced the necessity of complex surgical 
approaches for selected subset of patients.
C-023
NOVEL THERAPIES FOR 
ACUTE PANCREATITIS
S. Connor
Abstract not available at time of publication.
C-024
THE MIRRIZZI SYNDROME
N. Jarufe
Digestive Surgery Department, Pontifi cia Universidad 
Católica de Chile
The Mirrizzi Syndrome (MS), was fi rst described by Pablo 
Mirrizzi in 1948 as “Hepatic duct Syndrome”. This syn-
drome is rare and occurs as a result of an impacted stone in 
the Hartmann pouch compressing the common bile duct 
(CBD) and develop of a cholecyscholedocal fi stula, replac-
ing the entire CBD in advanced cases.
The diagnosis is suspected by the presence of jaundice in 
an atrophic gallbladder with stones in the Hartmann pouch 
and dilation of proximal bile duct. The cholangioMRI is the 
best non-invasive diagnostic test. The endoscopic retrograde 
cholangiography may be useful in doubtful cases or associ-
ated cholangitis.
The treatment of the MS depends to the grade of replace-
ment of hepatic duct wall and can range from CBS plasty to 
Roux en Y biliary reconstruction. The historic approach to 
the MS had been by open surgery, however, some authors 
have development a laparoscopic approach with a complete 
resolution for initial grade. The best evidence nowadays sug-
gests that laparoscopic surgery is possible in selected cases, 
therefore a precise preoperative diagnosis is required for best 
results.
We will discuss someone aspect about the MS with a 
particular emphasis in the diagnosis by image tools and the 
alternatives of treatment by open and laparoscopic surgery.
C-025
CASE PRESENTATION: GALLBLADDER 
POLYP(S)
A. K. Agarwal
Abstract not available at time of publication.
C-026
BILE DUCT INJURY CASE DISCUSSION
R. Ardhanari
Meenakashi Mission Hospital & Research Centre, Tamil 
Nadu, India
Three case scenarios are presented
1. On table recognized bile duct injury during laparoscopic 
cholecystectomy.
Questions to be answered:
• 1. In the absence of a specialist HPB surgeon what is to 
be recommended.
2. 8 days post cholecystectomy patient has bile leak with 
ERCP showing complete cut-off. No evidence of sepsis
Questions to be answered:
• On present evidence what is best approach
Immediate repair or late repair (6–8 weeks)
3. Established bile duct stricture with evidence of portal 
hypertension (Varices)
Question: What approach to be adopted?
Question: Role of endoscopic stenting in this or other 
patients of BDI.
C-027
CASE PRESENTATION: COMPLEX 
CHOLEDOCHAL CYST
V. Sitaram
Abstract not available at time of publication.
C-028
LAPAROSCOPIC EXCISION OF 
CHOLEDOCHAL CYSTS
J.-Y. Jang
Department of Surgery, Seoul National University College 
of Medicine, Seoul, Korea
Introduction: In spite of benign disease, choledochal cyst 
must be removed with the gallbladder (GB) due to the cancer 
risk in the biliary tract. The most of patients are young female 
or children, who have strong interest in cosmetic results in 
addition to complete resolution of medical problems. Here 
we introduce laparoscopic management of choledochal cyst.
Methods: Between 2003 and 2011, we performed laparo-
scopic choledochal cyst excision in 82 patients using 4 hole 
method. There were 3 open conversion cases. There was one 
case of robotic surgery and one case of combined laparo-
scopic liver resection due to liver involvement of cyst. 
Excision of cyst and anastomosis were performed laparo-
scopically. We will present our method showing video.
Results: The mean operation time was 230 minutes. The 
estimated blood loss was 197 ml. The average length of 
hospital stay was 8.6 days. The most common complication 
was minor bile leakage (7%) and fl uid collection (2.5%), 
which was managed conservatively.
Conclusions: The laparoscopic management can be a treat-
ment of choice for the most of choledochal cyst considering 
good cosmetic result as well as operative safety.
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C-029
RESECTION FOR ADVANCED 
GALLBLADDER CANCER
M. Masaru, S. Hiroaki, O. Masayuki, Y. Hiroyuki, I. K. 
Atsushi, K. Fumio, Y. Hideyuki and F. Katsunori
Department of General Surgery, Chiba University, Chiba, 
Japan
Introduction: Advanced gallbladder cancer has been 
revealed to result in an ominous prognosis despite of aggres-
sive surgical resection, especially in cancer of stage III and 
IV.
Methods: Therefore, we changed the surgical strategy for 
advanced gallbladder cancer for obtaining a suffi cient 
outcome after aggressive surgical resection. The newly 
developed strategies are the severe patients selection for sur-
gical indication, and the utilization of pre-operative down-
staging chemotherapy.
Results: Herein I like to show the typical two cases of 
advanced gallbladder cancers, one of which was treated fol-
lowing severe patient selection despite of bile duct involve-
ment, and the other one was a patient following preoperative 
down-staging chemotherapy with video presentation of sur-
gical resection.
The fi rst case is of a gallbladder cancer who had under-
gone CABG using the right gastroepiploic artery before. 
Tumor of the gallbladder neck invaded the bile duct, and she 
presented with jaundice. After preoperative biliary drainage, 
she underwent preoperative portal vein embolization of the 
right portal branch. Extended right hepatectomy and bile 
duct resection was done. Pathological fi ndings revealed pT4, 
pN1 stage IVa. She recovered well after surgery, and still 
alive over 3 years after surgery.
The second case of advanced gallbladder cancer was 
57-year-old woman.
Gallbladder cancer invaded the bile duct and the hepatic 
artery. We applied right portal vein embolization, and neo-
adjuvant chemotherapy with Gemcitabine was given for the 
aim of neoadjuvant down-staging.
After neoadjuvant chemotherapy gallbladder cancer 
decreased in size and right hepatic artery invasion appeared 
to be remarkably improved.
She underwent extended right hepatectomy with bile duct 
resection. She recovered well, and still alive 3 year after 
surgery.
Conclusions: Aggressive surgical resection might improve 
the outcome by the introduction of the new strategies such 
as severe patients selection and preoperative down-staging 
chemotherapy in the patients with advanced gallbladder 
cancer.
C-030
MASTER VIDEO SESSION: RESECTION 
OF HILAR CHOLANGIOCARCINOMA 
WITH VASCULAR RECONSTRUCTION
T. Ebata
Nagoya University Hospital, Japan
Abstract not available at time of publication.
C-031
COMPLEX LIVER RESECTION FOR 
HILAR CHOLANGIOCARCINOMA
D. W. Choi
Department of Surgery, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, 
Korea
Bile duct resection and major hepatectomy is considered as 
standard treatment for hilar cholangiocarcinoma (HC). 
However, the extent of hepatic resection according to the 
Bismuth classifi cation is still controversial. Among hepatic 
resection which can be performed for hilar cholangiocarci-
noma, liver parechyme preserving surgery including central 
bisectionectomy with caudate lobectomy or isolated caudate 
lobectomy for Bismuth type I or II is very complex proce-
dure. I would like to present these 2 procedures for HC in 
the master video session.
After bilirubin level was below 3 mg/dl through bile duct 
drainage with PTBD, surgery was performed. I prefer bilat-
eral subcostal incision with median extension for the surgery 
of hilar bile duct cancer. For the details of central bisectio-
nectomy with caudate lobectomy, the hepatoduodenal liga-
ment was dissected to clear lymph nodes and to ascertain 
vascular invasion, and then the CBD was divided near the 
pancreas. After division of hepatic artery and portal vein to 
the anterior section of the right hemiliver, several small 
portal vein branches to the caudate and the Spigelian’s lobe 
were also controlled. Next the right hemiliver and the caudate 
lobe were mobilized through division of small hepatic veins 
to the IVC and the Arantius duct. Liver parenchymal dissec-
tion was begun between left lateral and medial section with 
CUSA dividing vessels to the medial section and bile duct at 
the peripheral level of the confl uence of B2 and B3, and the 
middle hepatic vein was divided at the level of vena cava 
using Endo-GIA. Finally, liver parenchyma between right 
anterior and posterior section was transected along with the 
right hepatic vein and bile duct was divided at the confl uence 
level of B6 and B7. Hepaticojejunostomy was performed 
with interrupt sutures using 5.0 Vicryl.
For the details of isolated caudate lobectomy for type II 
hilar cholangiocarcinoma, the hepatoduodenal ligament was 
dissected to clear lymph nodes and then distal bile duct was 
divided near the pancreas. Then small portal vein infl ow was 
controlled with very meticulous technique and the whole 
caudate lobe was mobilized after small hepatic vein was 
dissected from inferior vena cava. Liver parenchyma dissec-
tion was performed with CUSA and 3 hepaticojejunostomy 
was carried out.
These parenchyma preserving technique could offer safe 
and radical resection for type II hilar cholangiocarcinoma 
without substantial parenchymal volume loss.
C-032
KLATSKIN TUMOR BISMUTH IIIB 
WITH CONTRALATERAL 
VASCULAR INVASION
J. Iniesta, F. A. Alvarez and E. de Santibañes
Sección de Cirugía Hepatobiliopancreática, Hospital 
Italiano de Buenos Aires-Argentina
Introduction: Since the fi rst resection of a Klastkin more 
than 50 years ago, a signifi cant progress in the different 
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surgical and palliative treatment alternatives has been made. 
This has improved the resecability and long term prognosis 
of this disease. Although there is still controversy about 
extension of the resection, decision of which hepatic lobe to 
preserve, mortality and survival rates in extended liver 
resections.
Methods: We report two patients who had a Klatskin tumor 
(Type IIIB) with contralateral vascular compromise. In both 
cases there was right hepatic artery (RHA) and portal vein 
involvement (one case at the main portal vein and the other 
at the right portal vein). In both cases an arterial microsurgi-
cal reconstruction was made as the fi rst step between the 
posterior branch of the RHA and the common hepatic artery 
in both cases. Subsequently, a left trisectionectomy with 
caudate lobe resection was performed. Portal reconstruction 
was done by an end-to-end anastomosis between the right 
portal vein and the common portal vein in one case and 
resection with lateral suture on the other case.
Results: Both patients had an uneventful recovery and the 
mean hospital stay was 13 days. Currently, after 18 months 
from surgery both patients are free of disease.
Conclusions: The surgical procedure done allowed a com-
plete resection (R0) and disease-free margins. Neither patient 
developed postoperative liver insuffi ciency. Vascular recon-
struction with the microsurgical technique applied improved 
the results of the anastomosis without thrombotic complica-
tions and allowed us to perform portal repair without total 
arterial and venous vascular exclusion.
C-033
ROBOTIC-ASSISTED LAPAROSCOPIC 
RADICAL RESECTION WITH MAJOR 
HEPATECTOMY FOR HILAR 
CHOLANGIOCARCINOMA
Hospital & Institute of Hepatobiliary Surgery, Chinese 
PLA General Hospital, Beijing, China
Background: Laparoscopic hepatectomy has been reported 
extensively in the literature. However hilar cholangiocarci-
noma still remains contraindication for laparoscopic 
technique due to diffi cult radical resection and hepaticojeju-
nostomy. At present, the robotic technique made the differ-
ence, allowing the performance of procedure with complex 
manipulative maneuvers otherwise not feasible in minimally 
invasive surgery. This video demonstrates technical aspects 
of the fi rst case of robotic-assisted laparoscopic anatomic left 
hepatectomy and caudate segmentectomy, Roux-en-y hepati-
cojejunostomy for radical resection of hilar cholangiocarci-
noma in China.
Methods: A 54-year-old man with hilar cholangiocarci-
noma was referred for surgical treatment. The robotic-
assisted laparoscopic anatomic left hepatectomy and caudate 
segmentectomy, Roux-en-y hepaticojejunostomy for radical 
resection of hilar cholangiocarcinoma was performed. The 
operation followed several distinct phases: liver mobiliza-
tion, skeletonized hepatoduodenal ligament, dissection and 
division of the left hepatic artery and left portal vein, paren-
chymal transection with harmonic shears and endoscopic 
stapling device for division of the left hepatic vein, plasty of 
the right bile ducts and Roux-en-y hepaticoenterostomy. Two 
abdominal drainages were placed posterior to the anastomo-
sis. No Pringle maneuver was used. The specimen was 
extracted through a suprapubic incision using an endobag.
Results: The operative time was 600 min, and the blood 
loss was 600 ml, with no blood transfusion. The surgical 
resection margins were free of tumor. The transient bile 
leakage was observed and cured with conservative treatment 
on postoperative third day. The postoperative stay was 12 
days.
Conclusions: Robotic-assisted laparoscopic anatomic left 
hepatectomy and caudate segmentectomy, Roux-en-y hepati-
cojejunostomy for radical resection of hilar cholangiocarci-
noma is safe and feasible. For the patients with hilar 
cholangiocarcinoma, robotic surgery builds upon the 
advances to open surgery introduced by minimally invasive 
surgery.
C-034
MOLECULAR TARGETING OF 
PANCREATIC CANCER
A. Biankin
Abstract not available at time of publication.
C-035
THE APPLICATION OF STEM CELL 
TECHNOLOGY IN HPB DISORDERS
D. G. Croagh
Monash Medical Centre, Melbourne, Australia
Introduction: Hepatocellular carcinoma is the third leading 
cause of cancer related mortality worldwide. 75% of patients 
are not amenable to locally curative therapy and current 
chemotherapeutic treatments have limited effi cacy. Liver 
transplantation remains the only effective treatment for end 
stage liver disease and acute hepatic failure. However the 
magnitude of this intervention and the limited supply of 
donor livers have spurred efforts to fi nd alternative solutions. 
Both of these areas are being addressed by advances in our 
understanding of stem cell biology and the use of cell based 
therapies.
Methods: A review was undertaken of recent developments 
in stem cell biology especially as it relates to the understand-
ing and treatment of hepatobiliary and pancreatic disorders.
Results: Advances in our knowledge of liver and pancreatic 
stem cells combined with an appreciation of the importance 
of the cancer stem cell hypothesis has lead to greater under-
standing of hepatocellular carcinoma and offers great promise 
for better therapeutic strategies in the future. Recent advances 
in basic cell biology have also provided a variety potential 
useful source of cells for cell based therapies. This could 
successfully over come one of the major stumbling blocks in 
the fi eld thus far.
Conclusions: Developments in cell biology and stem cell 
biology in particular are providing exciting new insights into 
hepatobiliary disorders. Although these advances have not 
led to tangible therapeutic interventions yet, this is likely to 
change in the coming years.
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C-036
LAPAROSCOPIC APPROACH FOR 
CYSTIC DISEASE OF THE BILIARY 
TRACT
H.-S. Han, Y.-S. Yoon and J.-Y. Cho
Department of Surgery, Seoul National University Bundang 
Hospital, Seoul National University College of Medicine, 
Seoul, Korea
With rapid development and wide application of laparo-
scopic procedure, advanced laparoscopic operation is being 
performed more frequently in complex biliary diseases 
including choledochal cyst. Laparoscopic excision of 
choledochal cyst and Roux-en-Y choledocho-jejunostomy is 
being gradually introduced to the treatment of choledochal 
cyst. Between August 2004 and September 2011, 42 patients 
underwent laparoscopic excision of choledochal cyst and 
Roux-en-Y choledocho-jejunostomy for choledochal cyst. 
We retrospectively analyzed of the clinical outcomes of the 
41 patients, excluding 1 patients requiring conversion to 
open surgery. There were 12 men and 29 women, with a 
mean age of 30.2 years. The operation was performed with 
total laparoscopic method using the four-port technique in 
40 patients and with laparoscopic assisted method in 1 
patient. The mean operation time was 278 minutes. 
Intraoperative transfusion was needed in three patients 
(7.3%). The postoperative complication occurred in 9 
patients (21.9%), including bile leakage (n = 3), aspiration 
pneumonia (n = 1), bacteremia (n = 1), melena (n = 1), 
intraabominal fl uid collection (n = 1) and intraabominal 
bleeding (n = 2); one patient with intraabominal bleeding 
was treated by re-operation and the others were improved by 
conservative management. The mean postoperative hospital 
stay was 9.6 days. After a mean follow-up of 30 months, 5 
patients (12.1%) experienced the anastomotic stricture, 
which were managed by radiologic intervention in four 
patients and revision of anastomosis in two patients. This 
study shows that laparoscopic excision of choledochal cyst 
and Roux-en-Y choledocho-jejunostomy is a useful thera-
peutic option in the treatment for the patients with choledo-
chal cyst. Laparoscopic approach for biliary disease is more 
and more used than before, including cystic disease as well.
C-037
PARASITIC DISEASES OF THE BILIARY 
TRACT (BILIARY ASCARIASIS)
S. O. Javed
Sher-i-Kashmir Institute Medical Sciences, Srinagar, 
Kashmir, India
Parasitic Infestation of the biliary tract is mostly caused by 
Ascaris lumbricoides, Clonorchis sinensis, Fasciola species, 
Opisthorchis species, Matorchis conjunctus and Dicrocoelium 
dendriticum. Ascariasis, a helminthic infection of humans, is 
the most common parasitic infestation of the gastrointestinal 
tract. It infects about 25% of the world’s population; around 
20 thousand deaths occur per year from an adverse clinical 
course of the disease. The adult parasite commonly infests 
the small intestine without producing any signifi cant symp-
toms. However, it may migrate via the papilla into the biliary 
ductal system leading to a wide range of features This pre-
sentation is focused on biliary ascariasis, examining in some 
detail the pathogenesis of the disease with special reference 
to post cholecystectomy biliary ascariasis, postoperative 
biliary ascariasis, bilary ascariasis in pregnancy and related 
issues. Ultrasonography is a highly sensitive and specifi c 
method of detection of worms in the biliary tree. ERCP is an 
excellent diagnostic tool playing a defi nite therapeutic role 
in worm extraction. Surgery is only indicated in complicated 
cases. Although an endemic disease of tropical and subtropi-
cal countries, increasing population migration facilitated by 
fast improving communication facilities demands that clini-
cians everywhere be familiar with the clinical profi le and 
management of biliary ascariasis.
C-038
ASYMPTOMATIC COMMON DUCT 
STONES – EXPLORE OR LEAVE ALONE
R. Finch
Abstract not available at time of publication.
C-039
MANAGEMENT OF PERIAMPULLARY 
DIVERTICULUM
M. Nikfarjam
University of Melbourne Department of Surgery, Austin 
Health, Heidelberg, Victoria, Australia
Background: Periampullary diverticula (PAD) are out-
pouchings of the duodenum that occur within 2 to 3 cm from 
the ampulla of Vater. In the majority of cases they are 
acquired and are most commonly noted in the elderly. They 
have been associated with a number of pancreaticobiliary 
diseases.
Methods: Management of PAD and their association with 
pancreaticobiliary disorders are evaluated.
Results: The prevalence of PAD ranges from 12–27% based 
on endoscopic studies and is rare below the age of 40 years. 
There are anecdotal accounts implicating PAD with choledo-
cholithiasis, and with acute and chronic pancreatitis. 
Increased bacterial colonization of the biliary tract has also 
been associated with PAD. Bacterial overgrowth symptoms 
more commonly complicate jejunal diverticula than purely 
PAD. Bleeding and perforation are also rare complications 
of PAD. There is no role for surgical or endoscopic treatment 
of asymptomatic PAD. When associated with recurrent cho-
ledocholithiasis, endoscopic sphincterotomy or surgical 
biliary drainage procedures have been advocated. Surgical 
diverticulectomy and repair is reported in cases of perfora-
tion. Bleeding complications can be managed by endoscopic 
techniques, angiographic embolization and rarely require 
surgical diverticulectomy and suturing.
Conclusions: PAD are common but rarely produce pancre-
aticobiliary disease. Endoscopic intervention or surgery is 
reserved for truly symptomatic cases and when complicated 
by perforation or bleeding.
C-040
MOTILITY DISORDERS OF THE GALL 
BLADDER AND SPHINCTER OF ODDI
J. Toouli
Abstract not available at time of publication.
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C-041
MANAGEMENT OF ENDOSCOPIC 
PERFORATION OF THE CBD 
AND/ OR DUODENUM
S. Banting
St Vincents Hosptial, Fitzroy, Australia
Perforation of the duodenum or bile duct is an uncommon 
complication of ERCP. With the advances of non-invasive 
imaging of the biliary tree, rarely is an ERCP required for 
diagnosis. The vast majority of ERCP’s is now done with 
therapeutic intent, and with that comes an increased inherent 
risk of complications. However, in experienced hands, the 
risk of signifi cant perforation of the duodenum or bile duct 
is less than 1%.
Management of such perforations requires a selective 
approach. The need for intervention depends on the type and 
mechanism of injury, and the fi ndings on CT imaging. Most 
perforations will be able to be managed conservatively, but 
a minority require prompt and effective surgical intervention, 
to minimize the risk of morbidity and indeed mortality.
The indications for and types of intervention will be 
discussed.
C-042
TRANSPLANTATION FOR 
HCC-OVERVIEW
C-L. Chen
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
Taiwan
Patients with unresectable hepatocellular carcinoma (HCC) 
were a part of the initial experiences with liver transplanta-
tion (LT). These experiences often led to poor outcome. With 
newer chemotherapy and multimodality approach in the 
1980s, LT was relegated to second line treatment. The largely 
ineffective neoadjuvant studies which included large and 
multi-focal tumors, and the long waiting time made LT for 
HCC impractical. This prompted the development of loco-
regional treatment modalities. Later experience showed that 
excellent results could be achieved in patients given proper 
selection. Renewed enthusiasm for LT resurfaced by the 
1990s with rigid selection criteria, improved organ alloca-
tion, and shorter waiting time for donor livers.
LT now offers the best chance for cure for selected patients 
with unresectable HCC. But not all patients with unresect-
able HCC are suitable to be transplanted. Improved outcome 
of LT for HCC greatly depends on recipient selection and 
accurate tumor staging. Both rely heavily on diagnostic 
imaging. The role of adjuvant and neoadjuvant treatments 
needs further evaluation in the overall objective of disease 
removal and liver replacement.
Henceforth, early cancer detection and accurate pretrans-
plant staging are the key factors to successful LT outcomes 
for HCC. Using Milan criteria, excellent recurrence-free sur-
vival of >92% at 3 years is now achievable.
Although living donor liver transplantation (LDLT) 
assumed a key role in the pre Model for End-stage Disease 
(MELD) era, the current MELD prioritization for HCC 
reduced the necessity for LDLT in countries like the U.S. and 
parts of Europe. Unfortunately, there is a prolonged waiting 
time for candidates to receive allocated deceased organs in 
some countries due to a very low deceased donation rate 
which contributes in patient drop-out due to tumor progres-
sion. Advances in adult LDLT demonstrate survival benefi ts 
over deceased donor liver transplantation (DDLT) as regards 
to decreasing waiting time and drop-out since it is not 
restricted by organ allocation system but other studies 
observe that although LDLT decreases waiting time, it may 
also be associated with higher rates of disease recurrence.
There are no consensus accepted criteria for the use of 
LDLT for HCC. Centers offering LDLT use currently 
accepted criteria in DDLT or adopted their own criteria. The 
Milan criteria have been expanded to UCSF, Pittsburgh, 
Tokyo, Kyoto, and Hangzhou criteria. Novel approaches to 
down-staging tumors initially beyond the Milan criteria were 
evaluated using loco-regional therapies or a combination of 
strategies. Currently, new paradigms that look into tumor 
biological behavior are being investigated to explain HCC 
recurrence.
C-043
RESECTION OR TRANSPLANTATION 
FOR HCC
S. Cleary
Abstract not available at time of publication.
C-044
TRANSPLANTATION VERSUS LOCO 
REGIONAL THERAPY FOR THE SMALL 
HCC
D. Mirza
Abstract not available at time of publication.
C-045
EXTENDED CRITERIA FOR LIVER 
TRANSPLANTATION IN HCC
S-S. Zheng
Division of Hepatobiliary and Pancreatic Surgery, 
Department of Surgery, First Affi liated Hospital, Zhejiang 
University School of Medicine, Hangzhou, China
Hepatocellular carcinoma (HCC) is the most common 
primary form of malignant liver tumor. Relative to other 
tumors, it ranks fi fth in overall frequency (fi fth in men and 
eighth in women) and fourth in annual mortality rate. China 
is one of the highest prevalent areas of HCC, mainly because 
chronic hepatitis B carriers account for more than 10% of 
the population. Liver transplantation (LT) is the ideal treat-
ment for patients with HCC in the setting of cirrhosis with 
liver dysfunction, since it treats both the tumor and the 
underlying liver disease, and the prognosis has also been 
greatly improved.
However, the shortage of donor resources is the negative 
factor that curtail the development of LT for HCC. Therefore, 
to choose the most suitable HCC patients and to explore the 
most scientifi c criteria are the present mainstream point 
of view. In recent years, several selection criterias for 
HCC patients have been established by some transplant 
centers. Such as Milan criteria, Pittsburgh modifi ed 
TNM criteria, University of California San Francisco (UCSF) 
criteria, Turkey criteria, Kyoto criteria, Tokyo 5-5 rule, Asan 
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criteria and so on. A scientifi c and effective criteria is consid-
ered to meet the following condition. First, The criterias 
should be not too restrictive. There are many patients with 
HCC who also have a signifi cant chance for cure. Second, the 
criteria should be able to select patients eliminating the risk 
of post transplant HCC recurrence. Macro morphological 
characteristics of HCC, in fact, give an imprecise estimate of 
the tumor’s aggressiveness since a signifi cant number of small 
HCC already have aggressive features such as a poorly dif-
ferentiated grade or microscopic vascular invasion. Moreover, 
in China, nearly 40% donor livers are offered to HCC patients, 
who have hepatitis B related backgrounds and more advanced 
or aggressive tumor characteristics. Based on more than 10 
years’ work, Hangzhou criteria was established by our center 
from Zhejiang University, Hangzhou, China. Apart from the 
presence of macrovascular invasion, HCC patients meeting 
Hangzhou criteria must fulfi ll one of the two following items: 
(a) Total tumor diameter less than or equal to 8 cm; (b) total 
tumor diameter more than 8 cm, with histopathologic grade I 
or II and preoperative AFP level less than or equal to 400 ng/
mL, simultaneously. The difference between survival curves 
of patients fulfi lling Milan criteria and patients fulfi lling 
Hangzhou criteria did not achieve statistical signifi cance.
There are two advantages of Hangzhou criteria. First, a new 
cut-off point of total tumor size at 8 cm was set. Second, the 
new criteria does not only rely on tumor size, but also increase 
reliance on the histopathologic grading and serum AFP level. 
Hangzhou criteria expands the Milan criteria without signifi -
cantly increasing the probability of post transplant HCC 
recurrence, and have achieved the similar long-term survival 
of Milan criteria through several transplant centers’ practical 
proof, so that more patients with HCC can be candidates for 
LT. This result is widely recognized and highly evaluated by 
many international transplant experts. Hangzhou criteria can 
lay a good foundation for not only the establishment of China 
criteria, but also the long-term development of LT in China. 
Liver transplantation (LT) offers a potential curative 
option for patients with HCC, but post-operative tumor 
recurrence remains one of the most prevalent causes of 
unsatisfactory long-term survival. Therefore, identifi cation 
of reliable prognostic factors for tumor recurrence and death 
could have signifi cant clinical importance. Detection of 
tumor-associated biomarkers, especially the serum ones have 
a more extensive clinical application. Over the past few 
years, many groups have focused on searching for reliable 
molecular biomarkers to better distinguish subtypes. Our 
group have indicated that the expression of CpG island meth-
ylator phenotype (CIMP), Multidrug resistance 1 (MDR1) 
gene, HOTAIR and the protein level of X-linked inhibitor of 
apoptosis protein-associated factor 1 (XAF1) could be can-
didate biomarkers for predicting tumor recurrence in HCC 
patients who have undergone liver transplant. With the devel-
opment of Molecular Biology and Genetic Engineering, 
more and more doctors transfer their viewpoint onto the gene 
which can be predicted the risk of tumor recurrence in HCC 
after transplantation. Future studies will be focused on 
searching for molecular biomarkers to refl ect the phenotype 
and Pathological features and to consummate the criteria of 
HCC for LT, and proposing a more reasonable and optimized 
model for patient selection and prognosis prediction, which 
will benefi t more HCC patients for LT.
C-046
MANAGEMENT OF HCC ON THE LIVER 
TRANSPLANT WAITING LIST
J. Lendoire
Liver & Transplant Division, Hospital Dr Cosme Argerich, 
Buenos Aires, Argentina
Liver transplantation is an effective therapy for patients suf-
fering from hepatocellular carcinoma and represents 26% to 
34% of the indications. The consequence of waiting for a 
cadaveric organ is that the tumor can progress with possible 
effects on outcome. Waiting list monitoring should be per-
formed every three months by contrast enhanced CT or con-
trast enhance MRI. The primary goal of bridging therapy will 
be to prevent waiting list drop-off by reducing tumor pro-
gression and secondary prevent HCC recurrence and improve 
survival after liver transplantation. Transarterial chemoem-
bolization (TACE), radiofrequency ablation (RFA) and 
resection (Rx) are the most common locoregional treatments 
reported for HCC Radioembolization and other ablative 
therapies are still under evaluation. Most evidence indicates 
that bridging strategies seems to be indicated for T2 patients 
likely to wait longer than 6 months, in particular for larger 
tumors high AFP, more likely to develop contraindications 
while waiting. Waiting time will depend on the national or 
regional organ distribution and the prioritization of an HCC 
patient in each country. Evidence suggests that there may be 
a marginal advantage for RFA in terms of local ablation. 
Although Rx has the advantage of a selection tool according 
to tumor characteristics, the procedure is rarely used as a 
bridging therapy at the moment. In some countries, like 
Argentina, patient will not receive HCC MELD-exception 
points after Rx because the tumor has been removed. Newer 
bridging strategies combining TACE and RFA or using new 
methods (Y-90, targeted therapies) are needed to be 
investigated.
C-047
DCD AND MARGINAL DONORS
M. Fink
The University of Melbourne, Austin Hospital, Melbourne, 
Australia
Liver transplantation is a highly successful treatment option 
for selected patients with end-stage liver disease or hepato-
cellular carcinoma (HCC). However, the relative lack of 
suitable donors in the face of a large potential recipient popu-
lation has lead to innovative approaches to increasing donor 
organ supply, including the use of extended criteria doors 
(ECD) and donation after cardiac death (DCD) organs.
A number of different defi nitions of ECD have been pro-
posed. One of the most widely accepted is the donor risk 
index (DRI) developed by Feng et al.1 This identifi ed donor 
age, race, height, cause of death, DCD and partial or split 
graft type as being independently signifi cant factors in pre-
dicting graft loss. One limitation of the DRI is the fact that 
donor hepatic steatosis, a factor shown to be important in 
other ECD models2, is not included.
It has been demonstrated that recipient selection for ECD 
organs is important. In a study comparing outcomes of 
patients with differing model for end-stage liver disease 
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(MELD) scores receiving livers from donors with differing 
DRI, the death censored graft survival of patients with a 
MELD score less than 15 was similar for those receiving 
grafts from donors with a DRI <1.8 and for those receiving 
grafts from donors with a DRI ≥1.8, whilst the outcome was 
worse for patients with MELD scores of 15 to 30 or >30 if 
they received a graft from a donor with a DRI ≥1.8. Another 
analysis of outcomes comparing patients of differing risk 
receiving organs from donors of differing risk revealed a 
much poorer outcome of high risk recipients receiving high 
risk grafts, whilst a low risk recipient receiving a high risk 
graft with a cold ischemia time (CIT) less than 6.4 hours had 
a similar outcome to a low risk recipient receiving a low risk 
graft3. On the other hand, it has been shown that the relative 
survival benefi t of transplantation over continued waiting is 
greatest for patients with the highest MELD score, even for 
high DRI grafts4. However, the allocation of high risk grafts 
into high risk recipients results in a higher rate of primary 
non-function5.
The outcome of liver transplantation using DCD grafts is 
inferior to donation after brain death grafts, with a HR of 
1.87 (95% CI 1.60–2.17) for graft loss6. In addition, there is 
a higher rate of ischemic cholangiopathy following DCD 
liver transplantation and this confers an increased risk of 
graft failure7. The risk of a composite endpoint comprising 
death, primary non-function, graft loss within 1 year and 
diffuse biliary ischemia is greater with increasing donor age 
and duration of postextubation hypotension (systolic blood 
pressure <50 mmHg)8.
Although it has been shown that there is an increased risk 
of graft loss associated with ECD, including DCD, with 
careful donor and recipient selection and transplantation with 
short CIT, satisfactory outcomes can be achieved. Patients 
with HCC are particularly suitable as recipients of ECD 
grafts, because the majority do not have liver failure.
References:
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outcomes, and retransplantation of liver allografts from 
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C-048
LIVING DONORS FOR LIVER 
TRANSPLANTATION FOR HCC
S. T. Fan
Department of Surgery, The University of Hong Kong, 
Queen Mary Hospital, Hong Kong, China
Introduction: Living donor liver graft was considered a 
more readily available graft for patients with hepatocellular 
carcinoma (HCC). However, early experience indicated that 
the recurrence-free survival rate was inferior compared with 
that of deceased donor liver transplantation (DDLT).
Methods: A retrospective study was made on the outcome 
of living donor liver transplantation (LDLT) for HCC at 
Queen Mary Hospital, Hong Kong.
Results: The 5-year survival rates of 104 HCC patients 
undergoing LDLT and 36 patients undergoing DDLT were 
73% and 87%, respectively (p = 0.055). On multivariable 
analysis, salvage transplant (HR 3.84, 95% C.I. 1.9–7.7) and 
patient age (HR 0.945, 95% C.I. 0.9–0.99) are signifi cant risk 
factors affecting survival. Excluding patients with salvage 
transplants, the 5-year survival rate of HCC patients under-
going LDLT as the primary treatment was similar to that of 
DDLT patients (79% vs. 89%, p = 0.144).
Conclusions: LDLT as a primary treatment for HCC carries 
a favorable prognosis as that of DDLT.
C-049
CHRONIC PANCREATITIS – THE ROLE 
OF SURGICAL INTERVENTIONS
M. D. Smith
Chris Hani Baragwanath Academic Hospital, University of 
the Witwatersrand Johannesburg, South Africa
Surgery has an important role to play in the management of 
chronic pain and complications associated with chronic pan-
creatitis. There is however lack of consensus as to the best 
treatment. The recent progress made in the development of 
minimally invasive approaches has further blurred the role 
of surgery in this disease. Surgery should be undertaken in 
a multidisciplinary environment when other options are not 
indicated. Proper training and expertise in pancreatic surgery 
is required. Surgery should aim to resolve the problem with 
minimal morbidity and mortality and with preservation of as 
much pancreatic function as possible. The goals of therapy 
in CP includes; pain relief, improved quality of life, manage-
ment of local complications, social and occupational reha-
bilitation and to exclude malignancy. There is a growing 
body of good evidence to support and guide surgical decision 
making. Surgical options include resection procedure, drain-
age procedures and a combination of the two with the recent 
development of organ preserving resections of the pancreas 
head. The duct drainage procedures result in recurrence of 
pain in about 30% of patients. The results from proximal 
distal resections are well reported and suggest that the pan-
creaticoduodenectomy (PD) has excellent long term results 
with acceptable morbidity and mortality outcomes. Distal 
resections should be avoided in CP. The combined proce-
dures including the Frey, Beger and Izbicki procedures 
combine resection of the abnormal head of the pancreas with 
preservation of the duodenum. The presentation includes the 
authors experience with the Frey procedure for pain and in 
particular the management of obstructive jaundice in CP.
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C-050
AUTOIMMUNE PANCREATITIS
P. Wagle
Abstract not available at time of publication.
C-051
TROPICAL PANCREATITIS
H. Ramesh
Surgical Gastroenterology & Liver Transplantation, 
Lakeshore Hospital & Research Center, Cochin, Kerala, 
India
Tropical Pancreatitis is a form of chronic pancreatitis affect-
ing young non alcoholic individuals in the tropics and sub-
tropics. The highest prevalence of this disease is in the South 
Western Indian state of Kerala, although it has been reported 
from other parts of the subcontinent, and from Africa, South 
America and other parts of Asia such as Indonesia, and 
Malaysia. The disease bears considerable similarity to 
chronic pancreatitis due to alcohol abuse in that abdominal 
pain, local complications, and functional defi ciency occur. 
Patients require surgical management either for intractable 
pain, or for complications such as pseudocysts, infl ammatory 
masses, biliary obstruction, or cancer. Pancreatic adenocar-
cinoma is frequently found and there is evidence that chronic 
pancreatitis may be premalignant. In selected patients with 
solitary head strictures, or a single stone, or dilated duct 
without stones, endotherapy may suffi ce, but most patients 
require surgery. The Frey procedure (head coring with lateral 
drainage) is the most suitable procedure as it allows a) con-
servation of pancreatic parenchyma and avoidance of a major 
head resection, b) wide drainage of the entire ductal system 
of the pancreas and relief of strictures, and c) tissue for 
biopsy to rule out cancer when there is a mass lesion (frozen 
section). In a series of 1000 patients with tropical pancreati-
tis, 94% of benign patients had good or excellent outcomes 
over a 10 year follow up. Major areas of failure included 
biliary obstruction, head masses (due to incomplete clear-
ance of the head ducts) and cancer.
C-052
HOW I DO IT – TECHNICAL TIPS IN 
SURGERY FOR CHRONIC 
PANCREATITIS
R. Carter
Abstract not available at time of publication.
C-053
HEAD CORING FOR CHRONIC 
PANCREATITIS: PROBLEMS 
AND PROMISES
A. Chaudhary
New Delhi, India
Persistent abdominal pain remains the leading indication for 
surgery in patients with chronic pancreatitis. In a subgroup 
of these patients, the pancreatic head is enlarged and the 
usual procedure of lateral pancreaticojejunostomy fails to 
relieve the pain in this situation. Head coring or Frey’s pro-
cedure involves coring out of this enlarged and infl amed 
pancreatic head along with drainage of the pancreatic duct 
into the jejunum. Pain relief with this procedure is better than 
lateral pancreaticojejunostomy and the morbidity and mor-
tality lesser than pancreaticoduodenectomy – which may be 
another operative option in such patients. We followed 60 
patients who underwent head coring procedure using the 
Izbicki pain score. In our experience pre operative opioid use 
and persistent pattern of pain were associated with compara-
tively poorer pain relief. Apart from being technically 
demanding, there are two main problems with this procedure, 
fi rst its diffi cult to rule out presence of malignancy and the 
optimum management of patients who continue to have pain 
despite a technically well performed procedure.
C-054
DUODENUM PRESERVING TOTAL 
PANCREATIC HEAD RESECTION FOR 
CHRONIC PANCREATITIS
C. Wang, H. Wu, J. Xiong, F. Zhou, J. Tao, T. Liu, Z. Yang 
and S. Gou
Pancreatic Center, Department of General Surgery. Union 
Hospital, Tongji Medical College, Huazhong University of 
Science and Technology, Wuhan City, Hubei Province, 
China
Introduction: The Beger procedure is a limited surgical 
procedure with the impact of replacing the Whipple proce-
dure for chronic pancreatitis, and it has been performed 
extensively in recent years. The purpose of this study was to 
describe a modifi ed Beger procedure for the treatment of 
chronic pancreatitis with an enlarged pancreatic head, in 
which total pancreatic head was resected without segment 
resection of the duodenum.
Methods: Between January 1999 and December 2010, 65 
patients were operated on by the modifi ed procedure. In the 
modifi ed procedure, the anastomosis of the residual pancre-
atic head and the jejunum in Beger procedure was avoided, 
and the posterior pancreaticoduodenal arcade was preserved 
for the blood supply of the duodenum. To preserve the 
common bile duct and its blood supply, a thin sheet of pan-
creatic tissue is preserved behind the intrapancreatic common 
bile duct and between the common bile duct and the 
duodenum.
Results: The mortality of the modifi ed procedure was 0. The 
overall morbidity was 17%. 1 patient developed duodenal 
fi stula caused by ischemia. No patient underwent re opera-
tion for severe complications. 40 patients who suffered 
abdominal pain in preoperative stage obtained complete pain 
relief, the mean EORTC QLQ-C30 pain scale decreased 
from 57 ± 28 to 11 ± 23. In the postoperative stage, the 
endocrine function of the patients compared equally to 
the preoperative stage.
Conclusions: Compared with Beger procedure in which the 
pancreatic head was subtotally resected, the modifi ed proce-
dure obtains acceptable postoperative outcomes, and benefi ts 
on extirpation of more infl ammatory lesions.
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C-055
RECURRENT PAIN FOLLOWING 
PRIMARY OPERATIONS FOR CHRONIC 
PANCREATITIS: MANAGEMENT 
OPTIONS
N. D. Merrett1,2,3, A. V. Biankin2 and D. Chang2
1University of Western Sydney, Sydney, Australia; 
2Department of Surgery, Bankstown Hospital, Sydney, 
Australia; 3Department of Surgery, Liverpool Hospital, 
Sydney, Australia
Chronic unremitting pain remains a major challenge in 
patients with chronic pancreatitis. These patients benefi t 
from multidisciplinary assessment by gastroenterologists, 
pancreatic surgeons and pain management teams. Endoscopic 
and surgical techniques to treat these symptoms have been 
well described and outcomes are discussed. An even greater 
therapeutic challenge is presented by those patients who do 
not respond after these procedures. The role, indications and 
outcomes associated with salvage procedures is discussed. 
Other modalities including immunotherapy, pancreatic sup-
pression, radiotherapy, nerve block, pain modifying agents 
and nutritional strategies are discussed.
C-056
MASTER VIDEO SESSION & 
DISCUSSION: NOTES 
CHOLECYSTECTOMY
G. V. Rao
Abstract not available at time of publication.
C-057
SILS CHOLECYSTECTOMY
P. Rao
Mamata Hospital, Maharastra, India
Since laparoscopic cholecystectomy became the gold stan-
dard for the treatment of symptomatic cholelithiasis in the 
last three decades, surgeons have tried to minimize the scars 
and reduce the port sites and achieve the elusive goal of 
scarless surgery. Mini laparoscopy caught everyone’s fancy 
for a while and there was much ado about NOTES. This led 
to the search for better avenues to render the procedure scar-
less. The authors have pioneered the technique of Single 
Incision Cholecystectomy since May 2007, using the R Port 
as an access device and trying to mimic a standard laparo-
scopic cholecystectomy. Improvements in the techniques, the 
access device and various curved and articulating instru-
ments, have led to the usage of a telescope and three instru-
ments via the umbilicus, thus mimicking a standard four-port 
cholecystectomy. The video shows how the critical view can 
be maintained and the procedure rendered almost scarless, 
using purely the umbilicus for access and organ retrieval.
C-058
MASTER VIDEO SESSION & 
DISCUSSION: A CASE OF SEVERE BILE 
DUCT INJURY IN LAPAROSCOPIC 
CHOLECYSTOMY
Q. Wang
Abstract not available at time of publication.
C-059
MANAGEMENT OF COMPLEX BILE 
DUCT INJURY
S. P. Haribhakti, H. N. Soni and A. P. Nagpal
Department of GI & Laparoscopic Surgery, Haribhakti 
Surgical Hospital & Sterling Hospital, Ahmedabad, India
Introduction: Common bile duct injuries represent a 
serious and challenging surgical complication. These 
complex injuries are most often a consequence of laparo-
scopic cholecystectomy (LC). Proper management requires 
a skilled and experienced hepatobiliary surgical team and 
interventional radiological team.
Method: Data reviewed from the review of published 
medical literature related to mechanism of bile duct injury, 
complications of bile duct injury as well radiological & sur-
gical treatment of bile duct injury.
Results: Commonest cause of bile duct injury is laparo-
scopic cholecystectomy. Contributing factors to bile duct 
injury include infl ammation of Calot’s triangle, a short cystic 
duct, excessive cephalad retraction on the gallbladder fundus, 
and insuffi cient or excessive lateral retraction of the gallblad-
der infundibulum. Complete transection of the common bile 
duct is the most frequent biliary injury, and the most chal-
lenging to manage.
Intra operative recognition of bile duct injury and accord-
ing management can prevent complications during post 
operative period. Delayed presentation like bile leak and 
biliary obstruction needs to be classifi ed and accordingly 
management should be performed.
Conclusion: Bile duct injury is a serious surgical complica-
tion and needs skilled & experienced surgical team. Intra 
operative recognition of injury can prevent post operative 
complications. For patients who present with bile leak, the 
biliary anatomy should be defi ned using percutaneous chol-
angiography, and leak should be controlled. For patients who 
present with complete biliary obstruction, cholangiography 
and biliary drainage are indicated to control sepsis before 
planning elective repair.
C-060
RIGHT HEPATECTOMY USING THE 
LIVER DOUBLE-HANGING MANEUVER 
THROUGH THE RETROHEPATIC 
AVASCULAR TUNNEL ON THE RIGHT 
OF THE INFERIOR VENA CAVA
X-P. Chen
Hepatic Surgery Center, Tongji Hospital, Tongji Medical 
College, Huazhong University of Science and Technology, 
Wuhan, China
The key to Belghiti’s liver-hanging maneuver is to develop 
a retrohepatic tunnel. This procedure requires a blind dissec-
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tion of the plane anterior to the inferior vena cava (IVC), 
with the inherent risks of damaging the short hepatic veins 
and consequential bleeding. Here we describe a liver double-
hanging maneuver with the advantage of being technically 
simple and safe. The operator uses his or her right index 
fi nger to dissect the space from below upward between the 
hepatic parenchyma and the anterior and superior edge of the 
right adrenal gland, which is situated just on the right side 
of the IVC. The operator then uses his left index fi nger to 
dissect the retrohepatic space from above downward on the 
right side of suprahepatic IVC, which is lateral to where the 
right hepatic vein joins the IVC. The retrohepatic tunnel is 
built when the 2 fi ngers touch each other. A kidney pedicle 
forceps is used to place 2 tapes around the liver for suspen-
sion. 65 patients underwent right hepatectomy using this 
maneuver. The study included 62 patients with hepatocellu-
lar carcinoma (tumor size: mean ± SD, 10 ± 3.7 cm), and 3 
patients had hepatic cavernous hemangioma, with a 
maximum diameter of 12.6 cm, 14.4 cm, and 22.6 cm, 
respectively. No major bleeding was encountered during the 
creation of the retrohepatic tunnel, with a success rate of 
100%.
Conclusion: To develop the retrohepatic tunnel in the space 
on the right of the IVC is absolutely bloodless, and it is 
technically easy and safe.
C-061
LIVER RESECTION COMBINED 
WITH INFERIOR VENA CAVA 
GRAFT REPLACEMENT
M. Yamamoto, S. Katagiri, S. Ariizumi, Y. Kotera and 
Y. Takahashi
Department of Surgery, Institute of Gastroenterology, 
Tokyo Women’s Medical University, Tokyo, Japan
The presented case was a 49-year-old woman with intrahe-
patic cholangiocarcinoma (ICC). The tumor was located at 
the hepatic vein confl uence. The tumor did not invade the 
right hepatic vein; therefore, the IVC just below the right 
hepatic vein and the IVC just below the tumor were cut over 
a length of 5 cm under active bypass using a bio-pump. An 
expanded polytetrafl uoroethylene graft (GORE-TEXFEP 
ringed vascular graft), with an internal diameter of 20 mm, 
was used and the IVC and the graft were sutured with 4–0 
prolene. After suturing the superior part, the clamp at the 
superior part of the IVC was released. After suturing the 
inferior part of the IVC, the clamp at the hepatoduodenal 
ligament was released. The operation time was 375 minutes 
and the blood loss was 3500 ml. The time of total vascular 
exclusion was 45 minutes. The patient’s postoperative course 
was uneventful, and she was discharged 14 days after surgery.
Eleven patients have undergone hepatectomy combined 
with graft replacement in our hospital. Liver resection com-
bined with IVC graft replacement is a complicated surgical 
procedure. However, this procedure is indicated in some 
selected patients because the procedure was safely performed 
without severe complication and offers hope for patients with 
liver cancer invading the IVC which cannot be cured with 
chemotherapy.
C-062
MASTER VIDEO SESSION & 
DISCUSSION: LAPAROSCOPIC LIVER 
RESECTION FOR ADENOMA
P. Herman
Abstract not available at time of publication.
C-063
SINGLE-PORT LAPAROSCOPIC LIVER 
SURGERIES: THE INITIAL 
EXPERIENCES IN 89 CASES
Y. K. You, H. J. Choi, G. H. Na, T. H. Hong, S. K. Lee, J. 
H. Park, Y. C. Yoon and D. G. Kim
Department of Surgery, Division of HBP & Liver 
Transplantation, Seoul St. Mary’s Hospital, The Catholic 
University of Korea, Seoul, Korea
Introduction: Surgeons have rapidly adopted single-port 
laparoscopic surgery for many abdominal operations. The 
aim of the present study was to assess our initial experiences 
with single-port laparoscopic liver surgery.
Methods: Between December 2008 and June 2011, 89 
patients underwent various single-port laparoscopic liver 
surgeries such as laparoscopy-assisted donor right hepatec-
tomy in living-donor liver transplantation (43 patients), 
hepatocellular carcinoma (21 patients), hepatic metastatic 
lesion from malignant neoplasm (9 patients), cholangitis 
associated with an intrahepatic duct stone (5 patients), chol-
angiocarcinoma, focal nodular hyperplasia (2 patients), 
hepatocellular adenoma (2 patients) and so on. Besides 43 
donor operation, 24 were right partial resections, 11 were left 
hepatectomies, 5 were left lateral sectionectomies, 3 were 
right hepatectomies and 3 were left partial resections etc.
Results: Median operating time and blood loss of single-
port laparoscopic liver resection patients were 201 minutes 
(range, 39–546 minutes) and 526 mL (range, 50–1000 mL), 
respectively. Four procedures were converted to multi-port 
laparoscopic hepatectomy due to instrument length limita-
tions. Conversion to laparoscopy-assisted hepatic resection 
took place in six because of technical failure (n = 2), stapling 
failure, old, bleeding, advanced tumor status. There was no 
serious intraoperative or postoperative complication in this 
series. Median postoperative stay was 8.3 days (range, 3–21 
days).
Conclusions: Our selected series has demonstrated the fea-
sibility and safety of single-port laparoscopic liver resection 
in a variety of hepatocellular carcinoma lesions, secondary 
liver tumors and benign hepatic lesions. However we need 
more cases and randomized studies for evaluation of role of 
this challenging technique whether it is applicable or not in 
the liver resection.
C-064
THE ASSESSMENT OF BIOLOGY OF HPB 
MALIGNANCY USING PET
S.-T. Lee1,2
1Centre for PET, Austin Health, Heidelberg, Victoria, 
Australia; 2Ludwig Institute for Cancer Research, Austin 
Hospital, Heidelberg, Victoria, Australia
Positron Emission Tomography (PET) has been used to 
diagnose and stage various malignancies, most commonly 
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using a radiolabelled glucose analogue known as 18F-
fl uorodeoxyglucose (18F-FDG). The utility of this radi-
otracer and other non-FDG radiotracers will be described in 
a range of hepatobiliary malignancies, including hepatocel-
lular carcinoma, cholangiocarcinoma and pancreatic 
carcinoma.
C-065
FUTURE DEVELOPMENTS IN 
CHEMOTHERAPY FOR COLORECTAL 
LIVER METASTASES
A. Haydon
Alfred Hospital, Melbourne
Early in the last decade a number of news chemotherapeutic 
agents for the treatment of metastatic CRC made their way 
into clinical practice. As a result, outcomes improved and 
median survivals approaching 2 years were commonly 
achieved in clinical trials. However, since the introduction 
of the monoclonal antibodies targeting VEGF and EGFR 
over 5 years ago, there have been no new chemotherapeutic 
agents reach the clinic.
Currently most of our efforts are focused on individualizing 
treatments based on patient factors, tumor factors and treat-
ment intent. My talk will cover these issues as well as 
looking at biomarkers that may predict therapeutic benefi t, 
optimum treatment duration and also touch on some of the 
new agents showing promise.
C-066
STAGING FOR GB CANCER – THE ROLE 
OF EUS AND PET SCANNING
D. S. Yoon
Department of Surgery, Gangnam Severance Hospital, 
Yonsei University Health System, Seoul, Korea
Introduction: The accurate preoperative staging is manda-
tory for appropriate planning of surgery in gallbladder 
cancer. The purpose of this study is to evaluate the role of 
endoscopic ultrasound and fl udeoxy glucose-positron emis-
sion tomography (FDG-PET) in establishing the benign and 
malignant of gallbladder lesions.
Methods: A total of 133 patients, with polypoid GB lesion 
or suspicious GB cancer, are enrolled in this retrospective 
study; 118 patients are evaluated with preoperative EUS and 
25 patients with PET. All patients are pathologically diag-
nosed by surgical resection or biopsy after preoperative EUS 
or PET scan. EUS or PET fi ndings are compared with histo-
pathologic reports.
Results: Of the 118 patients evaluated with EUS, there were 
105 (89%) cases of benign GB lesions and 13 (11%) cases 
of GB cancer. Diagnostic sensitivity of malignancy was 
69.2% and specifi city was 95.2%. EUS failed to show accu-
racy of diagnosis of lymph node metastasis. Of the 25 
patients evaluated with PET scan, there were 9 (36%) cases 
of benign GB lesions and 16 (64%) cases of GB cancer. 
Diagnostic sensitivity of malignancy was 100% and specifi c-
ity was 88.9%.
Conclusions: EUS is useful to diagnose GB cancer and 
predict the depth of invasion but not for evaluating the lymph 
node status. PET scan is useful to diagnose GB cancer and 
evaluate the lymph node status and distant metastasis.
C-067
INCIDENTAL CARCINOMA FOLLOWING 
CHOLECYSTECTOMY. WHAT DO I DO?
A. Richardson
Westmead Hospital, Westmead, Australia
The frequency of incidental gallbladder cancer detected in 
cholecystectomy specimens for presumed benign disease 
ranges from 0.2–2.1%. Prognosis for gallbladder cancer has 
improved over the last 20 years and fi ve year survival rates 
may approach 50% in some studies.
The treatment is dictated by the stage of disease, as is the 
prognosis. Lymph node involvement has an adverse prognos-
tic effect. The stage of disease will generally be treated as 
follows:
T1A – Probably cured with cholecystectomy alone
T1B – Controversial
T2–T3 – Defi nitive resection improves survival
There is probably no adverse effect on survival of a previous 
laparoscopic cholecystectomy. Port-site resection is not asso-
ciated with increased survival. Incidental gallbladder cancer 
should be managed in specialist hepatobiliary centers to 
achieve the best results.
C-068
THE SIGNIFICANCE AND 
MANAGEMENT OF LYMPH NODE 
INVOLVEMENT IN CARCINOMA 
OF THE GALLBLADDER
A. L. Montagnini
Abstract not available at time of publication.
C-069
EXTENT OF LIVER RESECTION IN 
GALLBLADDER CANCER (GBC)
P. Jagannath
Department of Surgical Oncology, Lilavati Hospital & 
Research Centre, Mumbai, India
The extent of liver resection depends on 1) Location of timor 
in gallbladder 2) triplanar (transverse, coronal and sagittal) 
extent of liver involvement.
Location of GBC – Fundic type GBC involves segment 
4B–5 in accordance with venous drainage and a radical cho-
lecystectomy with Seg 4B–5 excision is necessary for 
T1–T3.
The ‘neck type’ GBC mimics a mid ductal cholangiocarci-
noma with extension into porta hepatis. Surgical approach is 
similar to hilar cholangiocarcinoma and the resection is infl u-
enced by the vascular involvement at the porta.
Extent of liver involvement in GBC – A Triphasic Tri-
planar CT scan allows a simultaneous assessment of the 
extent of liver involvement in the axial, sagittal and coronal 
planes.
Tumors involving Seg 5 duct without involvement of seg 8 
duct: Seg. 4B–5 excision is necessary in such tumors. 
Resection starts from the round ligament preserving the 
portal pedicle to Seg 4A. Transection runs horizontally to 
connect to Seg 5/Seg 6 plane avoiding the posterior sector 
pedicle.
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Tumors involving Seg 5 & 8 of the anterior pedicle would 
need a median hepatectomy involving 4B–5 and 8 excision 
with ligation of middle hepatic vein.
Tumors involving P point (posterior and anterior sector 
would necessitate right hepatectomy along with seg 4B exci-
sion. PET CT scan and Laparosopy are useful.
Tumors involving duodenum/pancreas need extended 
resections like hepato-pancreatodoudenectomy with increased 
morbidity, mortality and no signifi cant survival advantage.
Surgery is not recommended in presence of para aortic 
nodal metastasis. Neoadjuvant Chemotherapy can downsize 
locally advanced GBC and a parenchyma preserving resec-
tion can be offered.
C-070
SURGICAL OPTIONS FOR 
ADVANCED GALLBLADDER CANCER – 
AN OVERVIEW
T. Sano and Y. Nimura
Aichi Cancer Center Hospital, Nagoya, Japan
Although aggressive surgical strategy for advanced gallblad-
der cancer (GBC) had been adopted, the long-term outcome 
after potentially curative surgery still remains dismal. To 
establish the radical surgery, type of liver resection, extent 
of lymph node dissection and necessity of extrahepatic bile 
duct resection and/or pancreatoduodenectomy have been dis-
cussed, and many retrospective studies revealed benefi cial 
effects on lymph node dissection in radical surgery for GBC. 
However any randomized controlled trial (RCT) has not been 
performed to clarify the value of paraaortic node dissection. 
Several types of hepatectomy have been applied to achieve 
negative resection margins for locally advanced GBC. 
Wedge resection of the gallbladder bed is popular for a small 
cancer with subserosal invasion or minimal liver involve-
ment. Segmental liver resection such as S4a + 5 resection is 
indicated for tumors with limited gallbladder bed invasion. 
Right hepatectomy + S4a + S1 resection plus extrahepatic 
bile duct resection is widely applied for advanced GBC 
involving the right portal pedicle or the hepatic hilum. The 
clinical impact of extensive hepatobiliary resection has been 
published mainly from Japan. However any RCT has not 
been done to clarify which type of hepatectomy is recom-
mended for locally advanced GBC. The value of combined 
portal vein and liver resection for locally advanced GBC has 
not been clarifi ed. Hepatopancreatoduodenectomy (HPD) 
has been carried out as an ultimate radical surgery for more 
advanced GBC with varying degree of success and high 
morbidity and mortality of this surgery were reported. 
Therefore HPD should be carefully indicated for selected 
patients with far advanced GBC.
C-071
TECHNICAL INNOVATIONS 
IN LIVER TRANSPLANTATION
S. T. Fan
Department of Surgery, The University of Hong Kong, 
Queen Mary Hospital, Hong Kong, China
Introduction: The technique of deceased donor liver trans-
plantation (DDLT) currently used was established largely by 
Starzl and Calne. Recent innovation of the technique of 
transplantation focuses on living donor operations.
Methods: Review of recent literatures.
Results: Liver transplantation is performed mostly without 
veno-venous bypass nowadays. Side-to-side inferior vena 
cava anastomosis results in profi cient drainage of graft and 
a better outcome. In living donor liver transplantation, right 
liver donation is the main stream whereas dual graft opera-
tion can overcome graft size discrepancy. Small-for-size 
graft syndrome is largely overcome by attention to portal 
fl ow and modulation by splenic artery ligation or splenec-
tomy. Biliary drainage is mainly established by duct-to-duct 
anastomosis. Caudal shifting of living donor graft and utili-
zation of hilar plate in 2 or 3 duct-to-common hepatic ducts 
may improve results further.
Conclusions: Continuous modifi cation of techniques of 
liver transplantation and improvement of results have been 
observed in recent years.
C-072
LIVE DONOR LIVER 
TRANSPLANTATION; AN OVERVIEW
K. H. Kim
Division of Hepatobiliary Surgery and Liver 
Transplantation, Department of Surgery, University of 
Ulsan College of Medicine and Asan Medical Center, 
Seoul, Korea
Owing to the shortage of deceased donor organs, live donor 
liver transplantation (LDLT) has become an established 
treatment for patients with acute and chronic disease. The 
fi rst successful pediatric LDLT, of a left lateral section graft 
from a mother to her son, was performed in Brisbane, 
Australia in 1989. Since then, this life saving procedure has 
been applied to adult patients. The greatest impact of LDLT 
has been in Asian countries, where cadaveric organ donation 
has been uncommon or non-existent. LDLT using left-lobe 
was introduced for adult recipients in 1993, but this proce-
dure did not become wide-spread owing to the inability of 
these relatively small-sized grafts to meet the metabolic 
demands of all adult recipients. To overcome the inadequate 
graft volume encountered with left-lobe grafts, transplanta-
tion with right-lobe liver grafts was introduced for adult 
recipients in 1996. Although this method rapidly led to the 
worldwide use of adult LDLT, right-lobe hepatectomies are 
associated with a greater surgical risk for live donors than 
left-lobe hepatectomies, and are associated with increased 
morbidity and mortality rates, owing to the reduced volume 
of remnant liver in the donor. In LDLT, donor safety is of 
paramount importance and cannot be compromised regard-
less of the implication for the intended recipient. Moreover, 
the absence of hepatic venous drainage to the right anterior 
sector has led to the right-lobe graft congestion and failure. 
Although graft size is critical for successful outcomes, the 
importance of uniformly good venous drainage of the ante-
rior sector of the right-lobe liver graft has been regarded as 
crucial for maximizing graft function. The reconstruction of 
the middle hepatic venous tributaries of a right-lobe graft 
was introduced in 1998. Not all potential donors can donate 
their right-lobes because safe donation is possible only when 
the estimated remnant liver volume is more than 30%. If the 
volume of the right-lobe in potential donors is more than 
70%, relative to the volume of the whole liver, one alterna-
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tive may be dual left-lobe graft LDLT, in which smaller 
left-lobe grafts from two donors are transplanted into one 
recipient. This technique was fi rst introduced in 2000 to 
minimize donor risk and alleviate the small-size graft 
problem. Until more cadaveric grafts become available, adult 
LDLT will continue to be a relevant therapy for patients with 
irreversible end-stage liver disease.
References
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C-073
SPECIAL ISSUES IN PAEDIATRIC 
LIVER TRANSPLANTATION
O. Imventarza
Hospital Garrahan, Hospital Argerich, Buenos Aires, 
Argentina
Several topics had change to improve the outcome in pedi-
atric liver transplantation, this issues include: the appropriate 
timing for referral, the optimal timing for surgery, the 
specifi c indications in children’s like biliary atresia or 
Hepatoblastoma. All of these issues were very important 
steps to increase the survival in this population.
The lack of suitable organs for children led to several 
innovations to improve donor availability, fi rst with reduced 
size liver, split livers and living related donors, these innova-
tions allowed pediatric waiting list mortality to fall.
The survival and outcome in terms of quality of life; 
current strategies for monitoring infectious complications 
and steroid withdrawal are very important issue in the pedi-
atric population.
We start our pediatric program in 1992 and we performed 
545 Pediatric liver transplant. 396 Cadaveric organs and 149 
living donors. We implant 196 whole liver and 346 reduce 
size including 55 splits. Median weight: 13.75 kg (R: 2.5–80 
kg), median age: 3 years(R: 40 d – 18 y.)
A special problem in Argentina was FHF due to Hepatitis 
A virus; since we start with the vaccination to this group we 
eradicate the transplant to this pathology. 
Previously age less than 1 year and weight less than 10 kg 
were signifi cant risk factors for infant survival after LTx. 
Currently; there are no limits on age or weight for referral 
for a patient for consideration of LTx.
Pediatric LTx continues to evolve and offer hope to chil-
dren with acute or chronic liver disease without limitations 
in age, weight or associate diseases.
C-074
TRANSPLANTATION FOR METASTATIC 
DISEASE OF THE LIVER
J. Belghiti
Abstract not available at time of publication.
C-075
TRANSPLANTATION FOR HILAR 
CHOLANGIOCARCINOMA
J. McCall
Abstract not available at time of publication.
C-076
QUALITY OF LIFE AFTER LIVER 
TRANSPLANTATION
C. W. Pinson
Abstract not available at time of publication.
C-077
MANAGEMENT OF ADVANCED 
PANCREATIC CANCER
A. Nakao1, S. Takeda2, S. Nomoto2, H. Sugimoto2, H. 
Kasuya2, T. Fujii2, S. Yamada2 and Y. Kodera2
1Department of Surgery, Nagoya Central Hospital, Nagoya, 
Japan; 2Department of Gastroenterological Surgery, 
Nagoya University Graduate School of Medicine, Nagoya, 
Japan
The resectability rate and postoperative survival rate for pan-
creatic carcinoma are poor. Aggressive resection including 
vascular resection and extended lymphadenectomy represent 
one strategy for improving survival. This study was carried 
out to clarify the indications for extended resection, espe-
cially vascular resection for pancreatic carcinoma.
From July 1981 to March 2011, we performed curative 
resection in 507 of 220 patients with pancreatic carcinoma 
in our department (70.0%). Vascular resection in 314 (62.3%) 
and portal vein resection without arterial resection was per-
formed in 297 patients. Combined portal and arterial resec-
tion was performed in 15 patients and arterial resection 
without portal vein resection in two. Extended lymphadenec-
tomy including para aortic lymph node was done. 
Postoperative survival rate was stratifi ed according to opera-
tive and pathologic fi ndings.
Operative mortality (any death within 30 days after surgery) 
occurred in 11 of 507 curative resection patients (2.2%), 
including one of 193 patients without vascular resection 
(0.5%), 5 of 297 portal vein resection patients without arterial 
resection (1.7%), and 5 of 15 arterial resection patients under-
going portal vein plus (33.3%). Most patients who survived 
for 2 or 3 years had carcinoma–free surgical margins.
The most important indication for vascular resection in pan-
creatic cancer is the ability to obtain cancer–free surgical 
margins. Recent postoperative adjuvant chemotherapy has 
been contributing to the survival.
C-078
THE EARLY DETECTION OF 
PANCREATIC CANCER – 
SURVEILLANCE OF HIGH RISK 
PATIENTS
A. Biankin
Abstract not available at time of publication.
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C-079
OBESITY AND PANCREATIC CANCER
H. A. Pitt
Indiana University, Indianapolis, USA
Obesity is a global epidemic which is fueled by dietary 
indiscretions related to both fatty acids and carbohydrates. 
Central obesity results in an altered adipokine milieu which 
is associated with diabetes, hyperlipidemia, cardiovascular 
disease (the metabolic syndrome) as well as with cancer. 
Patients with common malignancies have been found to have 
high circulating leptin and low adiponectin. Leptin has been 
shown to enhance cell growth and angiogenesis and to inhibit 
immune function whereas adiponectin has the opposite 
effects.
Human epidemiologic data suggest that obesity is associ-
ated with an increased incidence of pancreatic cancer as well 
as decreased survival after resection. Murine studies in our 
laboratory have confi rmed these observations and have dem-
onstrated more fat in the pancreas as well as more adipocytes 
in the tumor microenvironment of obese animals.
Therefore, we designed a human study to test the hypoth-
esis that pancreatic steatosis as well as adipocytes in the 
tumor microenvironment would be associated with increased 
dissemination and reduced survival in patients with resected 
pancreatic cancer. Twenty lymph node negative patients were 
matched with 20 node positive patients with adenocarcinoma 
of the pancreas undergoing pancreatoduodenectomy. The 
node positive patients had signifi cantly (p < 0.02) less fi bro-
sis and more adipocytes in the pancreatic neck as well as 
signifi cantly (p < 0.05) more adipocytes in the tumor micro-
environment. As expected, the node positive patients had a 
signifi cantly (p < 0.04) shorter survival.
These data suggest that pancreatic steatosis and adipocytes 
within the tumor microenvironment promote the dissemina-
tion and lethality of human pancreatic cancer.
C-080
THE ROLE OF PET IMAGING AND EUS 
IN PANCREATIC CANCER
B. N. J. Thomson
Peter MacCallum Cancer Centre, Melbourne; Royal 
Melbourne Hospital, Melbourne, Australia
The treatment of pancreatic adenocarcinoma remains prob-
lematic particularly due to the presence of metastatic disease 
even in small tumors. Approximately 95% of patients have 
lymph node metastases, local vascular involvement or distant 
metastatic disease at the time of diagnosis.
Computed tomography (CT) in combination with positron 
emission tomography with 19-fl ourodeoxyglucose (FDG 
CT-PET) is not currently medicare approved for staging or 
diagnosis of pancreatic cancer in Australia. The sensitivity 
of CT-PET is similar to CT in the detection of the pancreatic 
primary as well as metastatic disease. Detection of involved 
lymph nodes is higher, however the clinical signifi cance of 
such of fi nding remains unclear. The evidence for CT-PET 
to differentiate adenocarcinoma from chronic pancreatitis is 
also weak.
In comparison endoscopic ultrasound (EUS) has emerged 
as an important investigation for pancreatic cancer. Fine 
needle aspiration cytology allows defi nitive diagnosis prior 
to consideration of surgery, pre-operative chemoradiotherapy 
or palliative treatment. It has excellent utility in the detection 
and diagnosis of small pancreatic tumors as well as the 
assessment of local vascular invasion in locally advanced 
pancreatic cancer.
C-081
PANCREATODUODENECTOMY 
SHOULD BE PERFORMED AS A 
PALLIATIVE PROCEDURE FOR 
PANCREATIC CANCER
(for the ‘Yes’ side of the debate)
D. G. Chhabra
Department of Surgical Oncology. Dr. L.H. Hiranandani 
Hospital (Powai), Mumbai, India
Earlier, many considered pancreatoduodenectomy (PD) to be 
‘palliative’ as survival was dismal despite resection. This 
nihilistic attitude has turned to cautious optimism. Recently 
more aggressive surgical approach has emerged in managing 
pancreatic cancers due to declining morbidity, mortality and 
improved survival with PD. PD as a palliative treatment can 
be considered in carefully selected patients in high-volume 
centers. Currently, most palliative resections take place in 
operations with curative intention when irresectability is 
established after a ‘point of no return’ or, in R1-situation 
when the histopathology shows microscopically-involved 
resection margins. Implementation of Leeds protocol has 
resulted in increased recognition of R1 status in most high 
volume centers where resections have long been categorized 
R0. Thus in the oncological view, R1 resections are consid-
ered ‘palliative’. Despite this fact, studies have reported sig-
nifi cantly prolonged overall survival after PD in patients with 
positive surgical margins compared to unresectable patients 
palliated with biliary and/or gastric bypass. There is no evi-
dence based data comparing palliative resections with bypass 
procedures. A palliative PD can be considered in patients with 
a solitary liver deposit (limited liver metastases) as long as R0 
resection is warranted. Limited data is available on Quality of 
Life (QoL) after palliative pancreatic surgery; however it is 
clear that surgical techniques of resection and reconstruction 
do not affect QoL. A palliative PD may improve the effects of 
additional palliative chemo/radio-therapy. It is emphasized 
that successful palliative surgery depends on the ability of the 
institution to provide a safe operation with minimal peri-
operative morbidity and mortality.
C-082
PANCREATODUODENECTOMY 
SHOULD BE PERFORMED AS A 
PALLIATIVE PROCEDURE FOR 
PANCREATIC CANCER
(for the ‘No’ side of the debate)
S. V. Shrikhande
Tata Memorial Centre, Mumbai, India
Pancreatic cancer (PC) remains a dismal disease and the 
principal reason for its aggressive behavior is the number of 
growth promoting pathways that are active in this disease. 
The characteristic feature of PC is early involvement of ret-
roperitoneal nerves and lymph nodes with development of 
early metastases.
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Pancreatoduodenectomy (PD) is the only curative option 
for PC. This is a demanding procedure with a steep learning 
curve where the morbidity is 20–30% and mortality is 3–5% 
even in centers of excellence. Superior survival after PD is 
reported in node negative compared to node positive PC. The 
Leeds protocol for standardized reporting of PD specimens 
has regenerated interest amongst surgeons with regard to 
completeness of resections. Some series, reevaluating their 
R0 resections with the new Leeds protocol, observed that a 
number of them were in fact R1 resections. Such observa-
tions have pushed pancreatic specialists towards improving 
R0 resection rates. Neoadjuvant chemoradiotherapy, the 
uncinate fi rst technique and SMA fi rst approach have been 
important advances in that direction.
Thus, a major resection like PD should be offered only 
after a careful evaluation of the risk benefi t ratio in the indi-
vidual patient. R0 resections (and occasionally the inevitable 
R1 resection) should be the standard of care in high volume 
centers. On the background that curative R0 resections have 
superior survival rates compared to R1/R2 resections, pallia-
tive PD as a procedure is diffi cult to justify in an era that has 
witnessed impressive strides in chemoradiotherapy, targeted 
therapy, therapeutic endoscopy and interventional radiology.
C-083
PURE LAPAROSCOPIC MEDIAL AND 
VENTRO-ANTERIOR SECTIONECTOMY 
FOR HEPATOCELLULAR CARCINOMA
G. Wakabayashi
Department of Surgery, Iwate Medical University School of 
Medicine, Japan
Anatomical liver resection appears to be superior to non-
anatomical liver resection both in operative and oncological 
results. We present a case to describe pure laparoscopic ana-
tomical liver resection for HCC with poor hepatic reserve.
Case presentation: A 68 y/o male patient with HCV nega-
tive and HBV negative was referred to our institute for resec-
tion of a relatively large HCC (6.5 cm in diameter) located 
in S4 and S5/8. Central bisectionectomy was initially 
planned, but the hepatic reserve was estimated moderately 
poor. Child-Pugh score was grade A but indocyanine green 
(ICG) clearance was 20% at 15 min. The HCC was located 
mainly in S4 and ventro-anterior sector leaving caudal S5 
intact. The tumor seems to be compressing the middle 
hepatic vein (MHV) from ventral to dorsal side but not adja-
cent to the MHV. 
Operative procedure: Anatomical liver resection was per-
formed by Glissonian approach at the hilar plate. Several 
Glissons into S4 were clipped and divided at the right side 
of the ligamentum teres hepatis. Parenchymal transection 
fi rst started from the left margin of S4, then along the falci-
form ligament, and fi nished at the root of MHV. At this stage, 
the Cantlie line was visualized because the left medial sector 
was devascularized. Parenchymal transection continued to 
prepare the anterior trunk. Several Glissons coming ventrally 
from the anterior trunk into the ventro-anterior sector were 
clipped and divided leaving caudal S5 vascularized. The 
demarcation line moved from the Cantlie line to the border 
of the ventral and the dorsal part of anterior sector. 
Parenchymal transection along the right margin of the ven-
tro-anterior sector fi nished at the root of MHV. The root of 
MHV was stapled and divided. 
Results: Operative time was 424 min and blood loss was 
76 ml. The resected liver was 256 g. The patient was 
discharged on the 7th post-operative day without having 
any complications.
C-084
MASTER VIDEO SESSION: 
LIVER TRANSPLANTATION FOR 
HYDATID DISEASE
H. Wen
Abstract not available at time of publication.
C-085
RADICAL R HEPATECTOMY EXTENDED 
TO IVC FOR E ALVEOLARIS
G. A. Mantion and M. Ayav
University Hospital Besançon, France
This movie concerns the case of a 46 years old man with a 
right liver EA lesion treated with albendazole since 5 years. 
Due to radiological progression of the lesion and inferior 
vena cava (IVC) a radical resection was attempted including 
“en bloc” right hepatectomy, retrohepatic IVC and dia-
phragm. IVC reconstruction used a charrière 16 ringed PTFE 
prosthetic graft with an omental wrap. The patient was dis-
charged at day 10 and a treatment with albenzadole was given 
for two years with long term anticoagulation. The discussion 
will concern the benefi t of radical Ro resection in locally 
advanced AE and the interest of IVC reconstruction.
C-086
FREY’S OPERATION FOR 
CHRONIC PANCREATITIS
A. Chaudhary
Medanta Medicit Hospital, Delhi, India
This video demonstrates the technique of performing head 
coring and pancreaticojejunostomy for chronic pancreatitis. 
The procedure was performed in a young male with persis-
tent abdominal pain.
C-087
ROBOTIC-ASSISTED LAPAROSCOPIC 
ANATOMIC RIGHT HEPATECTOMY
J. H. Dong
Hospital & Institute of Hepatobiliary Surgery, Chinese 
PLA General Hospital, Beijing, China
Background: The surgical robotic system is superior to tra-
ditional laparoscopy in regards to 3-dimensional images and 
better instrumentations. Robotic surgery for hepatic resection 
has not yet been extensively reported. The fi rst case of 
robotic-assisted laparoscopic anatomic right hepatectomy in 
China was performed at our institution in July 2009. This 
video will show the pertinent steps to perform a robotic-
assisted laparoscopic anatomic right hepatectomy. 
Methods: A 53-year-old man with right-sided intrahepatic 
cholangiocarcinoma was referred for surgical treatment. The 
robotic-assisted laparoscopic anatomic right hepatectomy 
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was performed. Liver mobilization and cholecystectomy 
were performed in the usual fashion. After dissection and 
division of the right hepatic artery, right portal vein and right 
hepatic duct, parenchymal transection was performed with 
harmonic curved shears and bipolar electrocautery. The 
branches of the middle hepatic vein to segments V and VIII 
were either ligated intraparenchymally with Hem-o-lock 
clips or controlled by suture ligation with monofi lament 
suture. Right hepatic vein and connective liver tissue were 
transected with an endoscopic stapling device. The specimen 
was extracted through a suprapubic incision using an 
endobag. A single abdominal drainage was placed in the 
subphrenic space. No Pringles’ maneuver was used. 
Results: The operative time was 520 min, and the blood loss 
was 500 ml, with no blood transfusion. The surgical resection 
margins were free of tumor. The postoperative recovery was 
uneventful, with discharge on days 6. Until now, no intrahe-
patic recurrences or port-site metastases have been observed 
in this patient. 
Conclusions: Robotic-assisted laparoscopic anatomic right 
hepatectomy is safe and feasible. It should be performed only 
by surgeons with expertise in laparoscopy and hepatobiliary 
surgery.
C-088
SINGLE-PORT LAPAROSCOPIC 
SPLENECTOMY: 13 INITIAL CASES
Y. K. You, H. J. Choi, G. H. Na, T. H. Hong, S. K. Lee, J. 
H. Park, Y. C. Yoon and D. G. Kim
Department of Surgery, Division of HBP Liver 
Transplantation, Seoul St. Mary’s Hospital, The Catholic 
University of Korea, Seoul, Korea
Introduction: Today, laparoscopic surgery has replaced 
open surgery in most abdominal surgeries because there were 
clear benefi ts of laparoscopy over open surgery. Laparoscopic 
splenectomy has been the standard of care for splenic dis-
eases. The pursuit of minimal invasive surgery such as lapa-
roscopic surgery makes a trend toward less invasion and less 
scarring. So, single port laparoscopic surgery is rapidly 
gaining attention worldwide since Navarra published a tran-
sumbilical cholecystectomy technique in 1997. Therefore we 
have attempted the single port laparoscopic splenectomy 
from October, 2008.
Materials and Methods: From October 2008 to July 2011, 
We retrospectively reviewed 13 patients who had undergone 
single-port laparoscopic splenectomy. Preoperative and post-
operative management, including vaccination, was per-
formed in a routine manner. During operation, the patients 
was given a right lateral position as conventional laparo-
scopic splenectomy. A 3 to 5 cm transverse incision at the 
anterior axillary line on umbilicus level or transumbilical 
incision was used as a single-port entry point. We evaluated 
demographics of patients, operative and postoperative 
outcomes.
Results: Among 13 patients, 6 patients were men and 7 
patients were women. The median age was 36 years old 
(13~61) and median operative time was 125 minutes 
(75~245). We experienced no cases that converted to open 
procedure. There was one case that we added one port to 
reinforce GIA suture line. All patients recovered well and 
were discharged without any complications.
Conclusion: We propose that single-port laparoscopic sple-
nectomy is a feasible alternative to multiport conventional 
laparoscopic technique.
C-089
LAPAROSCOPIC CAUDATE LIVER 
RESECTION
X. J. Cai, H. Yu, X. Liang and Y. F. Wang
Department of Surgery, Sir Run Run Shaw Hospital, 
Zhejiang University, Hangzhou, P.R.China
Introduction: The complicated and highly diffi cult laparo-
scopic hepatectomy has been administrated due to surgical 
instrument improvement and experience accumulation. We 
presented here a successful case of laparoscopic resection of 
Spiegel lobe by curettage and aspiration.
Methods: Firstly, we bluntly dissected hepatoduodenal liga-
ment to expose the hepatic artery and identifi ed the extrahe-
patic portion of left hepatic artery branches to Spiegel lobe 
which were clipped and divided.
Then the left inferior border of the fi rst porta hepatis trans-
versal furrow was well exposed by assistant. In there the liver 
capsule and parenchyma was opened and blunt dissected 
with LPMOD and all of the left intrahepatic Glisson branches 
to Spiegel lobe were gradually exposed. The small vessels 
from left hepatic artery and portal vein to Spiegel lobe as 
well as small biliary ducts were identifi ed, isolated, clipped 
and divided.
Third step was disconnecting the Spiegel lobe bridge. The 
Spiegel lobe was gently pushed to the left and the bridge 
parenchymal was dissected along the border of tumor.
Finally, the Spiegel lobe had completed dissociated from 
liver. Subsequently the Spiegel lobe was lift upward to 
expose the retrocaudate short hepatic veins which were 
clipped in sequence of from lower one to upper, from right 
one to left with titanium clips.
Results: The operation was completed laparoscopically. 
Blood loss was 900 ml without transfusion. There were no 
major complications intro and postoperatively.
Conclusions: Laparoscopic resection of Spiegel lobe is a 
feasible and diffi cult laparoscopic surgery.
C-090
HEPATIC RESECTION FOR LARGE 
LIVER TUMORS
C. S. C. Teh
Makati Medical Center, Makati City, Philippines
A brief summary of our results for resection of large liver 
tumors will be presented. This includes resection of tumors 
more than 10 cms in size. A short video presentation of the 
techniques of liver resection using the liver hanging maneu-
ver will be demonstrated. Morbidity and mortality, long term 
outcome and histopathological characteristics will also be 
presented.
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C-091
LAPAROSCOPIC LIVER SURGERY: 
CURRENT STATUS
H.-S. Han
Seoul National University, College of Medicine, Seoul, 
Korea
Recently the indications and application of LLR have been 
changed a lot since its introduction. In early stage, only 
tumorectomy was possible, and major liver resection, such 
as right and left hepatectomy, has been challenging proce-
dures. With encouraging postoperative outcomes after LLR, 
there have been pioneering attempts to apply this procedure 
to more diffi cult cases. Therefore, LLR including major 
resection is more frequently performed recently. Previous 
limitation of laparoscopic approach to posterior and superior 
parts of the liver has been overcome with recent accumula-
tion of experiences as well. Liver resection in the vicinity of 
major vascular structures, such as the hilum, major hepatic 
veins and IVC, is still not indicated in laparoscopic proce-
dure. However, with the accumulation of the experiences, a 
dozen of cases, which are close to major vessels, have been 
performed with laparoscopic liver resection. When we 
perform liver parenchymal resection close to major vascular 
structures, there is high risk of injury to these vessels, which 
may cause massive bleeding, even in open surgery. 
Laparoscopic surgery has similar risks of unwanted mishaps 
as in open surgery, and furthermore, control of bleeding is 
more diffi cult due to limitation of freedom which is inherent 
in laparoscopic procedure. 
To minimize unwanted bleeding is performing anatomical 
liver resection as possible. In anatomical liver resection, the 
liver parenchyma is straightly transected under the guidance 
of the ischemia line after selective ligation of a portal pedicle 
supplying the section or segment where the tumor is located. 
In several series, anatomical liver resection has been shown 
to be more advantageous in performing parenchymal tran-
section and reducing bleeding. In addition, it has theoretical 
advantages of high survival outcomes after resection of HCC 
by eradicating all portion of liver supplied by portal pedicles. 
However, anatomical liver resection except left lateral sec-
tionectomy still remains diffi cult to perform with laparo-
scopic procedure. Laparoscopic CUSA is useful in detecting 
important anatomical structures and decreasing the risk of 
injury to these structures that is more likely to occur after 
blind application of ultrasonic shears. In conclusion, the limi-
tation of LLR for HCC will be overcome if advanced tech-
niques of LLR will be more widely applicable and more 
experiences will accumulate.
C-092
SINGLE INCISION LAPAROSCOPIC 
SURGERY FOR LIVER RESECTION
H. Kaneko
Toho University, Tokyo, Japan
The continuing evolution of laparoscopic surgery, which has 
been rapidly adopted as minimally invasive surgery, has been 
applied to the laparoscopic liver resection. Laparoscopic 
liver resection is a highly specialized fi eld, however, impor-
tant technologic developments and improved endoscopic 
procedures are being established. Thus, laparoscopic hepa-
tectomy has been more actively performed recently. We have 
pursued laparoscopic hepatectomy as a means of surgical 
therapy.
Recently, we have successfully performed laparoscopic 
extended liver resection such as laparoscopic pure-hemi-
hepatectomy, hepatectomy of giant HCC and tumor located 
upper segment, recurrence tumor.
Meanwhile, laparoscopic surgical procedure have begun 
to advance to scar-less technique of single incision laparo-
scopic surgery. It has been applied for liver resection.
In the congress, the technique of the single incision lapa-
roscopic hepatectomy will be shown to the patient with hepa-
tocellular carcinoma. Tumor size was 30 mm, located in Seb 
3. Blood loss was less than 20 ml, operative time 125 min 
with quick recovery.
Single incision laparoscopic hepatectomy appears to be a 
viable surgical alternative in selected cases. This procedure 
is expected to develop further in the future as a new surgical 
method for liver surgery as less invasive surgery although 
the indication is limited to feasible tumor location.
C-093
LAPAROSCOPIC ANATOMICAL LIVER 
RESECTION FOR HEPATOCELLULAR 
CARCINOMA
G. Wakabayashi
Department of Surgery, Iwate Medical University School of 
Medicine, Japan
Background: The introduction of laparoscopic liver resec-
tion has a great impact on liver surgery especially in the 
treatment of hepatocellular carcinoma (HCC). Anatomical 
liver resection appears to be superior to non-anatomical liver 
resection in operative and oncological results. The aim of the 
present study was to describe the procedure of laparoscopic 
anatomical liver resection and to review a single institution's 
experience of laparoscopic liver resection (LLR) including 
totally laparoscopic liver resection (TLLR) and laparoscopy-
assisted liver resection (LALR) as a minimally invasive 
surgery for HCC. 
Methods: Anatomical liver resection was performed by 
Glissonian approach either with TLLR or LALR. Between 
May 1997 and December 2010, 212 patients underwent LLR 
for hepatocellular carcinoma (HCC) (75 patients), liver 
metastases (92), cholangiocellular carcinoma (CCC) (3), car-
cinoid (1), benign liver lesions (16), and living donor (25). 
Operations included 119 TLLR (96 wedge resections, 17 left 
lateral sectionectomies, 4 major anatomical hepatectomy, 
two S5 subsegmentectomy), 93 LALR (2 right trisectionec-
tomy, 16 right hepatectomy, 17 left hepatectomy, 3 central 
bisectionectomy, 5 right anterior sectionectomy, 8 extended 
right posterior sectionectomy, 25 donor hepatectomy, and 
others). Nineteen percent of TLLR, 100% of LALR, and 
67% (141/212) in total, were anatomical liver resection. 
Results: Median operating time was 161, 324 min, and 
blood loss, 57, 546 ml for TLLR, LALR, respectively. One 
TLLR was converted to a LALR. Only ten patients (4.7%) 
experienced postoperative complications, 4 patients (1.9%) 
showed bile leakage, and 6 patients (2.8%) developed wound 
infections. Overall 5-year survival for HCC was 65%. 
Conclusions: Laparoscopic anatomical liver resection can 
be performed safely for a variety of primary, secondary liver 
tumors, and even for live donors. Procedures vary from 
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hybrid to pure technique and seem to offer at least short-term 
benefi ts in selected patients. The number of anatomical 
resections has increased as our experience increases.
C-094
SYMPOSIUM: LAPAROSCOPIC LIVER 
SURGERY: COMPLICATIONS OF 
LAPAROSCOPIC LIVER SURGERY
N. O’Rourke
Abstract not available at time of publication.
C-095
NEW INTERNATIONAL REGISTRY ON 
PERIHILAR CHOLANGIOCARCINOMA
P-A. Clavien
Abstract not available at time of publication.
C-096
STAGING AND PATIENT SELECTION 
FOR HILAR CHOALANGIOCARCINOMA
R. C. Shah and P. Jagannath
Department of Surgical Oncology, Lilavati Hospital & 
Research Centre, Mumbai, India
Goal of accurate preoperative staging in Hilar cholangiocar-
cinoma is to identify patients who demonstrate clinical or 
radiological conditions that would offer curable resection. 
Staging essentially involves assessment of ductal extent, 
periductal extension into soft tissue including Hepatic artery, 
Portal Vein and it’s branches, distant metastasis and function 
of future remnant Liver.
For ductal extent invasive methods include ERCP and 
PTC. ERCP underestimates the extent of tumor into primary 
and secondary biliary radicals. PTC has the utility in both, 
to defi ne the biliary anatomy and to decompress the obstructed 
Liver with it’s risk of cholangitis. Non invasive imaging of 
MRI/MRC has an accuracy of 90% and it has become 
primary imaging modality. Triphasic MDCT has sensitivity 
of 92% and specifi city of 100% in assessment of vascular 
involvement. CT and MRI are useful with 85% of sensitivity 
it should be done before stenting.
Evaluation of nodal status has been diffi cult. EUS with 
FNA has accuracy of 90%, CT accuracy is up to 50% and 
MRI up to 60%. PET-CT results are discordant from 15–86%. 
PET-CT has reliability up to 70 to 80% for distant 
metastasis.
Preoperative workup fails to ascertain the presence of peri-
toneal and hepatic metastasis which can only be seen on 
laparoscopy in 15 to 25%.
In jaundice without signs of infection or lobar atrophy, one 
can proceed to surgery after staging. In presence of cholan-
gitis, preoperative biliary drainage is mandatory, preferably 
unilateral on the future remnant liver. If the future remnant 
liver is less than 30–40% portal vein embolization with pre-
ventive biliary drainage is preferred.
C-097
SURGICAL STRATEGIES IN HILAR 
CHOLANGIOCARCINOMA
D. W. Choi
Samsung Medical Center Department of Surgery, 
Sungkyunkwan University School of Medicine, Seoul, Korea
Hilar cholangiocarcinoma was fi rstly described by Klatskin 
in 1965. He suggested that palliative surgery aimed at reliev-
ing biliary obstruction may restore the patient to a good state 
of health for a remarkably long period of time.
In 1980’s, efforts to resect this tumor were made, especially 
from UCLA, but combined liver resection was not accepted 
due to high postoperative mortality and low radicality. They 
insisted that curative resection was recommended when it was 
can be done without a concomitant hepatic resection.
In 1990’s, several excellent surgeon, including professor 
Nimura from Nagoya University, reported improved postop-
erative survival rates with combined hepatic resection. 
Professor Nimura suggested that curative resection should be 
designed according to the preoperative fi nding of the extent 
of cancer in each segmental duct, and caudate lobe resection 
should be performed together with hepatic segmentectomy.
On the other hand, Neuhaus from Berlin, Germany 
reported that combined hepatic resection should be regarded 
as the surgical procedure of choice. In addition, right trisec-
tionectomy with portal vein resection can offer best long-
term survival in terms of tumor biology and anatomical 
considerations in 1999. According to the large scaled report 
from MSKCC, they suggested that margin status is one of 
the important prognostic factors, and combined hepatectomy 
for hilar cholangiocarcinoma can offer best chance of radical 
R0 resection resulting in better survival. When D’Angellica 
from MSKCC analyzed several papers on the treatment for 
hialr cholangiocarcinoma, he elucidated that increased 
resectability and R0 resection rates can be obtained follow-
ing hepatic resection.
There are still controversies on the extent of hepatic resec-
tion, because extensive hepatic resection which may bring 
the best chance of R0 resection, is not always safe. Therefore, 
parenchymal preserving hepatic resection will be required to 
avoid the risk of postoperative liver failure. But, extensive 
liver resection including right trisectionectomy with caudate 
lobectomy can be required to achieve R0 resection for 
advanced hilar cholangiocarcinoma. Because the extensive 
liver resection for cholestatic liver is likely to bring about 
liver failure, preoperative management such as preoperative 
biliary drainage or preoperative portal vein embolization 
should be necessary. However, a consensus on the safe level 
of preoperative bilirubin level or safe future remnant liver 
volume to avoid the liver failure is lacking, now.
Anyway, we need to carry out liver resection including 
vascular resection with/without preoperative biliary drainage 
and portal vein embolization for hilar cholangiocarcinoma 
according to precise preoperative evaluation of this tumor.
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C-098
PREOPERATIVE PORTAL VEIN 
EMBOLIZATION IN HILAR 
CHOLANGIOCARCINOMA
X. Q. Jiang1, B. Yi1, Q. B. Cheng1, Z. Q. Qu1, A. M. Xu1, 
W. Y. Lau1,2 and M. C. Wu1
1Eastern Hepatobiliary Surgery Hospital, Second Military 
University, Shanghai, China; 2Faculty of Medicine, The 
Chinese University of Hong Kong, Hong Kong, China
Introduction: Portal vein embolization (PVE) increases the 
volume of future liver remnant (FLR) and thereby decreases 
the risk of postoperative liver failure. However, a few have 
reported PVE before major hepatectomy for hilar cholangio-
carcinoma due to the small number of surgery cases.
Methods: Between Jan 2007 and Jan 2010, 71 consecutive 
patients with hilar cholangiocarcinoma who were scheduled 
to receive major hepatectomy were involved in this study. 
All PVEs were performed in patients with an estimated FLR 
of <50%. Hepatic volume and function changes after PVE 
were analyzed, and operative outcomes were compared 
between patients with or without PVE.
Results: PVE procedures were performed in 27 patients. 
PVE-related complications occurred in 6 patients (22.2%) 
and did not preclude hepatectomy, which included bile 
leakage (n = 1) and coil displacement (n = 5). Two weeks 
after PVE, the FLR to total liver volume ratio increased 
statistically (40.7 ± 7.2% vs. 44.8 ± 6.9%; p < 0.001), and 
the mean increase in FLR was 4.9 ± 3.4 cm3/day. In the PVE 
group, 21 patients (77.7%) underwent radical surgery, and 
the rest were precluded because of insuffi cient hypertrophy 
of FLR and tumor dissemination. The PVE group had similar 
operative mortality and morbidity compared to the non-PVE 
group. The 1- and 2-year survivals for PVE group (radical 
surgery only) and non-PVE group were 72.5% and 54.2%; 
70.7% and 53.7%, respectively. There was no signifi cant 
difference of survival.
Conclusions: PVE is a safe and effi cacious procedure, and 
offers potential benefi t for patients in hilar cholangiocarci-
noma with small FLR.
C-099
SURGICAL TECHNIQUES FOR HILAR 
CHOLANGIOCARCINOMA: RIGHT OR 
LEFT HEPATECTOMY
M. Masaru, S. Hiroaki, O. Masayuki, Y. Hiroyuki, I. K. 
Atsushi, K. Fumio, Y. Hideyuki and F. Katsunori
Department of General Surgery, Chiba University, Chiba, 
Japan
Introduction: When you consider the appropriate surgical 
procedure for the patient with hilar cholangiocarcinoma, 
you should evaluate from the three points of views. 
Hepatectomy, Combined vascular resection, and combined 
pancreaticoduodenectomy.
Methods & Results: In hepatectomy, there are several pro-
cedures of hepatectomy for the surgical treatment of hilar 
cholangiocarcinoma. Right sided hepatectomy, left sided 
hepatectomy, central hepatectomy such as parenchyma-
preserving hepatectomy, extended hilar bile duct resection 
using transhepatic anterior approach.
The second issue for appropriate surgical resection is com-
bined vascular resection. Portal vein, hepatic artery, and 
hepatic vein are usually involved by hilar cholangiocarcino-
mas. Surgical margin-free, curative resection has brought 
about 37% of 5-year survival. On the contrary, non-curative 
resection has resulted in 5.6% of 5-year survival, which was 
signifi cantly worse than that of the curative resection group, 
but signifi cantly better than the survival of the irresectable 
patients.
In the curative resection, the non-vascular resection group 
had signifi cantly better survival than the vascular resection 
group, 42% of 5-year survival rate. However, the portal vein 
resection alone seems to be more benefi cial than the hepatic 
artery resection group, which brought about 21% of 5-year 
survival rate. Morbidity rate for left-sided hepatectomy was 
almost the same as for right-sided hepatectomy. However 
bilioenteric anastomotic leakage occurred in 18% in left-
sided hepatectomy. Surgical mortality rate was relatively 
high in right-sided hepatectomy, but was not statistically 
signifi cant. In the cases of left-sided hepatectomy, only 2 
independent factors infl uencing survival were revealed by 
multivariate analysis, curability and hepatic artery resection. 
In contrast in the cases of right-sided hepatectomy, multivari-
ate analysis demonstrated curability, lymph node metastases, 
and hepatic artery resection as independent prognostic 
factors. The survival after resection was not signifi cantly 
different between two groups of right-sided and left-sided 
hepatectomies. In the cases of combined portal vein resec-
tion, survival of left-sided hepatectomy was comparable to 
that of right-sided hepatectomy. Since left-sided hepatec-
tomy is a safe procedure and represents the only curative 
resectional option for type IIIb tumor, aggressive surgical 
resection should be performed even in cases with portal vein 
involvement.
Conclusions: Appropriate surgical procedures should be 
selected on the basis of preoperative imaging fi ndings of 
cancer extension and surgical fi tness of the patients among 
variable operative procedures.
Both of right- and left-sided hepatectomies could be appli-
cable to the patients with hilar cholangiocarcinoma as a suit-
able surgical procedure for obtaining a curative resection.
C-100
ANATOMICAL VARIATIONS IN THE 
SURGICAL TREATMENT OF HILAR 
CHOLANGIOCELLULAR CARCINOMA
Y. J. Lee
Seoul Asan Medical Center, College of Medicine, Ulsan 
University, Seoul, South Korea
Introduction: Surgical resection in Hilar cholangiocellular 
carcinoma is based on the Bisthmus classifi cation Normal 
variations in bile duct, hepatic artery and portal vein are very 
common and these anatomic variation should be considered 
in the surgical resection. Based on our experience, new 
guidelines have been used in the surgical decision making.
Methods: A total of 101 patients underwent surgery for hilar 
cholangiocarcinoma by a single surgeon at the Asan Medical 
Center. Clinical, radiological, and pathological data were 
analyzed retrospectively. Concomitant hepatic resection was 
performed in 64 patients, of whom 39 underwent conven-
tional resection (period I; 2004–2006), and 25 underwent 
surgery using the new guidelines (period II; 2007–2008).
The new guidelines were: a left hepatectomy for right-
sided HA variations such as a replaced RHA from the supe-
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rior mesenteric artery, an accessory RHA, and an early 
dividing HA; a right hepatectomy for left-sided HA varia-
tions such as a replaced LHA from the left gastric artery, an 
accessory LHA, and an early dividing HA; a right hepatec-
tomy for type I PV, and a left hepatectomy for PV types II, 
III and IV; a right hepatectomy for type A bile ducts; and a 
right hepatectomy or left trisectionectomy for types B and C 
bile ducts (Seyama’s bile duct classifi cation).
Results: There was no signifi cant difference in the clinical 
and radiological outcomes between the groups. The positive 
proximal margin rate was lower in period II than period I 
patients (8% (2/25) vs 31% (12/39)).
Conclusions: New hilar cholangiocarcinoma resection 
guidelines were developed based on a thorough preoperative 
assessment of the anatomy of hilar bilio-vascular structures. 
Application of these guidelines resulted in an improved 
proximal R0 resection rate.
C-101
A NEW APPROACH FOR THE 
TREATMENT OF HILAR CC 
WITH INVASION OF THE 
CONTRALATERAL SIDE
J. Iniesta, F. A. Alvarez and E. de Santibañes
Sección de Cirugía Hepatobiliopancreática, Hospital 
Italiano de Buenos Aires-Argentina
Introduction: Recent advances in liver surgery have led to 
a more effi cient approach of hilar cholangiocarcinoma 
(CCH). En-block resection of liver parenchyma with the 
extrahepatic bile duct is mandatory to obtain tumor-free sur-
gical margins and better long-term outcomes. One of the 
most important criteria for irresectability is the local exten-
sive invasion to major vessels. Since the CCH Bismuth IIIB 
often requires a left hepatectomy extended to the right ante-
rior segments, the invasion of the right hepatic artery (RHA) 
usually contraindicates performing these procedures.
Methods: We describe a novel technique that allowed us to 
carry out an oncological resection in two patients with CCH 
Bismuth IIIB and contralateral arterial invasion. By means 
of microsurgery an arterial reconstruction is made as the fi rst 
step between the posterior branch of the RHA and the 
common hepatic artery. Once arterial vascular fl ow is 
restored, left trisectionectomy with caudate lobe resection is 
done with or without portal vein reconstruction if needed.
Results: Neither patient developed postoperative complica-
tions. 18 months after surgery both are free of disease.
Conclusions: In patients with CCH, HA resection is associ-
ated with a higher operative mortality rate than PV resection 
due to the fact that most times the HA resection needs the 
combination of PV resection with longer periods of liver 
ischemia. This new surgical technique allows achieving a 
complete resection (R0) with less severe ischemic damage 
to the remnant liver and might improve the outcome in the 
selected patients with locally advanced CCH.
C-102
LONG OUTCOMES FOLLOWING 
VASCULAR RECONSTRUCTION FOR 
HILAR CHOLANGIOCARCINOMA
J. H. Dong and C. H. Xiang
Hospital & Institute of Hepatobiliary Surgery, Chinese 
PLA General Hospital, Beijing, China
Radical surgical resection has been revealed to be the only 
hope of cure for the patient with hilar cholangiocarcinoma. 
Therefore, major efforts have been made to increase the 
resection rate by surgeons employing combined hepatic 
resection and vascular resection of the portal vein and the 
hepatic artery.
The technical feasibility and surgical safety of hepatic 
resection with combined portal vein resection have recently 
been reported by several authors and they found no signifi -
cant difference between patients with and without portal vein 
resection in the occurrence of complications and mortality 
rates. 
The impact of portal vein resection on long-term survival 
is less clear. Multiple other studies have shown equivalent or 
worse survival in patient undergoing en bloc resection of the 
portal vein. In Ebata’s group, the 5-year survival rates were 
9.9% and 36.8%, respectively, being signifi cantly lower in 
patients with portal vein resection. According to the authors, 
portal vein resection contributed to long-term survival in a 
small number of patients with advanced cancer. In Miyazaki’s 
group, the 5-year survival rates in patients with curative 
resection were 25% and 41% for those receiving combined 
portal vein resection and those receiving nonvascular resec-
tion, respectively. Although the prognosis was signifi cantly 
poorer in patients with combined vascular resection, it 
was better compared with that in unresectable patients. 
Considering the difference of disease stage, more suffi cient 
scientifi c evidence are needed to clarify the signifi cance of 
combined portal vein resection.
On the other hand, there have been few reports of com-
bined hepatic artery resection in hilar cholangiocarcinoma. 
Most of the previous studies involved less than or about 10 
patients, showed negative results, and did not recommend 
combined resection of the hepatic artery for biliary cancer. 
Miyazaki et al reported that mortality was 33.3% (3/9) in 
patients who underwent hepatectomy plus hepatic artery 
resection. Furthermore, none of the patients survived for 
more than 3 years. However, Nagino et al reported 50 cases 
of hepatectomy with simultaneous resection of the portal 
vein and hepatic artery for advanced perihilar cholangiocar-
cinoma, the mortality was 2.0% and the 1-, 3-, and 5-year 
survival rates were 78.9%, 36.3%, and 30.3%, respectively, 
suggesting that this surgery can be performed with accept-
able morbidity and mortality by an experienced surgeon and 
offer a better chance of long-term survival in selected 
patients.
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C-103
TREATMENT OF CHOLANGIO 
CARCINOMA ARISING IN PSC
C. W. Pinson
Abstract not available at time of publication.
C-104
NON ALCOHOLIC FATTY LIVER 
DISEASE (NAFLD) – IMPLICATIONS FOR 
LIVER RESECTION AND 
TRANSPLANTATION
M. Rela
Abstract not available at time of publication.
C-105
MINIMIZING ISCHEMIA REPERFUSION 
INJURY IN LIVER SURGERY
J. Lendoire
Liver & Transplant Division, Hospital Dr Cosme Argerich, 
Buenos Aires, Argentina
Ischemia/reperfusion injury (IRI) is an inevitable pathophys-
iologic process still relevant due to its strong association with 
increased morbidity and mortality after liver resection. It 
includes a direct cellular injury as the result of ischemic 
insult and a delayed dysfunction and damage due to activa-
tion of infl ammatory pathways. Various methods have been 
attempted to limit the adverse consequences of IRI and 
improve function and regeneration of the remnant liver. 
Protective strategies proposed can be divided in the follow-
ing categories: surgical interventions, pharmacological inter-
ventions and gene therapy. Most relevant surgical strategies 
described are: intermittent clamping and ischemic precondi-
tioning preconditioning (IPC). Among the different methods 
of vascular occlusion, intermittent portal triad clamping has 
most evidence to support the clinical application. IPC dem-
onstrated benefi cial effects in human liver surgery, princi-
pally in specifi c groups such as young patients and patients 
with liver steatosis or cirrhosis. In a systematic review of 
randomized controlled trials, IPC showed that reduces blood 
transfusion requirements and decreases the enzymes markers 
of liver parenchymal injury after liver resections performed 
under vascular control but without clinical benefi t. New trials 
are necessary to assess the role of IPC according to type 
of resections, parenchymal characteristics and surgical 
approach. In reference to pharmacologic interventions 
several agents may have protective roles against IRI like 
methylprednisolone, trimetazidine, dextrose and ulinastatin. 
Based on current evidence they cannot be recommended for 
routine use in liver resection. Further research investigating 
how the immune system is activated after IRI may lead to 
develop novel protective strategies.
C-106
ENHANCING LIVER REGENERATION IN 
LIVER SURGERY
T. Van Gulik
Department of Surgery, Academic Medical Center, 
University of Amsterdam, Amsterdam, The Netherlands
The ability of the liver to regenerate is one of the most 
intriguing phenomena in liver physiology. In the regenerat-
ing liver, parenchymal cells divide at increased rate leading 
to an increase in volume of the regenerating (part of the) 
liver. 
One of the most effective methods to enhance liver regen-
eration is to occlude one of the main branches of the portal 
vein, either by ligation or (percutaneous) embolization. This 
will lead a compensatory hypertrophy of the liver segments 
with still complete portal venous perfusion, at the expense 
of atrophy of the liver segments in which portal venous fl ow 
is arrested. As a preoperative procedure or in two-stage liver 
resection, this allows for a larger volume of future remnant 
liver. Interestingly, selective hepatic arterial occlusion alone, 
will usually not result in ipsilateral atrophy and contralateral 
hypertrophy of the liver lobes. Sequential arterial and portal 
venous embolization however, is effective in boosting regen-
eration in the contralateral liver, while suppressing tumor 
growth during regeneration. There is little evidence that the 
combination of portal venous and hepatic venous occlusion 
increases the effi cacy of liver regeneration as compared to 
portal venous occlusion alone.
The factors mediating liver regeneration are poorly 
defi ned. Parenchymal perfusion, regeneration-specifi c cyto-
kines, growth factors and metabolic factors probably play a 
synergistic role. There are no confi rmed, clinically effective 
pharmacological interventions to enhance liver regeneration. 
Several experimental studies have shown that local tissue 
damage and selective administration of hormones such as 
erythropoietin potentially enhance liver regeneration.
C-107
STRATEGIES TO PRESERVE THE 
FUTURE LIVER REMNANT
G. Starkey
Abstract not available at time of publication.
C-108
MINIMIZING BLEEDING IN LIVER 
SURGERY: OPTIMUM ANAESTHESIA
N. Scurrah
Austin Health, Victoria, Australia
Major blood loss and the transfusion of allogeneic red cells 
is associated with adverse outcome in surgery. Historically, 
controlling blood loss and minimising transfusion require-
ment has fallen solely in the surgical domain. Increasingly, 
particularly in liver surgery, the importance of anaesthesia 
management is being recognised. During this session I will 
touch on general measures including temperature and guided 
coagulation management and discuss special techniques, 
some controversial, including low CVP anaesthesia, acute 
normovolemic hemodilution, epidural analgesia and intraop-
erative blood salvage.
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C-109
LOCAL HAEMOSTATIC AGENTS IN 
LIVER SURGERY
M. Brooke-Smith
Flinders Medical Centre, Bedford Park, Australia
Surgeons in the past have been reluctant to operate on the 
liver partly because it has a propensity to bleed. Liver dys-
function can also be associated with a coagulopathy which 
worsens this tendency. With understanding of the anatomical 
arrangement of the liver vasculature, understanding of paren-
chymal dissection techniques and improved anaesthetic man-
agement, more aggressive liver surgery is undertaken. Many 
technologies have been tried to locally enhance haemostasis, 
ranging from coagulation devices to topical haemostatic 
agents. The use of and the evidence of their effectiveness of 
these products will be discussed.
C-110
SYMPOSIUM: MINIMIZING BLEEDING 
IN LIVER SURGERY: SURGICAL 
TECHNIQUES AND TIPS IN MINIMIZING 
OPERATIVE BLOOD LOSS
T. C. Gamblin
Abstract not available at time of publication.
C-111
THE ROLE OF PANCREATIC 
ENUCLEATION IN 
PANCREATIC SURGERY
H. A. Pitt
Indiana University, Indianapolis, USA
At high-volume centers the mortality of pancreatic surgery 
has improved over the past four decades. As a result, the most 
common procedures performed for small neuroendocrine 
and cystic tumors of the pancreas are pancreatoduodenec-
tomy and distal pancreatectomy. However, the short- and 
long-term morbidity of a major pancreatic resection remains 
high. Thus, debate continues as to whether small benign and 
premalignant lesions of the pancreas should be observed or 
resected. In comparison, enucleation is a low-risk procedure 
which preserves pancreatic parenchyma and function. Thus, 
pancreatic enucleation may be an underutilized procedure 
that should be considered for small, frequently asymptom-
atic, pancreatic lesions that, if observed, have the potential 
to grow and metastasize.
Three recent studies have demonstrated that enucleation 
has advantages over resection. Analysis of the American 
College of Surgeons – National Surgical Quality Improvement 
Program database has shown that the relative mortality of 
enucleation is dramatically lower than for both distal pancre-
atectomy and pancreatoduodenectomy. Another comparative 
study of patients with small neuroendocrine tumors from 
four Midwestern university hospitals also demonstrated that 
short-term outcomes were better for patients with lesions in 
the pancreatic head and uncinate. Another case-control study 
from Indiana University has shown that enucleation is asso-
ciated with signifi cantly (p < 0.05) shorter operative time, 
blood loss, need for an ICU stay and serious postoperative 
complications as well as less subsequent endocrine and exo-
crine insuffi ciency.
Thus, for small benign and premalignant pancreatic 
lesions, enucleation should be considered the procedure of 
choice when technically appropriate.
C-112
LOCO-REGIONAL THERAPIES FOR 
PANCREATIC MALIGNANCY
I. Frigerio
Introduction: Radical resection, in combination with adju-
vant therapy, is reportedly the only strategy able to affect 
the prognosis of patients affected by pancreatic cancer. 
Unfortunately, the biggest majority of patients presents a 
locally advanced stage of disease at presentation (LAPC) 
being, as a consequence, no longer candidate for radical 
resection. At these stages, standard treatments are considered 
the combination of chemotherapy and radiotherapy for 
locally advanced disease, and chemotherapy alone for the 
metastatic setting. Encouraging results seems to come from 
locally ablative methods, such as radiofrequency, brachi-
therapy and cryosurgery techniques.
Aim: We briefl y analyze the different ablative techniques 
and report our experience in RFA ablation of LAPC with 
particular interest in feasibility, safety and effi cacy.
Patients and Methods: All patients with LAPC (diagnosis 
based on citology) were treated with RFA during laparotomy 
as fi rst step treatment or after different association of chemo-
radiotherapy, and received palliative surgery associated 
when needed. Pancreatic fi stula, acute pancreatitis, duodenal 
injuries and portal thrombosis were considered RFA related 
complications. After surgery patients were sent to the oncol-
ogist to begin or complete the adjuvant treatment and were 
revaluated every three months. For effi cacy evaluation only 
patients with a minimum of 12 months follow up were 
considered.
Results: One hundred and forty-eight patients underwent 
RFA between February 2007 and March 2011; of those, 82 
had a minimum follow-up of 12 months, and were consid-
ered eligible for the current analysis. When RFA was not 
performed as up-front treatment (n = 35; 42.7%), it followed 
different associations of chemo- and radiotherapy, with a 
median interval between diagnosis and RFA of 6 months. In 
46 cases (56.1%) RFA was performed together with pallia-
tive surgery. In particular, biliary by-pass was carried out in 
8 (9.8%) patients, digestive by-pass in 10 (12.2%), double 
by-pass in 27 (32.9%), and a pancreatico-jejunostomy in one 
patient. Forty out of 46 (87%) surgical palliations were per-
formed for tumors located in the pancreatic head. RFA 
related complications occurred in 9.4% of cases but none 
required re-operation. Mortality due to the procedure was 
3.7%. The Ca 19.9 serum levels decreased from a median 
preoperative value of 109.50 U/mL (range: 4–2558) to 
52.5 U/mL (range: 9–880) one week after RFA (P = 0.237). 
Median length of follow-up was 13 months (Range: 1–35). 
During follow-up, 40 (48.8%) patients died of their disease 
and 5 (6.1%) for causes non-related to primary tumor. 
Median disease-specifi c survival (DSS) was 20 months (95% 
CI: 13.1–26.3), and 2-year DSS rate was 46%. The progres-
sion-free survival (PFS) rate at 1 year was 33% with a 
median of (95% CI: 6.3–11.7). The 2-year disease-specifi c 
survival was 50% and 38% in both groups, respectively (P 
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= 0.257). Disease-specifi c survival was not different between 
patients who received upfront RFA and patients who were 
treated with upfront chemo-radiotherapy (2-year survival, 
47% and 45%, P = 0.363) (fi gure 4). During follow-up, 
within those patients who were judged to be downstaged 
(n = 12; 14.6%), 4 underwent a R0 pancreatic resection. At 
univariate analysis, timing of RFA (before or after chemo-
radiotherapy) did not signifi cantly correlate with a better 
survival rate, (median: 13.4 vs 17 months, respectively; 
P = 0.556).
Conclusions: RFA seems to provide a promising outcome 
in patients affected by unresectable locally advanced pancre-
atic cancer. To address this issue, a phase III trial comparing 
RFA versus surgical exploration along with palliative proce-
dures (when needed), both sequentially integrated with che-
motherapy, is currently ongoing.
C-113
MANAGEMENT OF THE ISOLATED 
METASTASES TO THE PANCREAS
P. Evans
Abstract not available at time of publication.
C-114
R1 RESECTION FOLLOWING PD FOR 
CARCINOMA PANCREAS – PREVENTION 
AND MANAGEMENT
M. D. Smith
Chris Hani Baragwanath Academic Hospital, University of 
the Witwatersrand, Johannesburg, South Africa
Surgery may have reached its maximum benefi t in the man-
agement of carcinoma pancreas. R1 resections have poorer 
survival but with the current reduction in morbidity and 
mortality may still have a role to play in the management of 
these patients. Preventing R1 resections begins with case 
selection and the accuracy of imaging. Surgical technique 
may offer some benefi t and dissection of the SMA may 
reduce positive margins. Vascular resections have been 
shown to benefi t survival. Better histo-pathological reporting 
has identifi ed a greater number of R1 resections. 
Understanding the pathology identifi es areas where this pro-
cedure fails most often. R1 resection may offer better pallia-
tion and quality of life outcomes. The role of adjuvant 
therapy has improved survival in R0 resections but the evi-
dence for a benefi t in R1 resections is less clear. This paper 
focuses on preoperative strategies, intra-operative approaches 
including vascular resections and dissection of the superior 
mesenteric artery. The role of adjuvant therapy will be dealt 
with briefl y.
C-115
MANAGEMENT OF PREOPERATIVE 
JAUNDICE IN PATIENTS WITH 
PANCREATOBILIARY MALIGNANCY
I. C. Cameron
Queens Medical Centre, Nottingham, UK
Introduction: The relative merits of preoperative interven-
tion to establish biliary drainage in patients undergoing 
surgery for peripancreatic malignancy has been debated 
extensively over the past two decades.
Methods: Studies debating the potential advantages and 
disadvantages of routinely draining jaundice before major 
pancreatic surgery have been reviewed, and the results to be 
presented will focus on distal obstruction of the common bile 
duct.
Results: Early studies favoured routine drainage of jaundice 
before major surgery as it allowed reversal of many of the 
pathophysiological disturbances seen in jaundiced patients. 
However recent evidence has contradicted this theory and it 
has been shown that preoperative routine biliary drainage 
cannot be justifi ed before major surgery for pancreatobiliary 
malignancy as it is associated with an increased rate of infec-
tive complications. This approach is not always feasible 
however, due to the constraints of different healthcare 
systems, and when necessary drainage may be undertaken 
via the percutaneous transhepatic route, or preferably endo-
scopically in cases of distal bile duct obstruction.
Conclusions: Surgery for pancratobiliary malignancy is 
safe in the presence of undrained jaundice and results in 
fewer postoperative complications. It should be the manage-
ment of choice in situations where it is feasible.
C-116
PROGNOSTIC INDICES OF PANCREATIC 
ADENOCARCINOMA – BEYOND 
CLINICAL AND RADIOLOGICAL 
CRITERIA
S. J. Mulvihill
Huntsman Cancer Institute, University of Utah, Salt Lake 
City, UT, USA
Establishing prognosis in pancreatic cancer has value in 
selection of patients for various treatment options. 
Historically, histologic assessment of cellular characteristics 
such as ductal differentiation, mucin production, nuclear 
arrangement and pleomorphism, and mitotic activity has 
been a mainstay of establishing tumor prognosis. A major 
advance has been the development of the UICC/AJCC TNM 
staging system which, for most cancers, more powerfully 
stratifi es patients by outcome and has proven usefulness in 
identifying patients who may benefi t from certain interven-
tions. In pancreatic cancer, tumor size, invasion of retroperi-
toneal structures or major arteries, nodal involvement and 
resection margin status all are statistically signifi cant factors 
predicting outcome. However, our current staging systems 
have limited usefulness because of overlap of survival curves 
for patients of various stages, their lack of predictability in 
terms of response to therapy, and the reliance on examination 
of resected specimens to establish stage. A strong trend in all 
cancer therapy has been towards multimodal therapies, 
including neoadjuvant treatment. To optimally select patients 
for these treatment pathways, it is becoming increasingly 
important to establish prognosis before the primary tumor is 
resected. Three general strategies are being employed, 
including advances in imaging, particularly functional 
imaging, determination of molecular characteristics from 
small volume tumor biopsies such as fi ne needle aspirations 
or circulating tumor cells, and identifi cation of biomarkers 
in plasma or serum that have either prognostic signifi cance, 
predict response to therapy, or identify novel treatment 
targets.
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Imaging advances: Accurate staging of pancreatic cancer 
includes both an understanding of the extent of the primary 
tumor, especially in terms of vascular and nodal involve-
ment, as well as identifying distant metastases. Empiric evi-
dence from survival curves of early stage, “resectable” 
pancreatic cancer patients shows that we dramatically under-
estimate the presence of distant metastases at the time of 
initial staging. Wider use of functional imaging, including 
FDG-PET, offers the potential for increased sensitivity in 
identifi cation of metastases, but current technology does not 
identify small deposits effectively and has a disadvantage of 
unacceptable specifi city.
Molecular characteristics: An improved understanding of 
the molecular characteristics of pancreatic cancer has 
occurred through study of biopsies and resected specimens. 
Activating point mutations in the K-ras oncogene, overex-
pression of Her-2/neu gene product, and inactivation of the 
p16, p53, SMAD4, and BRCA2 tumor suppression genes are 
hallmarks of this disease. The prognostic signifi cance of 
these genetic alterations is not clear, but may help guide 
approaches to therapy. BRCA2 mutations, for example, 
inhibit DNA repair mechanisms, making these patients more 
responsive to DNA cross-linking agents such as mitomycin-
C. Loss of p53 function is predictive of lack of response to 
drugs that induce apoptosis through p53, such as 5-fl uorou-
racil. The loss of SMAD4 signal transduction protein func-
tion is highly correlated with the presence of metastatic 
disease and poorer prognosis. P21 (CIP1), a cyclin-depend-
ent kinase inhibitor, regulates cell cycle progression through 
inhibition of cyclin D1 and retinoblastoma. Loss of p21(CIP1) 
is associated with poor prognosis in patients undergoing 
adjuvant chemoradiation following pancreatic cancer resec-
tion. Angiogenesis is a hallmark of cancer development, and 
expression of vascular endothelial growth factors (VEGF) in 
pancreatic cancer has been shown to be correlated with 
poorer prognosis. The epithelial adhesion molecule, EpCAM, 
is frequently overexpressed in epithelial cancers and in pan-
creatic cancer its expression has been linked to good prog-
nosis. Conversely, high S100A2 expression has been linked 
to poor prognosis and a metastatic phenotype in resected 
pancreatic cancer. Intensive effort is underway to assess the 
possible value of determination of these and other genetic 
alterations in circulating tumor cells prior to resection.
Biomarkers: Historically, CEA and CA 19-9 were the fi rst 
serum tumor markers examined in pancreatic cancer, and 
both have limited clinical utility. Generally, higher levels of 
these markers and lack of decrease during therapy are adverse 
prognostic factors. Easily measurable markers from blood 
that have high sensitivity and specifi city in pancreatic cancer 
would have value in early diagnosis screening programs – 
currently no markers with suffi cient accuracy are clinically 
useful. Small series suggest that certain markers may have 
prognostic signifi cance. For example, high serum MMP-7 
levels are associated with poor prognosis in resectable 
patients and high serum platelet factor-4 levels are predictive 
of poor prognosis and death related to venous thromboem-
bolism. A compendium of potential biomarkers in pancreatic 
cancer has been published based on upregulation of mRNA 
in tumor tissue, evidence of overexpression at the protein 
level, discrimination or expression in stromal or epithelial 
tumor elements, and presence on cell surface or secretion in 
body fl uids. With these criteria, over 200 molecules have 
been identifi ed as potentially important biomarkers in pan-
creatic cancer. Additionally, identifi cation of circulating 
microRNA may have potential in establishing diagnosis or 
prognosis. For example, miR-21 appears to differentiate 
patients with pancreatic adenocarcinoma from those with 
chronic pancreatitis and miR-196a is associated with poor 
prognosis in adenocarcinoma. Current efforts are underway 
to assess these molecules value as diagnostic, prognostic and 
predictive markers and as potential targets for chemopreven-
tion in high risk patients or therapy in affected patients.
C-117
OPTIMIZING POST OPERATIVE 
MANAGEMENT FOLLOWING 
PANCREATIC SURGERY
O. J. Garden
Abstract not available at time of publication.
C-118
INCIDENTAL CYSTIC LESION OF HOP
S. S. Sikora
Manipal Institute of Liver & Digestive Diseases, Manipal 
Hospital, Bangalore, India
Introduction: Incidentally detected cystic lesions of the 
pancreas presents numerous challenges in terms of diagnosis 
and management
Methods: We present a case of an elderly lady, detected to 
have a cystic lesion in the head of the pancreas on a routine 
ultrasonography of the abdomen for vague abdominal symp-
toms. An evaluation with a contrast enhanced computerized 
tomography, endoscopic ultrasound evaluation and aspira-
tion of fl uid for analysis was performed. The diagnostic 
approach and decision making algorithm is discussed and 
its application and outcome in this particular case is 
discussed.
Conclusions: Evaluation and management of incidental 
cystic lesions in the head of pancreas is best done through a 
well defi ned algorithm.
C-119
CASE PRESENTATION: IPMN
H. Ramesh
Surgical Gastroenterology & Liver Transplantation, 
Lakeshore Hospital & Research Center, Cochin, Kerala, 
India
A 39 year old woman developed abdominal pain and a mass, 
with some deterioration of general health. She sought medical 
attention, and was diagnosed as having chronic pancreatitis 
with a head mass. Surgery was advised, but at operation, the 
lesion was declared as unresectable owing to “portal vein 
infi ltration”. However biopsy from the mass suggested the 
possibility of intraductal papillary mucinous tumor. She lost 
considerable weight, and despite re-evaluation (CA 19–9 was 
152), was not operated, as the resectability was not guaran-
teed. Eventually, she developed obstructive jaundice, and 
was referred to this center. Side viewing endoscopy revealed 
a fi sh mouth appearance and mucin draining out of the 
papilla. She was operated, and two masses (in the head and 
the distal body) were encountered with a dilated pancreatic 
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duct containing mucinous material. She underwent total pan-
creaticoduodenectomy and has remained well and disease 
free over the last 4 years.
C-120
CASE PRESENTATION: CHRONIC 
PANCREATITIS WITH BILIARY 
OBSTRUCTION
A. K. Agarwal
Abstract not available at time of publication.
C-121
PANCREATITIS AND PANCREAS 
DIVISUM
S. Pongprasobchai
Siriraj Hospital, Bangkok, Thailand
Pancreas divisum (PD) is the most common congenital 
anomaly of the pancreas, which accounts for 8% of normal 
population. It is controversial whether the relatively obstruc-
tive outfl ow of Santorini duct in PD can lead to recurrent 
acute pancreatitis (RAP), chronic pancreatitis (CP), or just 
an innocent bystander of idiopathic CP.
Critical reviews showed that the prevalence of PD in 
patients with RAP or CP is probably similar to patients without 
pancreatitis. Isolated dorsal pancreatitis which is the hallmark 
and suggests that PD is a culprit of RAP or CP is not always 
present (30–88%). CFTR and SPINK1 mutations have been 
found commonly in patients with PD and RAP or CP (22% 
and 42%, respectively). There are many case series but there 
is only 1 small RCT on the effi cacy of endoscopic therapy for 
PD in RAP and none exists for CP. The proper endoscopic 
technique is not yet established. Results of the treatment also 
varied but are better in RAP (81%) than CP (69%).
Eventually, careful patient selection for the treatment is 
essential. Suitable patients are likely patients who present 
with RAP (not CP or pancreatic pain only), have isolated 
dorsal pancreatitis (by pancreatogram or EUS), dilated 
Santorini duct, Santorinicele or in the presence of CFTR or 
SPINK1 mutations.
C-122
LAPAROSCOPIC SPLEEN PRESERVING 
DISTAL PANCREATECTOMY
C-K. Ho
Nexus Surgical Associates, Mount Elizabeth Hospital, 
Singapore
Laparoscopic distal pancreatectomy with preservation of the 
spleen is a feasible surgical technique with acceptable 
outcome. The primary intent of spleen preservation is to 
reduce post-operative infectious morbidity. This video will 
briefl y go through the selection of cases, the advantages of 
spleen-preservation, the optimal method to preserve the 
spleen and our technique.
C-123
TECHNICAL TIPS FREY PROCEDURE
H. Ramesh
Surgical Gastroenterology & Liver Transplantation, 
Lakeshore Hospital & Research Center, Cochin, Kerala, 
India
The strategy for surgical treatment of chronic pancreatitis is 
as follows: a) clearance of stones and strictures, b) biopsy of 
suspicious areas, c) wide drainage of the pancreatic ductal 
system, d) preservation of the duodenum, and e) conserva-
tion of pancreatic parenchyma as far as possible. All these 
can eminently be achieved by the Frey procedure. The criti-
cal steps of the operation are: a) wide and thorough mobiliza-
tion of the pancreas from head to tail including release of the 
gland from the retroperitoneum by dividing the peritoneal 
attachments at the superior and inferior borders; b) division 
of the right gastro-epiploic artery to expose the neck ade-
quately, c) ligation of the gastroduodenal/superior pancreati-
coduodenal artery at the upper and lower border of the head/
neck junction; d) thorough Kocherization to allow control of 
the head to minimize bleeding, and also guide the coring 
process, e) use of intra operative C Arm fl uoroscopy to iden-
tify retained stones and assist clearance of strictured pockets 
of duct which are otherwise inaccessible; f) two layered 
anastomosis to a Roux loop of jejunum. The strategy for head 
coring depends on whether there is an infl ammatory mass in 
the head or if the head is mainly containing calculi. In the 
former, a serial coring out of the duct permits access to side 
branches and the process is continued till only a small rind 
of pancreas remains. In the latter, the approach is by fi lleting 
out the duct in the head, clearing the stones, and then excis-
ing the intervening tissue to complete the coring. 
Complications include anastomotic leak, secondary bleed, 
intestinal obstruction and wound infection. In a series of 400 
cases, 7 patients died (all within the fi rst 150 cases). Over a 
follow up of 10 years, 355 out of 400 patients had excellent 
or good result, with 92% having good quality-of-life scores. 
43 patients required re-intervention (all in the fi rst 4 years 
after the initial operation). In the author’s experience, a care-
fully performed Frey procedure relieves pain and preserves 
pancreatic function in the majority of patients with chronic 
pancreatitis.
C-124
LAPAROSCOPIC PSEUDOCYST 
ENTEROSTOMY
R. Ardhanari
Meenakashi Mission Hospital & Research Centre, Tamil 
Nadu, India
Laparoscopic pseudocyst enterostomy is performed for 
symptomatic pseudocyst which either has a lot of necrotic 
debris or as on alternative to endoscopic drainage.
It is performed under GA. The patient is in legs apart supine 
position. The surgeon stands between legs; the cameraman 
to the right of the patient and monitor is towards head end.
After establishing access the best route is selected. Here a 
laparoscopic pseudocyst gastostomy is shown. After anterior 
gastostomy the cyst is entered and disc of gastric and pseu-
docyst wall removed. All debris is removed and cavity 
irrigated.
 Concurrent Sessions: Invited Speakers 35
HPB © 2011 International Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 3), 5–64
Pseudocyst gastric anastomosis done with 2′0′ ‘VICRYL’.
Anterior gastostomy is closed with single layer 2′0′ 
‘VICRYL’.
C-125
PANCREATIC HEAD RESECTION WITH 
SEGMENTAL DUODENECTOMY (PHRSD)
A. Nakao1, S. Takeda2, S. Nomoto2, H. Sugimoto2, H. 
Kasuya2, T. Fujii2, S. Yamada2 and Y. Kodera2
1Department of Surgery, Nagoya Central Hospital, Nagoya, 
Japan; 2Department of Gastroenterological Surgery, 
Nagoya University Graduate School of Medicine, Nagoya, 
Japan
We proposed pancreatic head resection with segmental duo-
denectomy (PHRSD) for benign or low grade malignancy 
tumor of the pancreatic head region as a function-preserving 
operation instead of pylorus preserving pancreatoduodenec-
tomy (Hepatogastroenterol, 1998). This operation is simple, 
easy and safe procedure compared with duodenum preserv-
ing pancreatic head resection (DpPHR).
Laparotomy is done by upper midline skins incision. 
The gastrocolic and duodenocolic ligament is divided. 
Intraoperative US study is done. By conserving the right 
gastric artery and gastroduodenal artery, 5 to 7 cm of the fi rst 
portion of the duodenum is preserved with good arterial 
circulation. The anterior superior pancreatoduodenal artery 
and posterior superior pancreatoduodenal artery are ligated 
and divided. In addition, by conserving the anterior inferior 
pancreatoduodenal artery, the third portion and anal side of 
the second portion of the duodenum are preserved with good 
arterial circulation. Resection of the pancreatic head with 3 
to 4 cm of segmental duodenectomy including minor and 
major papilla completes PHRSD. The distal pancreas is 
examined by ultrathin pancreatoscope. Reconstruction of the 
alimentary tract is then performed with pancreatogastros-
tomy, end to end duodenoduodenostomy and end to side 
choledochoduodenostomy.
PHRSD is simple, easy, safe and function-preserving 
operations for benign or low grade malignancy tumor of the 
pancreas (Ann Surg, 2007; Pancreas, 2011). In this video, 
PHRSD for the branch duct type of IPMN of the pancreatic 
head is presented.
C-126
LAPAROSCOPIC APPROACH TO 
MIRIZZI SYNDROME
C-N. Tang
Department of Surgery, Pamela Youde Nethersole Eastern 
Hospital, Chai Wan, Hong Kong SAR, China
Mirizzi syndrome is a spectrum of disease process evolving 
from gallstone impaction with biliary obstruction to chole-
cystocholedocal fi stula to complete erosion of common 
hepatic duct. Surgery is the mainstay of therapy for Mirizzi 
syndrome and has long been known to present a great techni-
cal challenge to surgeons. The distortion of anatomy and the 
presence of cholecystocholedochal fi stula increase the risk 
of bile duct injury during cholecystectomy. In the era of 
minimally invasive surgery, the role of laparoscopic surgery 
in the management of Mirizzi syndrome is still not well 
defi ned and remains controversial.
Between 2004 and 2010, fi ve cases of Mirizzi syndrome 
were diagnosed in our institution. Three cases were per-
formed with total laparoscopic approach and two with 
robotic assistance. The mean operation time was 148.4 ± 18 
minutes. Median hospital stay was 5 days (range 3–11). No 
conversion, readmission and major complication including 
bile duct injury or residual stones were encountered.
The operative management of Mirizzi syndrome depends 
on the type of the lesion encountered. For McSherry type 1, 
the majority of patients can be successfully treated with lapa-
roscopic cholecystectomy, but with special caution during 
dissection around the area of infl ammation adjacent to 
common bile duct to avoid possible injury. While the surgical 
management for McSherry type 2 is largely dependent on 
size of cholecystocholedochal fi stula, which includes partial 
cholecystectomy with primary closure, Roux-en-Y hepatico-
jejunostomy, cholecysto-duodenostomy or choledochoplasty 
with gallbladder fl ap.
We concluded that with a correct pre-operative diagnosis, 
careful operative strategy, increasing expertise with laparo-
scopic technique and introduction of robotic surgical system, 
laparoscopic management of Mirizzi syndrome is safe and 
feasible.
C-127
ROBOT ASSISTED LAPAROSCOPIC 
WHIPPLE’S OPERATION FOR 
PERIAMPULLARY TUMOR
E. C. H. Lai
Department of Surgery, Pamela Youde Nethersole Eastern 
Hospital, Chai Wan, Hong Kong SAR, China
Traditionally, pancreatic surgery is considered as one of the 
most complex surgeries among the abdominal procedures. 
Minimally access surgery (MAS) development in pancreatic 
surgery is also lag behind that in other gastrointestinal 
organs. Recently, there has been growing interest in the 
ability to perform complex pancreatectomy using the lapa-
roscopic approach. These advanced MAS require surgeons 
to have highly experienced laparoscopic skills. The recently 
developed surgical robotic systems can overcome many of 
the limitations and drawbacks of conventional laparoscopic 
approach. This may fasten the MAS development of pancre-
atectomy. The advantages of robotic systems are many 
because they overcome many of the obstacles of conven-
tional laparoscopic surgery. They increase dexterity, restore 
proper hand-eye coordination and an ergonomic position, 
and improve visualization. Several steps of complex pancre-
atectomy may be improved with robotic surgery, including 
dissection of the pancreatic gland from major vasculatures, 
lymph node dissection, dissection and resection of the unci-
nate process, and reconstruction of anastomoses. There are 
also several disadvantages to these systems. First of all, 
robotic surgery is a new technology and its uses and effi cacy 
have not yet been well established. Another disadvantage of 
these systems is their cost. Clinical trials comparing the 
robot-assisted technique with the conventional laparoscopic 
technique for different pancreatectomy are not available. 
Based on the current evidence, despite technical feasibility 
of conventional laparoscopic or robot-assisted laparoscopic 
pancreaticoduodenectomy, in the absence of defi nitive 
advantages over the open approach, and in light of remaining 
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uncertainties regarding long-term oncologic outcome, 
caution should be exercised in the assessment of the appro-
priateness of this operation for individual patients.
C-128
MECHANISMS OF MALNUTRITION AND 
CACHEXIA IN PANCREATIC CANCER
T. Gilliver
Northern Health, Melbourne, Australia
Cachexia is a multifactoral syndrome causing marked mal-
nutrition, poor quality of life and reduced survival time. 
There are multiple mechanisms involved in this wasting 
process and the effects on body composition differ from that 
seen in starvation. Anorexia, caused by the tumour or the 
treatment is an important co-existing issue but is not directly 
related to the loss in body mass. Many patients with pancre-
atic cancer have a higher resting energy expenditure and this 
is often associated with the acute phase response. Futile 
metabolic cycles, including the Cori cycle can account for 
energy wastage of up to 300 kcal per day. Weight loss in 
patients with cachexia ranges between 15–30% in pancreatic 
cancer, and translates to an 85% loss of fat and 75% loss of 
skeletal muscle mass. Loss of skeletal muscle directly cor-
relates with respiratory muscle function deterioration and is 
an important prognostic factor. 
Cachexia affects both the fat and skeletal muscle mass. It 
appears that lipid mobilising products produced by either 
the host or the tumour cause increased lipolysis in cancer. 
These products include Lipid Mobilising Factor/Zinc 
α2-Glycoprotein, Tumour Necrosis Factor-α (TNF-α), 
Interleukins 1&6 and Interferon-γ. Studies results vary as to 
whether muscle mass is affected by increased protein degra-
dation, reduced protein synthesis or both. Tumour and host 
factors also affect muscle mass and include proteolysis-
inducing factor, glucocorticoids, TNF-α, Interleukin-6, and 
angiotensin II. Treatments include agents to stimulate appe-
tite, omega-3 to attenuate the loss of muscle mass, thalido-
mide to reduce the production of TNF-α, and nonsteroidal 
anti-infl ammatory agents.
C-129
NUTRITION IN PANCREATIC 
DISORDERS: NUTRITIONAL 
PREDICTORS OF POSTOPERATIVE 
OUTCOMES IN CARCINOMA OF THE 
PANCREAS
M. Brooke-Smith
Flinders Medical Centre, Bedford Park, Australia
Carcinoma of the pancreas is uncommonly managed opera-
tively, as it often presents late. The metabolic demands of 
cancer in addition to loss of function of the pancreatic gland 
mean that this group of patients is often malnourished. 
Surgery in the nutritionally impaired is associated with an 
increased risk of complications. The focus of this paper will 
be identifying nutritional issues in patients with pancreatic 
cancer, with particular reference to those undergoing major 
pancreatic surgery and potential strategies to improve 
outcomes.
C-130
EVALUATION OF NUTRITIONAL STATUS 
IN PATIENTS WITH PANCREATIC 
DISORDERS
J. Bailey
Austin Health, Melbourne, Australia
Patients with pancreatic disorders have many risk factors for 
malnutrition. Malnutrition is a common but unrecognized 
problem for hospitalized patients, and is associated with poor 
clinical outcomes including increased length of stay, 
increased infective complications, poor wound healing, func-
tional decline, and surgical wound dehiscence.
Malnutrition is treatable, but assessment of nutritional 
status is often overlooked in the busy healthcare environ-
ment. Early detection of nutritional risk or depletion can 
enable timely nutrition interventions. The pre-operative 
period provides a window of opportunity to optimize the 
nutritional status of surgical patients and thereby improve 
postoperative recovery and healing.
This presentation provides an overview of the anthropo-
metric, biochemical, clinical, and dietary components of 
assessing nutritional status in patients with pancreatic 
disorders.
C-131
OPTIMUM NUTRITIONAL SUPPORT 
IN PATIENTS UNDERGOING 
PANCREATIC SURGERY
B. N. J. Thomson
Peter MacCallum Cancer Centre, Melbourne; Royal 
Melbourne Hospital, Melbourne, Australia
Pancreatic cancer is frequently associated with signifi cant 
weight loss predominantly due to the infl ammatory response 
and production of cancer cachexins. Furthermore jaundice 
can also accelerate weight loss due to malnutrition and loss 
of appetite. Peri-neural invasion occurs frequently and leads 
to gastroparesis in as many as 40% of patients with further 
exacerbation of weight loss. For patients presenting for pan-
creatic surgery 70% are already suffering from weight loss 
with 40% having lost >10% of their stable weight. Post 
pancreaticoduodenectomy delayed gastric emptying remains 
the commonest post-operative complication.
There is little evidence in the literature specifi cally for 
nutritional support in pancreatic surgery patients however 
stronger evidence does exist for patients having major 
abdominal surgery (including pancreatic surgery). Total 
Parenteral Nutrition (TPN) only has a proven role for mal-
nourished patients in the pre-operative period. Enteral nutri-
tion remains the preferred route for feeding with good 
evidence for improved outcomes when administered pre-
operatively for malnourished patients. Further evidence also 
exists for the use of immuno-nutrition in all patients pre-
operatively. Recent prospective randomized trials of early 
enteral nutrition in pancreatic surgical patients have shown 
improvements in surgical outcomes as well as a decrease in 
the length of stay. For post-operative complications such as 
pancreatic fi stula and delayed gastric emptying enteral 
feeding remains a safe and effective route for the administra-
tion of nutrition.
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C-132
HEPATICOLITHIASIS – MANAGEMENT 
OPTIONS
J. H. Dong
Hospital & Institute of Hepatobiliary Surgery, PLA 
General Hospital, Beijing, China
Hepatolithiasis, which is defi ned as the occurrence of stones 
in any intrahepatic bile duct proximal to the confl uence of 
the right and left hepatic ducts, is a prevalent disease in 
China. 
An optimal classifi cation of hepatolithiasis can be helpful 
in determining treatment strategies. We have established a 
novel classifi cation based on the pathological characteristics 
of bililary tree and hepatic parenchyma. In the novel classi-
fi cation, hepatolithiasis was divided into two types: Type I 
and Type II. Type I is a localized stone disease with stones 
locating in unilaleral or bilolaleral lobe; Type II is a diffuse 
stone disease, which is divided into three subtypes: Type IIa 
(without any atrophy of hepatic parenchyma or stricture of 
inrahepatic bile ducts); Type IIb (with segmental atrophy or/
and stricture of inrahepatic bile ducts) and Type IIc (with 
biliary cirrhosis and portal hypertension). The letter “E” rep-
resent additional type for extrahepatic stone, which is divided 
into three subtypes- “Ea”, “Eb” and “Ec ”according to normal, 
relaxation and stricture of Sphincter of Oddi respectively.
Hepatectomy for hepatolithiasis can simultaneously 
remove the stones, the biliary stricture, and the atrophic part 
of the liver, thus reducing the risk of recurrent intrahepatic 
stones and of cholangiocarcinoma, thus, it would appear to 
be the most robust approach for the treatment of hepatoli-
thiasis. The classfi cations of Type I and Type II b are the best 
indications for hepatectomy; Type II is a high risk of stone 
recurrence type, so all of patients with Type II should be 
performed with stone removal combining with Roux-en-Y 
hepaticojejunostomy or hepaticocutaneous jejunostomy, fur-
thermore, for Type II b paitents accompanied hepatic lesions 
(e.g. segmental atrophy hepatic abscess,cholangiocarcinoma, 
etc.), hepatectomy is also the best choice to resect the lesions.
Type IIc patients with biliary cirrhosis, portal hypertention 
and liver failure should be a indication to liver transplanta-
tion. Moreover, for hepatolithiasis with “Eb” (relaxation of 
Sphincter of Oddi) and “Ec”(stricture of Sphincter of Oddi), 
a hepaticojejunostomy shuould be performed too.
C-133
INTRA HEPATIC STONES: REMOVE THE 
STONES OR RESECT THE LIVER?
M. T. Cheung
Department of Surgery, Queen Elizabeth Hospital, Hong 
Kong
Introduction: The long-term outcome for patients with 
hepatolithiasis treated with liver resection was good for a 
selected group of patients. Liver resection should also be 
offered to those patients with complex hepatolithiasis such 
as bilateral stones or those with strictures.
Methods: All patients suffering from hepatolithiasis who 
were treated with liver resection (LR group) or removal of 
stones primarily by percutaneous choledochoscopy (SR 
group) were studied. The patients’ characteristics, the results 
of each procedure and the long-term outcomes of both groups 
of patients were carefully compared and contrasted.
Results: Fifty-two patients underwent liver resection for 
hepatolithiasis. The majority of the group was patients with 
stones localized to the left side. The overall success rate of 
stone removal was 98%. Occurrence of biliary sepsis at 5 
years after resection was 13.3%. The overall success rate of 
stone removal primarily by percutaneous choledochoscopy 
was 70.5%. The bilaterality of stones, the presence of stric-
ture and the presence of atrophy were found to be signifi cant 
risk factors for a poor long-term outcome after just stone 
removal alone. The occurrence of biliary sepsis at 5 years 
was 26.4% and 43.2% for those without stricture and those 
with stricture, respectively.
Conclusions: The long-term outcome after liver resection 
for hepatolithiasis was excellent for a selected group of 
patients. Poor outcomes were recorded those patients whose 
intrahepatic stones were removed primarily by percutaneous 
choledochoscopy – especially those with strictures. Indication 
of liver resection for hepatolithiasis should be extended to 
those patients with strictures or those with bilateral stones. 
A combination of different treatment modalities is necessary 
to improve the outcome of these patients.
C-134
THE MANAGEMENT OF DIFFICULT 
INTRAHEPATIC BILIARY STRICTURES 
WITH COMPLEX HEPATOLITHIASIS
K.-S. Jeng
Department of Surgery, Far Eastern Memorial Hospital, 
Taipei, Taiwan
Introduction: Recurrent or residual (the so-called complex) 
hepatolithiasis is usually diffi cult to treat especially when it 
is associated with intrahepatic biliary strictures. After the 
improvement of diagnostic tools and technical skills with 
instruments, whether the treatment outcome of the recent 10 
years is signifi cantly better than that of the past 10 years 
remains to be elucidated. We compare the treatment modali-
ties and the outcome between the past decades (1990–2000) 
and the recent decade (2001–2010).
Methods: All the interventions of medicine, surgery and 
radiology had been reviewed. The resection policy, the chol-
angioscopic use, the radiological interventions, the proce-
dural complications, the rates of retained stones, recurrent 
cholangitis, and recurrent stones, the need of rehospitaliza-
tion and retreatment are compared between the two decades.
Results: The duct oriented resection, the modifi ed non-
surgical radiological interventions, the days of hospitaliza-
tion and the procedural complications improved signifi cantly 
in recent decade. The imaging studies, the improved skills 
and adequate cholangioscopic procedures and modifi ed non-
surgical radiological intervention signifi cantly decreased the 
treatment sessions, shortened the days of treatment, and the 
decreased the retained stone rate. However, recurrent chol-
angitis or/and hepatolithiasis may occur. The associated 
cholangiocarcinoma still exists.
Conclusion: Resection for regional hepatolithiasis and 
biliary stricture is the golden treatment. However, the non-
surgical interventions may be an alternative or adjunctive 
treatment to avoid reoperation and decrease the residual 
stones. How to eliminate biliary strictures to minimize recur-
rent hepatolithiasis need continuing investigations.
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C-135
MANAGEMENT OF MIRIZZIS 
SYNDROME
A. L. Montagnini
Abstract not available at time of publication.
C-136
ADVANCES IN DIAGNOSTIC AND 
THERAPEUTIC ENDOSCOPIC 
TECHNIQUES OF THE BILIARY TRACT
G. C. Vitale
Professor of Surgery, Department of Surgery, University of 
Louisville School of Medicine, Louisville, USA
Role of endoscopy in managing benign and malignant 
disease of the biliary tract has continued to increase in the 
era of minimally invasive surgery and laparoscopy. 
Endoscopy is useful in the treatment of choledocholithiasis, 
strictures of the bile duct secondary to iatrogenic injury, 
trauma and malignancy.
There is no consensus on the optimal management of 
patients with choledocholithiasis particularly in patients who 
undergo cholecystectomy. Local expertise in a given institu-
tion is critical to decision making for treatment of CBD stones. 
For suspected CBD stones if cholecystectomy is required, 
laparoscopic CBD exploration at cholecystectomy followed 
by ERCP for failure is probably the optimal approach. ERCP 
with stenting is now a valuable tool in the diagnosis and 
treatment of bile duct injuries. It is also the mainstay in the 
palliative treatment of malignant bile duct strictures.
ERCP for gallstone pancreatitis should be limited to 
patients with associated cholangitis and rising bilirubin. In 
all other cases, the patient should undergo cholecystectomy 
with intraoperative cholangiogram when pancreatic infl am-
mation subsides. Benign postoperative bile duct strictures 
can be manage primarily with ERCP with excellent results 
in 85–90% of selected cases with surgery being reserved for 
failures. Plastic and metallic stent placement for effective 
palliation of malignant bile duct and pancreatic tumors can 
be achieved in 80% of proximal tumors (Klatskin) and over 
90% of distal tumors (pancreatic) with minimal morbidity 
and mortality for long term palliation.
Advances in endoscopic therapy for benign and malignant 
biliary tract disease have yielded safe and effective treat-
ments which are increasingly being incorporated into surgi-
cal training and decision making.
C-137
HEPATIC INCIDENTALOMA
R. Padbury
Flinders Medical Centre, Bedford Park, SA, Australia
The problem of hepatic incidentaloma has increased progres-
sively with the number of imaging techniques and the volume 
of imaging performed in the patient population. When a 
hepatic incidentaloma is discovered it should be possible in 
the majority of circumstances to make a diagnosis without 
the need for diagnostic biopsy or resection for diagnostic as 
well as therapeutic reasons. The sophistication of currently 
available imaging techniques has signifi cantly increased the 
preoperative diagnostic accuracy. When confronted with a 
patient with hepatic incidentaloma the past history exposure 
to hormones evidence for compromised liver function is all 
important. With respect to the imaging of the liver the 
approach is to obtain information of the background liver 
parenchyma (normal v steatotic v fi brotic or cirrhotic) and 
the individual characteristics of the incidentaloma. An 
assessment of whether the incidentaloma is comprised of 
liver cells or non liver cells and if non liver cells, whether 
primary or secondary.
Different information can be obtained from ultrasound, CT 
and MRI scanning. Appropriately selected combinations of 
these modalities and the use of different contrast agents will 
allow identifi cation through utilization of excretion into dif-
ferent cellular or extra cellular elements. The usual IV con-
trast agents distribute in the extra cellular space and will 
allow identifi cation of the presence of lesions but not neces-
sarily the content. With MRI and CT it is important to do 
both arterial and portal phases and often a delayed phase will 
give further information. With MRI scanning some contrast 
agents will collect in Kupfer cells (iron oxide) and others 
into bile ducts (eg. GD-EOP-DTPA) which helps with dis-
criminating between focal nodular hyperplasia and hepatic 
adenoma.
Examples of the use of all the imaging modalities to estab-
lish a diagnosis will be given.
C-138
THE PATHOLOGICAL APPROACH TO 
HEPATOCELLULAR ADENOMA (HCA)
A. Clouston1,2
1Envoi Specialist Pathologists; Royal Brisbane & Women’s 
Hospital; 2Centre for Clinical Liver Disease Studies, 
University of Queensland, Brisbane, Australia
Although the diagnosis for many benign hepatocellular 
lesions is straightforward, there are some that remain chal-
lenging. Questions commonly asked include “Why are some 
tumours diffi cult to diagnose radiologically?”, “Why is the 
pathologist somtimes unable to classify a benign lesion as 
either focal nodular hyperplasia or HCA?” and “Is there 
really a malignant risk for HCA, since transformation seems 
vanishingly rare?”. The answers to these questions lies in the 
recent recognition that HCA is a heterogeneous group of 
neoplasms with at least 3 different groups based on muta-
tional analysis, each with distinctive radiological, pathologi-
cal and clinical features. 
Recent work has identifi ed three (3) major mutational 
groups: HNF1a-inactivated HCA, infl ammatory HCA with 
gp130 mutation (previously called “telangiectatic FNH”) and 
b-catenin-activated HCA.1 A fourth group remains unclassi-
fi ed. HNF1a-inactivated HCA (35–40%) has typical radiol-
ogy, is usually steatotic, and is the most common type found 
in adenomatosis. Immunoperoxidase staining shows a loss 
of normal staining for LFABP. 
Infl ammatory adenoma (45–60%) has atypical but often 
distinctive radiology (marked high intensity signal on 
T2-weighted sequences associated with delayed persistent 
enhancement)2, and unusual histological features including 
focal bile ductular reaction, variable steatosis, telangiectatic 
vessels and a morphological overlap with FNH. This explains 
our previous diffi culty in categorising these lesions as HCA 
or FNH in the past. The atypical radiology also explains why 
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many are biopsied. These lesions show positive immunos-
taining for amyloid A protein. 
The third group of b-catenin-activated HCA (10–15%) is 
the most common type found in males and those with gly-
cogenoses. These lesions frequently have cytological atypia, 
and this is the type with an increased risk of malignant trans-
formation. Immunostaining with b-catenin may show aber-
rant cytoplasmic or nuclear (rather than normal membrane) 
staining, but the downstream protein glutamine synthetase is 
a more reliable marker and shows diffuse positive staining 
in this form of HCA. Importantly, about 10% of infl amma-
tory HCA also have activating b-catenin mutations in addi-
tion to mutation in gp130.
References:
1. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa 
Cunha A, Rullier A, et al. Hepatocellular adenoma man-
agement and phenotypic classifi cation: the Bordeaux 
experience. Hepatology. 2009;50:481–9.
2. Ronot M, et al. Hepatocellular adenomas: accuracy of 
magnetic resonance imaging and liver biopsy in subtype 
classifi cation. Hepatology. 2011;53:1182–91.
C-139
MANAGEMENT OF HEPATIC ADENOMA
K. H. Liau
Nexus Surgical Associates, Mount Elizabeth Medical 
Centre, Singapore
Hepatic adenomas are benign tumors which carry rare poten-
tial complications of an unpredictable hemorrhage and 
malignant transformation. Studies have revealed that the 
risks of hemorrhage, spontaneous rupture and malignant 
change depend on the size of the adenoma. Clinical differ-
entiation of hepatic adenoma from focal nodular hyperplasia 
and hepatocellular carcinoma, especially the well-differenti-
ated subtype of hepatoma, can be challenging for physicians. 
Currently, dynamic multi-slice and multi-phasic computed 
tomography and magnetic resonance imaging are the main 
diagnostic imaging techniques to identify and characterize 
these tumors. With these modern imaging technologies, the 
accuracy of diagnosis has improved, albeit imperfect. The 
options of treatment range from conservative management 
to interventional ablation, enucleation, surgical resection and 
orthotopic liver transplantation. The indications for each 
option depend on the symptoms, diagnostic certainty and the 
growth of the tumor. This lecture reviews the current update 
on the recent improvement in imaging techniques and their 
signifi cant implications on surveillance and the choice of 
therapeutic management of hepatic adenoma.
C-140
LAPAROSCOPIC LIVER RESECTION 
FOR BENIGN LIVER TUMORS
N. Jarufe
Digestive Surgery Department, Pontifi cia Universidad 
Católica de Chile
Surgical treatment of benign liver tumors remains a contro-
versial topic. Candidates are patients with symptomatic 
tumors or high risk of rupture, bleeding or malignancy.
When feasible, minimally invasive hepatic surgery is asso-
ciated with less blood loss, less pain medication requirement, 
better cosmetic results and shorter length of hospital stay. All 
this benefi ts make the costs of the laparoscopic approach at 
least comparable with the traditional open surgery.
Because wide margins and anatomical resections are 
usually unnecessary in surgical procedures for benign liver 
tumor, more conservative resections are possible, making the 
laparoscopic approach a good strategy to reduce the 
morbidity.
In this conference we will discuss indications, benefi ts and 
contraindications of laparoscopic resection for benign tumor 
disease as well as provide selected videos from laparoscopic 
benign liver tumors resection.
C-141
THE SURGICAL MANAGEMENT OF 
POLCYSTIC LIVER DISEASE
C. W. Pinson
Abstract not available at time of publication.
C-142
DIAGNOSIS AND MANAGEMENT OF 
FOCAL NODULAR HYPERPLASIA
S. K. Wickremesekera
Capital & Coast District Health Board, Wellington, New 
Zealand
Focal nodular hyperplasia (FNH) is a common benign 
hepatic neoplasm. These lesions are often detected on inci-
dental imaging but can be symptomatic. Current imaging 
techniques, particularly contrast-enhanced MRI scanning 
is highly sensitive in characterizing these liver tumors. 
Differentiation of FNH from other liver lesions enables 
appropriate management decisions. Unlike premalignant and 
malignant neoplasms, the indication for hepatic resection is 
poorly defi ned and is determined by the stability of the 
lesion, patient symptoms and clarity of diagnosis.
C-143
HEPATIC CAVERNOUS HEMANGIOMA: 
AN ANALYSIS OF 172 CASES
X.-H. Fu, X.-P. Yao, F. Shen and M.-C. Wu
Eastern Hepatobiliary Surgery Hospital, Second Military 
Medical University, Shanghai, China
Objective: Hepatic hemangiomas are congenital vascular 
malformations and are the most common benign hepatic 
tumors. Surgery of hemangioma involving porta hepatis is 
technically more challenging than that for peripheral lesions. 
The indications for surgical resection of liver hemangiomas 
remain controversial. This study aimed to explore the feasi-
bility of operation on hepatic cavernous hemangioma.
Methods: The clinical data of 172 patients with hepatic 
cavernous hemangioma performed from 2004 to 2006 at 
Eastern Hepatobiliary Surgery Hospital of Second Military 
Medical University were analyzed retrospectively. The 
tumors were removed by dissecting the plane between 
the capsule of the hemangioma and normal liver tissue. The 
diameters of the tumors ranged from 4 to 32 cm. Among 
them, 128 patients with hemangioma involved porta hepatis 
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(77.4%) and peripherally located in 44 patients (22.6%). 
Clinical manifestation, operation and postoperative recovery 
were analyzed. In the study 89 patients were asymptomatic. 
In symptomatic patients, abdominal pain or discomfort was 
the most common presenting symptom.
Results: Enucleation of hemangioma involving porta 
hepatis had more intraoperative bleeding (P < 0.001), longer 
time of infl ow exclusion (P < 0.001), and higher incidence 
of postoperative pleural fl uid (P = 0.005), while no signifi -
cant difference exists in the complication of operation and 
postoperative recovery. There was no hospital mortality.
Conclusions: Surgery of hemangioma involving porta 
hepatis is safe and effective. For patients with symptoms or 
young patients with rapidly enlarging mass, the enucleation 
of the tumor is needed and feasible. Especially for the 
patients with hepatic hemangioma involving porta hepatic, 
delayed surgery may increase the risk of intraoperative 
bleeding and postoperative complications. It should be 
carried out strictly in accordance with the rules of the liver 
surgery and the characteristics of the hemangioma so as to 
ensure the safety of the operation.
C-144
STAGING FOR AMPULLARY 
CARCINOMA: THE ROLE OF EUS
S. Panpimanmas
Department of Surgery, Rajavithi Hospital, College of 
Medicine, Rangsit University, Bangkok, Thailand
Introduction: Endoscopic ultrasonography (EUS) is highly 
accurate for the staging of tumors of the biliary and pancre-
atic systems. Ampullary carcinoma is relatively rare cancer 
but it has better prognosis as it’s early symptoms and more 
chance for curative surgical treatment Preoperative staging 
is important in planning the most appropriate treatment.
Methods: Retrospective review of ampullary carcinoma 
patients from January 2009 to December 2010, there were 
85 patients admitted and treated in hospital. Every patients 
had preoperative CT scan, only twelve patients had EUS 
assessment before surgery. Accuracy and staging comparison 
of CT scan and EUS were evaluated.
Results: Twelve ampullary carcinoma patients (7 women 
and 5 men), only 50% could be detected by CT scan espe-
cially in early stage that diffi cult to be found by this imaging. 
Overall accuracy of EUS in detecting of ampullary tumors 
was 91.7% which was signifi cantly superior than CT scan. 
Tumor size, tumor invasion and regional lymph nodes detec-
tion were also superior by EUS, as accuracy of T stage by 
EUS was 83.3% and regional metastatic lymph nodes was 
75% compared with CT scan was only 25% but EUS had 
limitation in detecting far area lymph nodes and liver metas-
tasis, that CT scan had more benefi t.
Conclusion: EUS is more accurate in detecting and staging 
ampullary tumor and locally lymph nodes (T, N) and better 
for evaluating prognosis and resectability of ampullary 
tumor. EUS staging improve the treatment and prevent some 
unnecessary operations.
C-145
LOCAL EXCISION IS THE PREFERRED 
OPTION TO RADICAL RESECTION FOR 
EARLY TUMORS OF THE AMPULLA
(for the ‘Yes’ side of the debate)
C.-K. Ho
Nexus Surgical Associates, Mount Elizabeth Hospital, 
Singapore
All ampullary tumors should be resected. While there is 
general agreement that pancreatico-duodenectomy is the 
operation of choice for ampullary adenocarcinoma, the ideal 
treatment for benign neoplasms, with or without dysplasia, 
and lesions with micro-invasion remains controversial. As it 
is, ampullary cancers have the best survival amongst the 
various types of periampullary malignancy. For early tumors, 
local excision, whether by an endoscopic technique or a 
transduodenal approach, is an attractive alternative. As 
opposed to radical resection, local resection has a signifi -
cantly shorter operation time, a signifi cantly lower incidence 
of surgery-related morbidity, and hence consequently, a sig-
nifi cantly shorter postoperative hospital stay. The Proposition 
will present the care on why local excision is the preferred 
option for early tumors of the ampulla.
C-146
DEBATE: LOCAL EXCISION IS THE 
PREFERRED OPTION TO RADICAL 
RESECTION FOR EARLY TUMORS OF 
THE AMPULLA
(For the ‘No’ side)
S. Connor
Abstract not available at time of publication.
C-147
THE MANAGEMENT OF MULTIPLE 
DUODENAL – AMPULLARY ADENOMAS 
IN FAP
T. G. Wilson
Flinders Medical Centre, Adelaide, Australia
Up to 90% of patients with Familial Adenomatous Polyposis 
(FAP) develop duodenal adenomas. The cumulative risk of 
development of duodenal or peri-ampullary carcinoma by 60 
years of age is between 5–10%. Duodenal adenomas may 
present at a young age in this group of patients. The inci-
dence and severity of duodenal adenomatosis increase with 
age and close endoscopic surveillance is indicated. There is 
some evidence that chemoprevention by the use of celecoxib 
may slow the progression of the adenomatosis in FAP. Local 
endoscopic techniques are not effective in controlling 
adenoma progression.
Spigelman devised a classifi cation stratifying the risk of 
malignant change according to the number, size, histological 
type and presence of dysplasia1. The risk of malignant change 
in Spigelman Stage IV disease is such that prophylactic duo-
denal resection, typically by pancreaticoduodenectomy, is 
indicated.
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C-148
PANCREATIC-SPARING 
DUODENECTOMY: INDICATIONS 
AND TECHNIQUE
S. Y. Peng1,3, L. J. Liang2, Y. B. Liu4, D. F. Hong3, J. T. Li1, 
Y. F. Wang3 and X. A. Wang5
1Zhejiang University Second Affi liated Hospital, Hangzhou, 
China; 2Zhongshan University First Affi liated Hospital, 
Guangzhou, China; 3Zhejiang University Sir Run Run 
Shaw Hospital, Hangzhou, China; 4Shanghai Jiaotong 
University Xinhua Hospital, Shanghai, China; 5Xinjiang 
Universitytumor Hospital, Ulumuqi, China
Introduction: In pancreatic surgery, as in other organs there 
is a tendency towards organ-preserving techniques. Pancreas-
sparing duodenectomy (PSD) was introduced as an alterna-
tive to pancreatoduodenectomy (PD) in a variety of conditions 
Methods From 1989 to 2010, 19 patients with nine different 
kinds of disease underwent PSD at our institutions.
Methods: 1) Dissection: Duodenum is dissected from the 
pancreas. Owing to dense adhesion, the proximal part of the 
duodenum is separated from the pancreas leaving the outer 
muscular layer of the duodenum on the pancreas. The proxi-
mal part of the duodenum is then separated from the pan-
creas. 2) Resection: Duodenum is transected at both ends. 
Whether the major papilla is preserved or not depends on the 
pathology. 3) Reconstruction: Reconstruction of the alimen-
tary tract is performed after either the Billroth I or Billroth 
II method. Papillojejunostomy is the most important anasto-
mosis. Generally the cut edge of the major papilla is anasto-
mosed to a small opening on the jejunum with about ten 5–0 
interrupted absorbable sutures. In the case where the major 
papilla is preserved, we would suggest to use binding duct 
to mucosa anstomosis (Peng et al. CJS 2011, in print), which 
is very easy and safe to perform.
Results: Total morbidity was 30%, including anastomotic 
leak in two cases. One patient died of underline disease of 
heart attack on the 5th post-op day.
Conclusions: PSD is a safe surgical procedure for a variety 
of conditions involving the duodenum. As a new procedure 
binding duct to mucosa anstomosis is recommended.
C-149
IPMN – CLASSIFICATION, 
INVESTIGATION, AND MANAGEMENT 
GUIDELINES
M. Tanaka
Department of Surgery and Oncology, Kyushu University, 
Fukuoka, Japan
IPMN of the pancreas is a fascinating entity that is drawing 
more and more attention. The international consensus guide-
lines were published by the working group in the International 
Association of Pancreatology (IAP) in 2006 (Tanaka, et al. 
Pancreatology 2006;6:17), based on the yield of a sympo-
sium in the IAP congress in Sendai, Japan, in 2004. Although 
these guidelines greatly contributed to our improved under-
standing, some issues still remain to be solved especially on 
IPMN of the pancreas.
#1. Uncertainty exists regarding classifi cation of IPMNs. 
Necessity of mixed-type category of IPMN and whether clas-
sifi cation should be defi ned radiographically or histologi-
cally needs to be defi ned.
#2. Preoperative distinction of branch duct (BD-) IPMNs 
from non-mucinous cysts should be further investigated so 
that potentially malignant lesions can be identifi ed and man-
agement strategies guided effectively. The role and safety of 
cystic fl uid analysis remains to be clarifi ed.
#3. With regard to diagnosis of malignancy in BD-IPMNs, 
criteria for identifying malignancy need to be re-evaluated. 
Presence of mural nodules is a reliable predictor; however, 
controversy exists over the value of size of BD-IPMN 
(Tanaka M. Nature Rev Gastroenterol Hepatol 2011;8:56). 
Criteria with increased specifi city are needed, perhaps 
including histological subtype, to reduce the false-positive 
rate of present Sendai criteria.
#4. Finally, the best modality and interval for surveillance of 
BD-IPMNs requires determination because of its signifi -
cance in terms of malignant transformation, development of 
distinct pancreatic ductal adenocarcinoma during surveil-
lance, and the same phenomenon and IPMN recurrence after 
resection.
C-150
LAPAROSCOPIC 
PANCREATICODUODENECTOMY
S. C. Kim
Department of Surgery, Ulsan University College of 
Medicine & Asan Medical Center, Seoul, Korea
Since the introduction of laparoscopic pancreatic surgery for 
staging of advanced pancreatic cancer in the early 1980s, its 
use has been widened to include palliation of unresectable 
pancreatic cancers, drainage of pancreatic pseudocyst, and 
pancreatic resection including distal pancreatic resection or 
pancreaticoduodenectomy. In contrary to laparoscopic distal 
pancreatic resection is widening its application, laparoscopic 
pancreaticoduodenectomy (LPD) remains as complicated 
operation to perform safely until now because of its compli-
cated procedures and possibility of high mortality and mor-
bidity. Since LPD was introduced to reduce the postoperative 
morbidity fi rstly by Gagner et al in 1994 as a most advanced 
laparoscopic surgical trial, limited reports only have been 
described by some experienced centers with unsatisfi ed clini-
cal outcomes. Some barriers are present for the LPD to be a 
widespread clinical application for the resection of pancre-
atic head lesions; long operation time, technical diffi culties 
from proximity to large vessels to dissect and reconstruction 
procedures. Therefore LPD was not accepted as a general-
ized surgical modality for the resection of pancreatic head 
lesions. Most surgeons are reluctant against LPD for malig-
nant lesion of pancreas head because of oncologic point of 
view yet. However, as for the benign or low grade malignant 
lesions, if technical feasibility and safety are, LPD can be 
accepted as an alternative option for open pancreaticduode-
nectomy. Technical progress for LDP has been made since 
Gagner’s fi rst trial by some pioneer laparoscopic surgeons, 
such as hand assisted LPD, laparoscopic assisted pancreatic-
duodenectomy, robotic assisted pancreaticduodenectomy. 
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We performed 75 cases of LPD in mainly in benign or low 
grade malignant disease of pancreas head. Male was 36, and 
female was 39. Mean age was 50.5 years. The number of 
operation was increased year by year from 10 cases in 2007 
to 20 cases in 2011. July Mean operation time was 8.5 hr, 
which is markedly decreased in 2011, 6.5 hr. Mean hospital 
stay was 15 days, which also decreased in 2011, 11.6 days. 
Complication rate was also decreased year by year.
In conclusion, technically, LPD is feasible with acceptable 
mortality and morbidity in benign or low grade malignant 
disease in pancreas head. Clinical outcomes have improved 
by accumulation of experiences. When it comes to advanced 
malignant disease, more experience and research would be 
required.
C-151
TECHNIQUES IN LIVER 
TRANSPLANTATION
S. S. Zheng
Division of Hepatobiliary and Pancreatic Surgery, 
Department of Surgery, First Affi liated Hospital, Zhejiang 
University School of Medicine, Hangzhou, China
The past 20 years have seen the development of liver trans-
plantation in China. One-year patient survival of liver trans-
plant patients approaches 90% in many leading medical 
centers. The number of liver transplantation increases dra-
matically. Techniques in liver transplantation developed very 
quickly as well.
In early stage of in China, classic orthotopic liver trans-
plantation with venous-venous bypass was adopted in almost 
all centers in china. In 2003, we abandoned venous-venous 
bypass, and adopted modifi ed piggy-back orthotopic liver 
transplantation. We totally blocked IVC blood fl ow and 
sutured the suprahepatic IVC of graft to the anterior wall of 
IVC in recipients. Totally blocking IVC and abandoning 
bypass had no effect on renal function and bowl function.
As to biliary reconstruction, we experienced for stages. In 
the fi rst stage, we placed a T-tube in the CBD after duct-to-
duct anastomosis. In the second stage, we abandoned T-tube. 
In the third stage, we performed biliary anastomosis with 
continuous suture in posterior wall and interrupted suture in 
anterior wall. In the fourth stage, we reperfused the graft after 
both portal vein and hepatic artery reconstruction. After 
4-stage technique innovation, biliary complication in liver 
transplant recipients was as low as 5.8%.
The donor shortage was the most important problem in 
organ transplantation all over the world. Therefore, Living 
donor liver transplantation ( LDLT) and split liver transplan-
tation developed very quickly in China. In adult-to-adult 
LDLT, we usually adopted right liver graft without middle 
hepatic vein. More and more attention was paid to hepatic 
veins in segment 5 (V5) and segment 8 (V8). Generally we 
reconstructed V5 and V8 with frozen allograft vessels if the 
diameters of V5 and V8 were larger than 3 mm, particularly 
in patients with high blood fl ow in V5 and V8. Enough graft 
volume, reconstruction of V5/V8, and control of portal 
pressure were very important to prevent small for size 
syndrome.
C-153
MASTER VIDEO SESSION: BYPASS 
PROCEDURES FOR BUDD-CHIARI 
SYNDROME
L. A. Carneiro D’Albuquerque
Abstract not available at time of publication.
C-154
LIVE DONOR LIVER 
TRANSPLANTATION; AN OVERVIEW
K. H. Kim
Division of Hepatobiliary Surgery and Liver 
Transplantation, Department of Surgery, University of 
Ulsan College of Medicine and Asan Medical Center, 
Seoul, Korea
Owing to the shortage of deceased donor organs, live donor 
liver transplantation (LDLT) has become an established 
treatment for patients with acute and chronic disease. The 
fi rst successful pediatric LDLT, of a left lateral section graft 
from a mother to her son, was performed in Brisbane, 
Australia in 1989. Since then, this life saving procedure has 
been applied to adult patients. The greatest impact of LDLT 
has been in Asian countries, where cadaveric organ donation 
has been uncommon or non-existent. LDLT using left-lobe 
was introduced for adult recipients in 1993, but this proce-
dure did not become wide-spread owing to the inability of 
these relatively small-sized grafts to meet the metabolic 
demands of all adult recipients. To overcome the inadequate 
graft volume encountered with left-lobe grafts, transplanta-
tion with right-lobe liver grafts was introduced for adult 
recipients in 1996. Although this method rapidly led to the 
worldwide use of adult LDLT, right-lobe hepatectomies are 
associated with a greater surgical risk for live donors than 
left-lobe hepatectomies, and are associated with increased 
morbidity and mortality rates, owing to the reduced volume 
of remnant liver in the donor. In LDLT, donor safety is of 
paramount importance and cannot be compromised regard-
less of the implication for the intended recipient. Moreover, 
the absence of hepatic venous drainage to the right anterior 
sector has led to the right-lobe graft congestion and failure. 
Although graft size is critical for successful outcomes, the 
importance of uniformly good venous drainage of the ante-
rior sector of the right-lobe liver graft has been regarded as 
crucial for maximizing graft function. The reconstruction of 
the middle hepatic venous tributaries of a right-lobe graft 
was introduced in 1998. Not all potential donors can donate 
their right-lobes because safe donation is possible only when 
the estimated remnant liver volume is more than 30%. If the 
volume of the right-lobe in potential donors is more than 
70%, relative to the volume of the whole liver, one alterna-
tive may be dual left-lobe graft LDLT, in which smaller 
left-lobe grafts from two donors are transplanted into one 
recipient. This technique was fi rst introduced in 2000 to 
minimize donor risk and alleviate the small-size graft 
problem. Until more cadaveric grafts become available, adult 
LDLT will continue to be a relevant therapy for patients with 
irreversible end-stage liver disease.
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MASTER VIDEO SESSION: LIVER 
RESECTION FOR COLORECTAL 
METASTASES
T. C. Gamblin
Abstract not available at time of publication.
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IN VIVO-EX SITU TREATMENT OF 
INTRAHEPATIC 
CHOLANGIOCARCINOMA
F. A. Alvarez, J. Iniesta, E. de Santibañes
Sección de Cirugía Hepatobiliopancreática, Hospital 
Italiano de Buenos Aires-Argentina
Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 
second most common primary liver tumor. Vascular invasion 
is a negative prognostic factor. Since complete resection 
offers the only chance for cure, an aggressive surgical 
approach with extended liver resection in combination with 
complex vascular or biliary reconstructions is justifi ed.
Methods: We present a 54-year-old male patient with an 
abdominal mass found during a routine examination. Tumor 
markers were within normal limits. A CT-scan revealed a 
liver tumor in the right lobe with compromise of the right 
portal vein, the right and middle hepatic veins and the infe-
rior vena cava (ICV). Preoperative right portal embolization 
was performed. Under venous extracorporeal circulation by 
cannulation of the left femoral vein, the inferior mesenteric 
vein and the left axillary vein, total vascular exclusion was 
achieved and a right trisectionectomy with en-block resec-
tion of the retrohepatic IVC was performed. Caval recon-
struction was accomplished using a gore-tex graft 
with reimplantation of the left hepatic vein. Biliary recon-
struction was performed in an end-to-side fashion 
hepaticoyeyunostomy.
Results: The patient developed a hemoperitoneum that 
required relaparotomy and bilateral pleural effusion that was 
treated by chest tubes placement. The histo-pathological 
report informed ICC with negative lymph nodes and tumor 
free margins. Twenty eight months later the patient is free of 
disease and in good condition.
Conclusions: The presented in vivo-ex situ major hepatec-
tomy performed with techniques of vascular exclusion and 
caval resection was feasible with satisfactory results. In 
patients with tumoral involvement of the IVC this surgical 
alternative offers the possibility to achieve complete tumor 
removal.
C-157
SURGICAL TREATMENT OF GIANT 
HEPATIC HEMANGIOMAS: TECHNICAL 
POINT OF VIEW
Y-J. Lee
Division of Hepatobiliary & Pancreatic Surgery, Asan 
Medical Center, University of Ulsan College of Medicine, 
Seoul, Republic of Korea
Introduction: Hepatic hamangiomas are the most common 
benign tumors of the liver. Surgical treatment can be diffi cult 
as a result of the high risk of intraoperative hemorrhage. The 
present study reviewed the clinical features of patients with 
hepatic hemangioma and surgical techniques used in their 
treatment.
Methods: Eight patients with giant hepatic hemangiomas 
underwent hepatectomies at the Asan Medical Center 
between January 2006 and March 2009. Patient demo-
graphic, clinical, and surgical characteristics and outcomes 
were reviewed retrospectively.
Results: There were 7 females and 1 male with a mean age 
of 48.5 years (range, 33 to 58 years). Indications for surgical 
interventions were abdominal pain (62.5%), an abdominal 
mass (37.5%), Kasabach-Merritt syndrome (25%), and 
increased size (25%). The hemangiomas were usually mul-
tiple (87.5%) and bilobar (75%) and had a median size of 
14.5 cm (range, 7 to 29 cm). All patients underwent major 
hepatic resection with early vascular control using the 
Glissonean pedicle transection method (GPTM), the liver 
hanging maneuver (LHM), and preparation for total vascular 
exclusion (TVE). There was no major morbidity or mortality. 
The minor morbidity rate was 25% with transfusion rate of 
37.5%.
Conclusions: Early vascular control using the GPTM, the 
LHM, and preparation for TVE is essential for safe resection 
of large hepatic hemangiomas
C-158
CHRONIC PANCREATITIS: 
MANAGEMENT OF BILIARY 
OBSTRUCTION
P. C. Bornman
Department of Surgery University of Cape Town and 
Groote Schuur Hospital South Africa
Bile duct obstruction (BDO) is common during the advanced 
stages and may be caused by edema, pancreatic pseudocyst 
fi brosis or a combination thereof. The clinical presentation 
varies from an incidental discovery to overt jaundice with or 
without associated cholangitis. Jaundice which occurs during 
acute exacerbations is often transient and may resolve com-
pletely without requiring intervention. The risk of develop-
ing secondary biliary cirrhosis is low particularly in 
non-jaundiced patients.
Management is largely dictated by the clinical presentation 
and morphological changes of the pancreas. Clinical factors 
to consider include the presence and severity of associated 
pain, the occurrence of jaundice and duration thereof, 
concern about malignancy and co-morbid diseases. Surgical 
strategy will depend on the presence of an infl ammatory 
mass in the head of the pancreas and the degree of bile duct 
and pancreatic duct dilatation.
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Patient with asymptomatic BDO should be treated conser-
vatively with regular follow-up. Endoscopic interventions 
and stenting should be discouraged in these patients as this 
may cause secondary infection. Patients who present with 
jaundice should initially be treated conservatively unless 
associated with cholangitis when a temporary stent should 
be placed.
A hepatico-jejunostomy is preferred for persistent jaun-
dice and, when associated with pain, a pancreatic drainage 
operation (e.g. Frey procedure) should be added. A pylorus 
preserving pancreatico-duodenectomy is indicated when a 
malignancy is suspected.
Stenting should be preserved for cholangitis and those 
unfi t for surgery. The role of covered and biodegradable 
expandable stents requires further evaluation.
C-159
SYMPOSIUM: CHRONIC PANCREATITIS: 
RESECTION VS BYPASS FOR 
CHRONIC PANCREATITIS
D. Martin
Abstract not available at time of publication.
C-161
KEYNOTE LECTURE: SURGICAL 
MANAGEMENT OF PORTAL 
HYPERTENSION: WHICH SHUNT AND 
WHEN?
J. Y. Zhu
Abstract not available at time of publication.
C-162
MANAGEMENT OF PORTAL 
HYPERTENSION AS A BRIDGE TO LIVER 
TRANSPLANTATION
L. A. Carneiro D’Albuquerque
Abstract not available at time of publication.
C-163
NON SHUNT SURGERY FOR PORTAL 
HYPERTENSION
S. K. Mathur
Abstract not available at time of publication.
C-164
PORTAL BILIOPATHY
A. Chaudhary
New Delhi, India
The term portal biliopathy is used to describe biliary ductal 
and gall bladder wall abnormalities in patients with portal 
hypertension. These changes are predominantly seen in 
patients with extra hepatic portal vein obstruction and present 
as strictures and dilatation of both the intrahepatic and extra-
hepatic bile ducts and are believed to be caused by the pres-
sure of the varices in and around the bile duct wall. Majority 
of these patients are asymptomatic and these changes are 
seen on endoscopic retrograde cholangiography or magnetic 
resonance cholangiography. Occasionally these patients are 
symptomatic due to presence of either bile duct calculi, a 
stricture in the bile duct and rarely due to the varices them-
selves causing the obstruction. Only symptomatic patients 
need intervention. Bile duct calculi can be managed endo-
scopically. Patients who have bile duct strictures may need 
endoscopic stenting. Surgery when needed, is always in the 
form of a porto systemic shunt which decompresses the bile 
duct varices and can relieve the obstruction if the varices 
were responsible for biliary obstruction. In patients with a 
dominant stricture in the bile duct, the portosystemic sunt 
allows access to the bile duct to permit performance of a 
biloenteric drainage. Direct approach to the bile duct in these 
patients can cause signifi cant bleeding.
C-165
RADIOLOGICAL AND ENDOSCOPIC 
TECHNIQUES IN THE MANAGEMENT 
OF PORTAL HYPERTENSIVE BLEEDING: 
RADIOLOGICAL
M. Brooks
Austin Health, Heidelberg, Australia
A range of effective image guided interventions exist for the 
management of bleeding varicose. The development of TIPS 
in the 1990s overshadowed alternatives such as transhepatic 
embolisation. Retrograde transrenal balloon occlusion for 
the obliteration of gastric varicose has developed over a 
number of years but has only recently been adopted outside 
of Japan and Korea.
With a wide range of treatments now available the chal-
lenge is to develop a rational approach to selection of appro-
priate treatment modality.
When in the course of an acute presentation should we 
switch from endoscopic to an image guided approach. Which 
patients should be treated primarily with TIPS or other image 
guided techniques?
C-166
ENDOSCOPIC TECHNIQUES IN THE 
MANAGEMENT OF PORTAL 
HYPERTENSIVE BLEEDING
R. B. Vaughan
Austin Hospital, Heidelberg, Melbourne, Australia
Introduction: Endoscopic techniques play a central role in 
the management of patients with portal hypertensive bleed-
ing. Therapy is guided by careful diagnostic upper endos-
copy to identify patients with gastro-oesophgeal varices and 
to stratify risk of bleeding. Therapeutic techniques such as 
endoscopic variceal ligation (EVL), sclerotherapy, glue 
injection and other novel approaches such as insertion of 
fully covered self-expanding metal stents (SEMS) will be 
discussed.
Diagnostic endoscopy: All patients should be screened for 
the presence of gastro-oesophageal varices by diagnostic 
upper endoscopy at the time the diagnosis of cirrhosis is 
made. Oesophageal varices should be characterized accord-
ing to size as small (<5 mm) or medium/large (>5 mm) and 
the presence of red signs (red wale marks or red spots) noted. 
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Gastric varices are best characterized as gastro-oesophageal 
(GOV) or isolated gastric varices (IGV).
Therapeutic endoscopy: Endoscopic variceal ligation is a 
proven technique for primary prophylaxis of large oesopha-
geal varices and lacks much of the local morbidity associated 
with sclerotherapy. In acute bleeding, EVL is preferred 
although sclerotherapy may be performed in patients in 
whom EVL is not feasible. EVL should be continued every 
1–2 weeks until variceal obliteration. Use of glue has a role 
in therapy of bleeding gastric fundal varices, although can 
be associated with rare embolic complications. Fully covered 
SEMS have been described as a rescue therapy in patients 
failing conventional endoscopic therapy and in whom alter-
native rescue therapies (eg surgery, TIPS) is not indicated.
C-167
GENERAL SURGICAL PROCEDURES IN 
THE PATIENT WITH PORTAL 
HYPERTENSION
K. Raman
Selayang Hospital, Kuala Lumpur, Malaysia
Patients with portal hypertension (most commonly due to 
cirrhosis of the liver), who require surgery, are subject to 
greater risk for surgical and anesthesia related complications 
compared to normal patients. The magnitude of complica-
tions depends upon the type of anesthesia used, the specifi c 
surgical procedures, and the severity of liver disease. 
Emergency surgery and surgery in patients with previously 
undiagnosed portal hypertension prove especially hazardous 
as there is no time for optimization of these patients. In addi-
tion, perioperative events, such as hypotension, sepsis, or the 
administration of hepatotoxic drugs, can compound injury to 
the liver occurring during the procedure.
In an attempt to predict outcomes in this group of patients, 
researchers have adopted various methods of assessment. 
The most reproducible of these have been with the Child-
Pugh classifi cation where mortality rates of 2, 12, and 20 
percent for patients undergoing abdominal surgery with 
Child-Pugh class A, B, and C cirrhosis, respectively, are now 
being reported.
The MELD score, a statistical model predicting survival 
in cirrhotic patients being evaluated for liver transplantation, 
is now being used increasingly in predicting surgical risk in 
the nontransplant setting. Results have been promising and 
this may ultimately supplant the Child’s classifi cation as the 
principal method for determining surgical risk in all patients 
with liver disease undergoing any form of surgery.
The Mayo group has proposed a post operative mortality 
risk prediction model that uses the Child’s or MELD score 
together with the ASA physical class and patient age. This 
model has recently been validated in Korean cirrhotic 
patients. More studies however, are needed to determine the 
best method of risk assessment for this group of patients.
C-168
KEYNOTE LECTURE: RESECTION FOR 
CRC LIVER METASTASES – OVERVIEW
J. Belghiti
Abstract not available at time of publication.
C-169
THE ROLE OF PET IN THE DIAGNOSIS 
AND TREATMENT OF CRLM
S-T. Lee1,2
1Centre for PET, Austin Health, Heidelberg, Victoria, 
Australia; 2Ludwig Institute for Cancer Research, Austin 
Hospital, Heidelberg, Victoria, Australia
Positron Emission Tomography (PET) is a non-invasive 
imaging investigation to diagnose and stage colorectal car-
cinoma, with a signifi cant impact on management. The role 
of PET in colorectal cancer and in particular those with liver 
metastases will be discussed, including the use of novel 
tracers and parameters to assess the prognostic implications 
of PET.
C-170
THE INFLUENCE OF CHEMOTHERAPY 
ON SURGICAL STRATEGIES FOR 
COLORECTAL LIVER METASTASES
M. (M.) Rees
Basingstoke, UK
Surgical decision-making in the management of colorectal 
liver metastases (CRLM) used to be straightforward. Can I 
remove it – yes or no? The downside to this simplistic surgi-
cal decision was that less than one in ten patients with 
CRLMs confi ned to the liver were deemed ‘operable’.
The introduction of more effective chemotherapy drugs, 
biological agents and differing regimes of administration 
over the past two decades has revolutionized how we manage 
patients with CRLMs. Whilst up to 50% of such patients may 
now come to surgery, the planning and the timing of all 
interventions has become increasingly complex and spawned 
the development of specialist multi-disciplinary teams. 
Options must now include all permutations of the order of 
play for colorectal surgery, chemotherapy and liver surgery. 
The tumor load of either the primary or liver metastases is 
now the driving force behind decision-making. Inoperable 
but potentially operable CRLMs now dictate that chemo-
therapy is our fi rst therapeutic endeavor. With those CRLMs 
that are at the limit of resectability, we would adopt the 
‘liver-fi rst’ approach to surgery, with the colorectal surgeons 
unusually last in the queue. Bilateral distribution of CRLMs 
may require the fi rst intervention to include colorectal resec-
tion and clearance of the left liver lobe (±right portal vein 
ligation) as the fi rst move. This presentation will include 
examples of novel approaches in what is becoming an 
increasingly complex treatment algorithm.
C-171
SURVIVAL BENEFITS OF COMBINED 
RESECTION OF LIVER AND 
EXTRAHEPATIC DISEASE FOR 
COLORECTAL METASTASES
I. C. Cameron
Queens Medical Centre, Nottingham, UK
Introduction: The survival benefi ts of the resection of 
colorectal liver metastases are well documented, with exten-
sive publication on this subject over the last 15 years. 
46 Concurrent Sessions: Invited Speakers
HPB © 2011 International Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 3), 5–64
Improvements in systemic therapy have allowed the indica-
tions for liver resection to continually expand, and combined 
or staged resection of liver metastases together with extrahe-
patic disease has become established practice in many HPB 
centres.
Methods: A literature search was performed to enable a 
detailed review of the potential indications for combined 
resection of colorectal liver metastases and extrahepatic 
disease. Evidence for the combined or staged resection of 
lung, adrenal, splenic, brain, peritoneal and lymph node 
metastases will be presented, with emphasis on case selec-
tion for this type of surgery and the potential survival benefi ts 
of this strategy.
Results: There are now clear indications for an aggressive 
surgical approach with combined resection of liver and ext-
rahepatic disease in patients with advanced colorectal cancer, 
although this surgical approach has never been subjected to 
a randomised controlled trial.
Conclusions: Patient selection is crucial for this aggressive 
surgical approach, combined with systemic chemotherapy, to 
be helpful in terms of survival benefi t in patients with 
advanced colorectal cancer.
C-172
PARENCHYMAL PERFUSION AND 
RECONSTRUCTION TECHNIQUES IN 
RESECTION FOR CRC LIVER 
METASTASES
I. D. McGilvray
Toronto General Hospital, University of Toronto, Toronto, 
Canada
Outcomes following liver resection for colorectal metastases 
have improved to the point that it is reasonable to consider 
major vascular reconstruction in conjunction with liver 
resection for this diagnosis. There are a number of techniques 
that allow vascular reconstruction in the context of liver 
resection. These generally involve total vascular exclusion 
of the liver, and more recently have included cold perfusion 
of the liver to optimize parenchymal preservation over the 
time of vascular exclusion. The ultimate example of this 
approach is ex vivo liver transplantation; however, due to its 
high morbidity and mortality this approach cannot be recom-
mended for metastatic CRC. On the other hand, in situ cold 
perfusion of the liver accomplishes much the same and 
allows a great deal of fl exibility in dealing with vascular 
problems. In situ cold perfusion is tolerated remarkably well 
by the liver and the patient, with an overall mortality of 
roughly 10% in published series (all diagnoses; likely less 
for patients with metastatic CRC). In this talk technical 
issues and patient cases are discussed, as are critical selection 
criteria (Patient – what constitutes a reasonable patient for 
the approach; Tumor – selecting reasonable tumor biology; 
Liver – what constitutes a reasonable liver remnant and liver 
function). As with metastatic CRC in general, decisions 
regarding the application of in situ perfusion are best dealt 
with in a multidisciplinary forum.
C-173
LAPAROSCOPIC PANCREATIC SURGERY 
– AN OVERVIEW
C. Palanivelu
GEM Hospital and Research Centre, Tamil Nadu, India
In the fast growing era of laparoscopic surgery, the feasibility 
of wide variety of pancreatic procedures by the laparoscopic 
approach is well established. The list of procedures being 
performed by laparoscopy is growing daily with innovations 
in techniques and technology. The indications for laparo-
scopic intervention may be elective or emergent and both 
benign and malignant diseases can be tackled by this approach.
In the emergent setting of infected pancreatic necrosis, 
laparoscopic pancreatic necrosectomy reduces the stress 
response and wound healing complications associated with 
the more morbid open surgery and helps in faster recovery 
and better outcome. Various approaches have been described 
including transperitoneal and retroperitoneal routes for 
debridement of the necrosed pancreas. Among the most 
common elective indications is pseudocyst of the pancreas 
which is mainly done by laparoscopy though the endoscopic 
approach is fast catching up. The main drainage procedure 
is cystogastrostomy which can be performed transgastrically 
or intragastrically. Laparoscopic cystojejunostomy using 
Roux en Y limb of jejunum is the next most commonly 
performed procedure for pseudocyst. Chronic calcifi c pan-
creatitis is endemic in many tropical countries including India 
and is associated with dilated pancreatic duct with multiple 
intraductal calculi. Laparoscopic lateral pancreatojejunos-
tomy (modifi ed Puestow’s procedure) for chronic calcifi c 
pancreatitis is being commonly done in our center and has 
yielded good long term results comparable to open surgery 
with advantages of laparoscopy. Tumors of pancreas can be 
tackled with laparoscopic approach. Tumors in the body and 
tail of pancreas which are less than 5 cms are amenable to 
lap resections. In cases of benign tumors, spleen can be 
preserved as for as possible. Cases of laparoscopic distal 
pancreatectomy have been done with a minimal leak rate. 
Besides this, small tumors of the central body are amenable 
to median pancreatectomy which is also possible by laparos-
copy and preserves maximum pancreatic mass and function. 
Laparoscopy for management for carcinoma of pancreas is 
a formidable procedure due to the unique anatomy of the 
organ surrounded by major vascular structures and diffi cult 
exposure. Though not initially accepted widely, in centers of 
laparoscopic excellence with a high volume of cases like 
ours, we have established a safe and feasible technique of 
pancreatoduodenectomy and have one of the largest case 
series in the world. The results of our series show the onco-
logical radicality of resection and long term results similar 
to that of open surgery with the potential advantage of less 
immunosuppression. Of course, extensive laparoscopic and 
open experience with careful patient selection is necessary 
before such advanced procedures can be routinely attempted.
The entire laparoscopic community is moving towards the 
single incision revolution and laparoscopic pancreatic 
surgery is no exception. Recently, cystogastrostomy, cysto-
jejunostomy, lateral pancreatojejunostomy and distal pancre-
atectomy have all been performed through a single incision 
at the umbilicus by use of special access or routine ports and 
instrumentation. Our centre has been a pioneer in this revolu-
tion and has good short term results but need further studies 
to establish them as standard procedures.
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IS DRAINAGE NECESSARY AFTER 
PANCREATIC SURGERY?
A. Chaudhary
Medanta Medicit Hospital, Delhi, India
Pancreatic resections have traditionally been associated with 
a high morbidity and higher mortality than most other 
abdominal procedures. The leading cause of death and com-
plications is the development of a pancreatic fi stula. 
Pancreatic fi stulae are responsible for intra abdominal sepsis, 
bleeding and even gastroparesis. With improvements in 
operative technique and a greater familiarity with the proce-
dure, the incidence of pancreatic fi stulae has decreased. In 
addition, with advances in interventional radiology, the man-
agement of these fi stulae and their complications has also 
become better. Therefore the mortality associated with pan-
creatic leaks has reduced. In view of these improvements, 
there has been a trend to avoid routine drainage in pancreati-
coduodenectomy. We are sharing our experience with selec-
tive drainage in patients undergoing pancreaticoduodenectomy 
at our center. Drains were not placed in patients in whom the 
operating surgeon felt that the chances of development of a 
pancreatic fi stula are unlikely. Our results showed that avoid-
ance of drainage in these patients did not adversely affect 
their outcome.
C-175
BINDING PANCREATOGASTROSTOMY: 
A RELIABLE TECHNIQUE TO PREVENT 
ANASTOMOTIC LEAKAGE
S. Y. Peng1,2, D. F. Hong2, J. T. Li1, Y. B. Liu3 and Y. F. 
Wang2
1Zhejiang University Second Affi liated Hospital, Hangzhou, 
China; 2Zhejiang University Sir Run Run Shaw Hospital, 
Hangzhou, China; 3Shanghai Jiaotong University Xinhua 
Hospital. Shanghai, China
Introduction: Binding pancreaticojejunostomy (BPJ) can 
be safely used in most circumstances when pancreaticoduo-
denectomy is indicated. However, when the pancreas stump 
is too large it might be diffi cult to be inserted into 
the jejunal lumen. To solve these problems, Binding 
Pancreaticogastrostomy (BPG) is developed
Methods: The stump of pancreas is inserted into stomach 
and held in place with only two purse-string sutures which 
do not penetrate the pancreas. Four steps are included: 1) 
Isolation of pancreatic stump for 2 cm. 2) A piece of sero-
muscular layer at the posterior gastric wall is excised, the 
size being equivalent and the location being opposite to the 
pancreas stump. Around the sero-muscular defect a purse-
string suture is pre-placed A small incision is made later at 
the mucosa layer to accommodate pancreas stump; 3) An 
incision is made at the anterior gastric wall. In the gastric 
cavity, the edge of the mucoal opening at the posterior gastric 
wall is held up by forceps forming a mucosal tube, around 
which the second purse-string suture is pre-placed. 4) 
Binding anastomosis: After the pancreas remnant is pulled 
into the gastric lumen. The fi rst purse-string suture is tied 
(outer binding) and then the second one is also tied (inner 
binding). Pancreaticogastrostomy is thus easily and reliably 
established.
Results: The overall postoperative complications developed 
in 25 patients (24.9%), while there is no anastomotic leak.
Conclusions: Clinical use has proved BPG to be very effec-
tive, safe and better than BPJ in terms of manipulation and 
accommodating a large pancreas stump.
C-176
MEASURES TO PREVENT PANCREATIC 
FISTULA FOLLOWING 
PANCREATICODUODENECTOMY
E. C. H. Lai
Department of Surgery, Pamela Youde Nethersole Eastern 
Hospital, Chai Wan, Hong Kong SAR, China
Improvements in anesthesia, and perioperative management 
decreased the surgical mortality rate of pancreaticoduode-
nectomy to less than 5%. Unfortunately, the postoperative 
morbidity rate remains high and approaches 50% even in 
large series. The key determinant of outcome after pancreati-
coduodenectomy remains the pancreaticoenteric anastomo-
sis. Sepsis and hemorrhage, caused by pancreatic fi stula, are 
associated with a mortality rate of 20–40% and result in 
prolonged hospitalization and increased hospital expenses. 
The terminology in the medical literature to describe pancre-
atic fi stula, pancreatic leakage or anastomotic insuffi ciency 
is confusing and the terms have been interchangeably used. 
The reported pancreatic fi stula rate ranged from 2% to 22%, 
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depending on the defi nition used. However, there is no uni-
versally accepted defi nition of pancreatic fi stula. A number 
of pharmacologic measure, such as the use of somatostatin, 
and different techniques of pancreaticoenteric anastomosis, 
such as pancreaticojejunostomy, pancreaticogastrostomy, 
different positions of the jejunal loop (antecolic, retrocolic, 
or retromesenteric), isolated Roux loop pancreaticojejunos-
tomy, dunking technique, duct-to-mucosal anastomosis, the 
use of internal or external pancreatic duct stent, have been 
suggested to decrease the pancreatic fi stula rate, but the 
results have been controversial. The only consistently repro-
ducible factor for preventing pancreatic fi stula is the estab-
lishment of specialist centers performing pancreatic surgery 
in a high volume. More large scale comparative studies and 
randomized controlled trials are required to determine the 
optimum pharmacological interventions and technique of 
pancreaticoenteric anastomosis.
C-177
DRAINAGE OF PANCREATIC 
PSEUDOCYSTS – OPTIONS?
K. Raman
Selayang Hospital, Kuala Lumpur, Malaysia
A pancreatic pseudocyst is the most common cystic lesion 
of the pancreas and is defi ned as a localized collection of 
fl uid rich in amylase within or adjacent to the pancreas, 
enclosed by a nonepithelialized wall. It occurs as a result of 
acute or chronic pancreatitis, pancreatic trauma, or pancre-
atic duct obstruction. Treatment may be broadly divided into 
i) percutaneous drainage ii) surgical intervention and iii) 
endoscopic drainage.
Percutaneous drainage is simple, diagnostic, requires 
minimal sedation and multiple drains can be placed. However, 
complications and a high failure rate limit its use to the most 
ill patients.
Surgical intervention may be in the form of external drain-
age, cystogastrostomy, cystoduodenostomy, cystojejunos-
tomy, resection, and laparoscopic drainage. Internal drainage 
is dictated by the anatomic location of the pseudocyst – in 
general, the pseudocyst should be drained into the closest 
segment of bowel be it stomach, duodenum or jujenum.
Endoscopic drainage can be performed through the major 
papilla (transpapillary) or through the gastric (endoscopic 
cystogastrostomy) and duodenal (endoscopic cystoduode-
nostomy) walls. Endoscopic drainage can be performed with 
or without EUS guidance. EUS should be the initial proce-
dure because its fi ndings can change/affect management in 
up to 20% of cases. Based on EUS fi ndings, either transen-
teric drainage or ERCP followed by a transpapillary approach 
should be considered. The endoscopic experience, with the 
aid of EUS, has the lowest complication rate of all drainage 
procedures. Among endoscopic procedures, EUS-guided 
drainage is associated with the lowest recurrence rates, with 
comparable success and mortality rates relative to other 
drainage procedures.
C-178
MANAGEMENTS OF GROOVE 
PANCREATITIS
S. V. Shrikhande1 and S. G. Barreto2
1Tata Memorial Hospital, Mumbai, India; 2Modbury 
Hospital, Modbury, Australia
Groove pancreatitis is an uncommon manifestation of 
chronic pancreatitis occurring in the pancreatoduodenal 
groove formed by the pancreas, duodenum and the common 
bile duct. Patients with groove pancreatitis present with 
weight loss, pain in the upper abdomen, nausea and occa-
sionally vomiting after meals possibly due to an element of 
duodenal stenosis secondary to the ‘pseudotumour’ forma-
tion. Groove pancreatitis has been regarded as a rare clinical 
entity resulting in it often being misdiagnosed as other clini-
cal lesions including pancreatic cancer and autoimmune pan-
creatitis. An increased awareness of the disease has resulted 
in a steady increase in the number of cases reported in litera-
ture in recent years. This has enabled a better delineation of 
the radiological features of this disease. Radiology, coupled 
with the use of duodenal biopsies, whenever feasible, has 
been found to be useful in diagnosing these lesions. While 
pain control, lifestyle modifi cations and endoscopic stenting 
of the minor papilla have been shown to afford relief in the 
short term, surgery (pancreatoduodenectomy) remains the 
fi nal frontier in patients with uncontrolled pain, worsening 
duodenal obstructive symptoms, and more importantly in 
those patients in whom the diagnosis of a cancer cannot be 
completely excluded. The current presentation aims to 
provide an overview of the current understanding of the 
pathology of this disease and the outcomes of its manage-
ment based since its fi rst description, 40 years ago!
C-179
CASE PRESENTATION: MULTI ORGAN 
HYDATID DISEASE INVOLVEMENT
H. Wen
Abstract not available at time of publication.
C-180
CASE PRESENTATION: MULTIPLE 
HEPATIC ADENOMAS
M. Fink
Abstract not available at time of publication.
C-181
CASE PRESENTATION: HEMOBILIA
V. Sitaram
Abstract not available at time of publication.
C-182
CASE PRESENTATION: HILAR 
CHOLANGIOCARCINOMA
A. K. Agarwal
Abstract not available at time of publication.
 Concurrent Sessions: Invited Speakers 49
HPB © 2011 International Hepato-Pancreato-Biliary Association, HPB, 13 (Suppl. 3), 5–64
C-183
LAPAROSCOPIC LIVER RESECTION 
FOR HCC
H.-J. Kim
Yeungnam University Hospital, Korea
With accumulation of experience, laparoscopic liver resection 
is increasing recently. Laparoscopic liver resections are asso-
ciated with less intraoperative bleeding, fewer postoperative 
complications, less postoperative analgesic consumption, and 
a shorter hospital stay. Laparoscopic liver resections are 
expanding to operation for malignancy, major hepatic resec-
tion, and diffi cult locations. Advantages of laparoscopic liver 
resection (LLR) for HCC are avoidance of collateral vessel 
ligation, decreased postoperative ascites, decreased postoper-
ative hepatic insuffi ciency, fewer postoperative adhesion, and 
wound complications. One of the major advantages of lapa-
roscopy in liver resection is that it decreases operative bleed-
ing. Recent report indicates that prior LLR for HCC compared 
OLR facilitated subsequent salvage liver transplantation with 
decreased morbidity. Laparoscopic HCC resection is safe and 
leads to good postoperative and oncologic outcomes.
We have experienced 61 LLR for malignant liver tumors. 
Among 61 patients, 33 were HCC patients. Patients with 
wedge resection, Lt. lat. sectionectomy, segmetectomy, post. 
sectionectomy and left hepatectomy were 10, 8, 9, 4, and 2, 
respectively.
I will introduce our technique with a representative case 
who received left lateral sectionectomy and segment 8 wedge 
resection for bilateral HCCs.
In conclusion laparoscopic resection for HCC is feasible 
in a large number of patients, with good operative and onco-
logic results. Laparoscopic liver resection for HCC should 
be considered in selected patients in centers experienced in 
open liver surgery and in advanced laparoscopic surgery.
C-184
CENTRAL HEPATECTOMY USING THE 
GLISSONEAN TRANSECTION METHODS
M. Yamamoto, S. Katagiri, S. Ariizumi, Y. Kotera 
and Y. Takahashi
Department of Surgery, Institute of Gastroenterology, 
Tokyo Women’s Medical University, Tokyo, Japan
Central hepatectomy is a complicated operation in liver 
surgery. A J-shape or a reversed T laparotomy is performed 
in the right subcostal area. The tertiary branches to S4 from 
the umbilical portion are ligated and divided. The liver 
parenchyma is dissected along the falciforme ligament and 
then the middle hepatic vein is ligated and divided. The 
anterior surface of the inferior vena cava and the trunk of the 
right hepatic vein are confi rmed. The right anterior Glissonean 
pedicle is encircled and clamped. The tumor location should 
be checked by ultrasonography. After confi rming the tumor 
location, the liver parenchyma is dissected on the borderline 
between the right anterior and the posterior section. The 
small branches from the right hepatic vein are divided and 
liver dissection is performed along the main right hepatic 
vein. We performed central hepatectomy for 57 HCC patients 
from 1990 to 2010. The morbidity and mortality are the same 
as those in other type of sectionectomy or himihepatectomy. 
Central hepatectomy is a feasible and safe operation for 
tumors located in the central area of the liver.
C-185
LAPAROSCOPY-ASSISTED RESECTION 
FOR HILAR CHOLANGIOCARCINOMA
G. Wakabayashi
Department of Surgery, Iwate Medical University School of 
Medicine, Japan
Precise skeletonization of the hepatoduodenal ligament and 
a safe and reliable hepaticojejunostomy are essential for 
resection of hilar cholangiocarcinoma. We present a case to 
describe laparoscopy-assisted left trisectionectomy for hilar 
cholangiocarcinoma of Bismuth–Corlette classifi cation type 
IV with both portal vein and hepatic artery reconstructions.
Case presentation: A 68 y/o female patient was diagnosed 
with hilar cholangiocarcinoma located at the bifurcation and 
invaded to both the portal vein and the hepatic artery. 
Laparoscopy-assisted left trisectionectomy with S1 resection 
was planned with both portal vein and hepatic artery 
reconstructions. 
Operative procedure: After a full mobilization of the left 
lateral sector, the Spiegel lobe was carefully detached from 
the inferior vena cava under pneumoperitoneum. A 10 cm 
upper midline incision was made and a Penrose drain was 
placed between the middle hepatic vein (MHV) and the right 
hepatic vein (RHV) for hanging the transection line. The 
hepatoduodenal ligament was precisely skeletonized with 
lymph node dissection through the mini-laparotomy. 
Parenchymal transection started from the root of RHV and 
fi nished around the right posterior portal pedicle at the hilum. 
The posterior branch of the right portal vein and the right 
hepatic artery were taped and the posterior bile ducts were 
divided. The duct margin was cancer free. The portal vein 
was resected and the posterior branch was anastomosed with 
the main portal branch. The left trisectionectomy with S1 
resection was completed after the hepatic artery resection. 
The posterior branch of the right hepatic artery was anasto-
mosed with the main right hepatic artery using a magnifi er 
loupe. Hepaticojejunostomy was performed through 
mini-laparotomy. 
Results: Operative time was 682 min and blood loss was 
640 ml. The patient was discharged on the 42nd post-
operative day after having a minor leakage of the 
hepaticojejunostomy.
C-186
LAPAROSCOPIC EXTENDED LIVER 
RESECTION
H. Kaneko
Toho University, Tokyo, Japan
The continuing evolution of laparoscopic surgery, which has 
been rapidly adopted as minimally invasive surgery, has been 
applied to the laparoscopic liver resection. Laparoscopic 
liver resection is a highly specialized fi eld, however, impor-
tant technologic developments and improved endoscopic 
procedures are being established. Thus, laparoscopic hepa-
tectomy has been more actively performed recently. We have 
pursued laparoscopic hepatectomy as a means of surgical 
therapy.
We have accumulated laparoscopic hepatectomy cases, 
and the operative time has been shortened with less bleeding 
in recent cases. Laparoscopic hepatectomy was found to be 
less invasive than conventional hepatectomy. The patients 
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were given more rapid recoveries consequently allowed 
shorter hospitalizations.
The fi ve-year survival rate and the survival rate without 
recurrences for HCCs are almost same as that by open con-
ventional hepatectomy although further analysis would cer-
tainly be necessary to reach defi nitive conclusions.
Recently, we have successfully performed laparoscopic 
extended liver resection such as laparoscopic pure-
hemihepatectomy, hepatectomy of giant HCC and tumor 
located upper segment, recurrence tumor.
Laparoscopic extended liver resection appears to be a 
viable surgical alternative in selected cases. This procedure 
is expected to develop further in the future as a new surgical 
method for liver surgery as less invasive surgery.
The technique of the laparoscopic extend liver resection 
of laparoscopic hemihepatectomy, hepatectomy of giant 
HCC and tumor located upper segment, recurrence tumor 
will be shown in the congress.
C-187
SYMPOSIUM: ACUTE LIVER FAILURE: 
MEDICAL MANAGEMENT OF ACUTE 
LIVER FAILURE
P. Angus
Abstract not available at time of publication.
C-188
ORTHOTOPIC LIVER 
TRANSPLANTATION FOR ACUTE LIVER 
FAILURE
A. Bartlett
Hepatopancreaticobiliary and Liver Transplant Surgeon, 
University of Auckland, Auckland City Hospital, Auckland, 
New Zealand
Acute liver failure (ALF) is an uncommon condition in 
which the rapid deterioration of hepatic synthetic function 
leads to jaundice, coagulopathy and encephalopathy in a 
previously healthy individual. Common causes include 
paracetamol, idiosyncratic drug reactions, viral hepatitis, 
metabolic derangements or idiopathic in approximately 25%. 
Treatment is primarily focused on the optimization of fl uid 
balance to maintain end organ perfusion, prevention of cere-
bral edema, cardio-respiratory support, monitoring of meta-
bolic parameters, surveillance for infection and providing 
adequate nutritional support. While the majority of patients 
with ALF recover with supportive measures, orthotopic liver 
transplantation (OLT) is the only potential curative treatment 
for those who continue to deteriorate or have adverse prog-
nostic factors. The use of hepatic assist devices remains 
experimental as they have not been shown to improve sur-
vival. Several prognostic scoring systems have been devised 
to select patients who require OLT, including the Kings 
College, Clichy and APACHE II criteria. As a result of 
improved patient selection, peri-operative care and surgical 
techniques many centers are now achieving >80% one year 
survival in patients undergoing OLT for ALF.
C-189
SYMPOSIUM: ACUTE LIVER FAILURE: 
AUXILLARY LIVER TRANSPLANTATION 
FOR ACUTE LIVER FAILURE
M. Rela
Abstract not available at time of publication.
C-190
SYMPOSIUM: ACUTE LIVER FAILURE: 
ARTFICIAL LIVER SUPPORT SYSTEMS
G. Starkey
Abstract not available at time of publication.
C-191
IATROGENIC BILE DUCT STRICTURES 
– AN OVERVIEW
M. Joshi Rajeev
T.N.Medical College & Nair Hospital, Mumbai, India
Iatrogenic bile duct strictures are often seen in young patients 
and injuries during surgery account for more than 90% of 
cases. Strictures may occur in the extrahepatic and/or intra-
hepatic bile ducts and may be solitary or multiple. Bismuth 
classifi cation is useful for localization but does not encom-
pass the entire spectrum. Strasberg et al have proposed a 
comprehensive classifi cation system that incorporates 
Bismuth’s scheme but is much broader in scope.
These pose a diffi cult management proposition. Unlike in 
malignant biliary obstruction, where short term palliation is 
often the goal of therapy, benign strictures require durable 
repair since most patients are in otherwise good health and 
are expected to survive longer. Improper or inadequate man-
agement may lead to biliary fi stula, biliary cirrhosis, PHT or 
recurrent cholangitis. It is therefore imperative that any 
attempt at repair be carried out in a precise and expert 
manner.
Surgical reconstruction remains the “Gold Standard”. It is 
well recognized that strictures involving the distal duct are 
easier to repair than proximal strictures. Factors associated 
with stricture recurrence are proximal strictures, multiple 
prior attempts at repair, PHT, hepatic parenchymal disease, 
end-to-end biliary anastomosis, surgeon inexperience, con-
current cholangitis and hepatic abscess, intrahepatic stones, 
external or internal biliary fi stula and hepatic lobar atrophy. 
In recent years, endoscopic stenting has been successful in a 
selected subgroup of patients. However, long term results of 
endotherapy as defi nitive treatment are debatable. Surgery is 
a reliable and results of numerous studies show its long-term 
success with minimal morbidity. To push or sidestep? The 
debate continues!
C-192
ASSESSMENT OF INJURY AND TIMING 
OF SURGERY
V. Muralidharan
Abstract not available at time of publication.
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C-193
SURGICAL TECHNIQUES OF REPAIR OF 
BILE DUCT STRICTURES
S. Harjit
Hospital Selayang, Kuala Lumpur, Malaysia
Several different surgical techniques have been used to repair 
benign bile duct strictures. The choice of technique is deter-
mined by the anatomical location, extent and nature of the 
stricture and the presence or absence of any biliary obstruc-
tion associated complications. Preoperative imaging and 
delineation of the biliary anatomy is crucial for the planning 
of surgery.
Repair of strictures involving the extrahepatic portion of 
the bile duct is relatively straight forward while that involv-
ing the confl uence and intrahepatic bile ducts is complex and 
technically demanding. The key-factors for a successful 
repair include complete excision of the strictured segment 
and reconstruction of a tension-free, meticulous, anastomosis 
between the bile duct stump and the bowel using fi ne, single 
layer, interrupted, monofi lament absorbable sutures.
Although various surgical operations have been described, 
the best long-term outcomes are obtained with the 
Roux-en-Y hepaticojejunostomy or choledochojejunostomy. 
Various modifi cations of the bilio-enteric anastomosis have 
been utilized for the repair of the different types of bile duct 
strictures. The presence of intrahepatic strictures with 
atrophy of the corresponding segments of the liver is best 
managed by resection of the affected segments while the 
presence of secondary biliary cirrhosis and its associated 
complications is best remedied by liver transplantation.
The results of surgical repair of bile duct strictures in 
specialized units are excellent with successful long-term out-
comes being in excess of 90% in most series. Proper and 
prompt management of bile duct strictures by skilled & expe-
rienced hepatobiliary surgeons is mandatory to avoid long 
term morbidity and mortality.
C-194
DIAGNOSIS AND MANAGEMENT OF 
VASCULAR INJURIES ASSOCIATED 
WITH BILE DUCT STRICTURES
K. Madhavan
National University Health System, Singapore
Bile duct injury during cholecystectomy is an uncommon 
complication (3/1000) but with serious consequences to the 
patient and often to the surgeon. Bile duct injury at chole-
cystectomy may present soon after the operation or indeed 
at a late stage with bile duct strictures. Vascular injuries 
sustained at the time of bile duct injuries are of little conse-
quences in late stricture presentations except infl uencing the 
nature of a planned operation specially if the ipsilateral liver 
is atrophic and there are intrahepatic strictures in the bile duct 
on that side. The surgeon may in these circumstances, elect 
to offer the patient a hemihepatectomy rather than biliary 
reconstruction. However, the implication of a vascular injury 
at the time of bile duct injury presenting acutely is very dif-
ferent. So is the case if the vascular injury in arterial, portal 
venous or both.
For medicolegal reasons, it is very important that a surgeon 
called upon to repair a bile duct injury document or establish 
by appropriate investigations, whether a concomitant vascu-
lar injury existed. Controversy still exists as to whether at 
the time of a defi nitive repair of the bile duct, any evident 
arterial injury should be also repaired. Technical diffi culties 
under such condition as well as results of such “double 
repairs” will be discussed.
Portal vein injuries are rarely associated with bile duct 
injuries and much literature does not exist about how this 
should be managed. A review of the published literature on 
this rare condition will be undertaken and some personal tips 
will be provided as to their management.
C-195
LIVER RESECTION AND 
TRANSPLANTATION FOR BILE DUCT 
INJURY
O. J. Garden
Abstract not available at time of publication.
C-196
DEBATE: PERCUTANEOUS AND/OR 
ENDOSCOPIC APPROACHES VS 
SURGERY FOR CHRONIC BILE DUCT 
STRICTURES (SURGERY)
V. Sitaram
Abstract not available at time of publication.
C-197
PERCUTANEOUS AND ENDOSCOPIC 
APPROACHES TO CHRONIC BILE DUCT 
(CBD) STRICTURES
M. Cox
Nepean Hospital, Sydney, NSW, Australia
CBD strictures include:
1. Post operative strictures due to some form of operative 
injury following cholecystectomy, gastric surgery or 
hepatic resections. These may present early (<2 years) or 
late.
2. Anastomotic strictures following biliary-enteric 
anastomosis.
3. Strictures associated with complications of pancreatitis, 
including chronic pancreatitis.
For many cases of biliary stricture the debate is not should 
they have an endoscopic or surgical approach, but rather it 
is part of a management algorithm.
Post operative strictures below the biliary confl uence 
should be managed initially with a trail of endoscopic dilata-
tion and serial stenting (multiple plastic or removable metal 
stents) and surgery performed for cases that are not success-
fully managed endoscopically. Most (90%) of post operative 
strictures distal to the confl uence are successfully managed 
long term with an endoscopic approach.
The management of post operative strictures at or above 
the biliary confl uence is more controversial. Endoscopic 
management has a much lower success rate with a 
higher incidence of cholangitis and other complications. 
Percutaneous management may be trialled initially but has a 
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moderately high failure rate. Therefore, strictures at or above 
the confl uence are probably better managed with surgical 
intervention from the outset.
Anastomotic strictures following a biliary-enteric anasto-
mosis are best managed with percutaneous dilatation tech-
niques rather than revision surgery. This is the case whether 
the biliary anastomosis was performed as part of a planned 
resection or for the management of a post operative stricture.
Distal biliary strictures due to complicated acute or chronic 
pancreatitis are best initially managed with a trail of endo-
scopic dilatation and stenting and treatment of any causative 
factors of pancreatitis. If there is a signifi cant component of 
acute infl ammation in the causation of the stricture there is 
a chance of resolution without requiring surgery. If the endo-
scopic therapy fails then surgical intervention is required.
Therefore, with the exception of high biliary strictures 
endoscopic therapy is preferred as the initially treatment 
modality and surgery for the failures. Biliary enteric anasto-
motic strictures are best managed with PTC techniques.
C-198
CARCINOMA OF THE SIGMOID WITH 
SYNCHRONOUS METASTASIS RIGHT 
LOBE LIVER
P. Herman
Abstract not available at time of publication.
C-199
HEMIHEPATECTOMY WITH LIMITED 
RESECTION FOR MULTIPLE LIVER 
METASTASES FROM CRC
N. Kokudo, S. Tamura, K. Hasegawa, M. Takahashi, 
Y. Inoue, J. Kaneko, Y. Sakamoto, T. Aoki and Y. Sugawara
Hepato-Biliary-Pancreatic Surgery Division, Department 
of Surgery Graduate School of Medicine, University of 
Tokyo, Tokyo, Japan
Introduction: Hepatic resection has been the only treatment 
for cure against liver metastasis from colorectal carcinoma 
(CRC), however, the signifi cance of major hepatectomy for 
multiple tumors, which can be regarded as potentially R1 
resection, remains unclear.
Methods: From 1994 to 2010, total 402 patients with CRC 
liver metastasis underwent hepatic resection in Tokyo 
University Hospital, among which 37 underwent left or right 
hemihepatectomy with limited resection in the contra-lateral 
hemiliver. Portal vein embolization was performed in 13 
patients before hepatectomy, because future liver remnant 
was estimated to be less than 40% of total liver volume. The 
median size of the largest tumor and number were 5 cm and 
5, respectively.
Results: No mortality occurred in the 37 cases of hemihepa-
tectomy with limited resection. The 3-year survival rate was 
49%, although the recurrence rate at 2 years was high up to 
92%.
Conclusions: Hemihepatectomy with limited resection can 
be safely performed for multiple liver metastases from CRC, 
although it may be invasive. Portal vein embolization is 
useful to increase the safety of major hepatectomy. The long-
term outcomes after the aggressive therapy were acceptable, 
even though the tumor status was advanced.
C-200
COMPLETE RESOLUTION OF CRC 
RESECTABLE LIVER LESIONS AFTER 
NEOADJUVANT CHEMOTHERAPY
M. (M.) Rees
Basingstoke, UK
The improved effectiveness of chemotherapy for colorectal 
liver metastases (CRLM) has enabled a stepwise increase in 
the percentage of patients suitable for surgery. Some centers 
are now operating on approximately half of the patients pre-
senting with metastatic spread confi ned to the liver. A major 
drawback of this chemotherapeutic success story is what to 
do with lesions that “disappear” on sequential imaging. Our 
fi rst rude awakening more than a decade ago was to realize 
that such “total” eradication is short-lived. We and others have 
shown that more than 90% of these “eradicated” lesions 
become apparent either at the time of surgery or within the 
post-operative period, sometimes up to two years later. If 
possible, the latter group will be subjected to further therapeu-
tic intervention of the liver by ablation or surgery. Avoidance 
of this can only be achieved by careful pre-treatment planning 
and liaison between oncologists, radiologists and surgeons. 
Examples of novel treatment strategies will be highlighted 
during the presentation. The key take-home message is, get 
your best and most thorough imaging prior to starting any 
chemotherapy. Using this baseline “roadmap” in any subse-
quent surgery will minimize the risk of further intervention.
C-201
RESECTABLE LIVER METASTASES 
WITH AN UNKNOWN PRIMARY 
CANCER (UPC)
J. Pekolj
Hospital Italiano Buenos Aires, Buenos Aires, Argentina
Approximately 5% of cancer patients are diagnosed with 
UPC. Of these, 10–30% have liver metastases. In different 
series the liver was the only metastatic site in 32–38% of 
patients, while it was accompanied with other metastatic sites 
in 62–68% (the commonest: lung, bone and lymph nodes).
Hepatic metastases in UPC patients are associated gener-
ally to a poor prognosis and encompass a variety of different 
pathologic entities. However, subsets of patients with more 
favorable outcomes can be identifi ed by available clinical 
and pathologic data and as example neuroendocrine CUP are 
associated with a signifi cantly better prognosis than the other 
malignancies (adenocarcinomas).
Before patients are considered for surgery, a multidisci-
plinary team assessment and evaluation consisting of com-
puted tomography, PET, tumor markers, somatostatin 
receptor scintigraphy, and upper and lower endoscopy should 
be done.
The pathologic approach is stepwise and uses the clinical 
context, morphology, and immunohistochemistry. The most 
frequent histological types observed were adenocarcinoma, 
undifferentiated, neuroendocrine and squamous-cell carcino-
mas. Liver biopsy could be essential for histological diagno-
sis and important to identify the tumors who may benefi t 
from specifi c and effective therapy (breast cancer, prostate 
cancer, ovarian cancer and small-cell carcinoma of the lung). 
Systemic chemotherapy represents the most frequently 
treatment.
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For patients with liver metastases and neuroendocrine 
UPC, there is a consensus that surgical exploration is indi-
cated and effectively identifi es and resects occult primary 
tumors in the majority of the cases. The tumors are often 
located in the small intestine, and are usually small and multi-
focal, so careful palpation of the small intestine is essential.
Adenocarcinoma metastases carry a dismal prognosis; 
however in selected cases the surgical exploration is indi-
cated and could identifi es the original digestive tumor and 
also resects it. Prognosis is poor mainly by the biology of 
the tumor and the synchronous appearance.
Few series of liver resections for UPC metastases are 
described. In the Adam’s series of no colorectal non neuro-
endocrine metastases resections, twenty-nine patients with 
UPC origin were included in the study. This indication was 
associated with a 5-year survival of 38% with low morbidity. 
Liver resections were safe and effective, with outcomes 
mainly dependent on primary tumor site and histology.
Improved patient selection, new and of more effective 
systemic treatments, and the low morbidity and mortality 
rates of liver resections in centers of excellence are likely to 
provide continued improvements in outcomes. The under-
standing of the underlying tumor biology for each cancer 
type and application of individualized care to each patient 
may also improve the results.
In summary liver resectables metastases of UPC should be 
resected in selected patients with good status performance, 
due to low mortality of liver surgery in reference centers and 
the potential benefi t to improve the survival according to the 
histology of the tumor. Also by abdominal exploration is 
possible to identify and resect the original tumor. When 
applied in these situations, surgery may be able to offer a 
benefi t in long-term survival.
C-202
THE APPROACH TO SYNCHRONOUS 
RESECTABLE LUNG AND LIVER CRC 
METASTASES
T. C. Gamblin
Abstract not available at time of publication.
C-203
NON RESECTABLE LIVER ONLY CRC 
METASTASES: WHAT SHOULD I DO AND 
WHY?
R. S. Stubbs
Wakefi eld Gastroenterology Centre, Wellington, New 
Zealand
Years ago, the knowledge that individuals dying from CRC 
frequently had liver-only disease encouraged surgeons to 
take what often appeared to non-surgeons, to be a fool-hardy 
local approach to what was widely believed to be a systemic 
problem. However, time and experience has vindicated this 
seemingly aggressive attitude to the problem of liver-only 
CRC metastases. Despite this, there commonly remains 
something of a dichotomy of opinion between surgeons 
and non-surgeons, with respect to the management of non-
resectable liver-only CRC metastases.
The fall back position was once masterful inactivity and 
palliative care. Time has shown we can do better than this. 
Not so long ago, when systemic chemotherapy options 
revolved only around single agent chemotherapy with 5-fl u-
oruracil, surgical enquiry and endeavor ruled. A variety of 
what might be termed ablative or regional approaches were 
explored and variably employed. These included such 
modalities as devascularization procedures, regional chemo-
therapy, cryoablation, microwave ablation, radiofrequency 
ablation and selective internal radiation therapy. Each have 
had their proponents, and each have had demonstrable 
success. However, the advent of more effective systemic 
chemotherapy options, coupled with the increasing reliance 
on the randomized trial as the only method of validation of 
effi cacy, has seen these regional approaches lose out to the 
widespread adoption of fi rst-line chemotherapy, followed by 
successive lines of usually increasingly expensive, toxic, and 
inevitably less effective chemotherapy regimens. The knowl-
edge that at times such chemotherapy can downstage non-
resectable disease to resectable disease has become a real 
drawcard. In the process, it is possible that a variety of effec-
tive, but less well studied physical and regional approaches 
are being ignored. These approaches should not necessarily 
be seen as being in competition with systemic chemotherapy, 
but might rather be used in a complementary fashion, for the 
ultimate benefi t of the patient. This possibility will be 
explored in the course of the presentation.
C-204
IS THERE A ROLE FOR TOTAL 
PANCREATECTOMY IN CARCINOMA OF 
THE PANCREAS?
J. Samra
Abstract not available at time of publication.
C-205
SIGNIFICANCE AND MANAGEMENT OF 
MAJOR VESSEL INVOLVEMENT IN 
CARCINOMA OF THE PANCREAS
W. S. Helton
Abstract not available at time of publication.
C-206
MANAGEMENT OF RESECTABLE LIVER 
METASTASES FROM PERIAMPULLARY 
CARCINOMA
K. H. Liau
Nexus Surgical Associates, Mount Elizabeth Medical 
Centre, Singapore
With better understanding of tumor biology and improve-
ment in liver surgery, hepatic metastasectomy is an accepted 
treatment for colorectal, ovarian and neuroendocrine tumour. 
However, the role of hepatic metastasectomy for periampul-
lary carcinoma is controversial. Even though attempts have 
been made to resect a minority of patients with solitary 
hepatic metastatic periampullary carcinoma, the result on 
survival improvement has yet to be demonstrated. It is not 
surprising to witness the continuing evolution of this 
approach as better outcome from liver resection and better 
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systemic and targeted therapies become available in the 
recent years. Although pancreaticoduodenectomy and liver 
resection can be performed safely in experienced centers, the 
benefi ts and long-term outcome of surgery for liver metasta-
ses from periampullary carcinoma, even in a highly selected 
group of patients, have yet to be proven. While surgeons are 
pushing the forefront of surgery in metastatic diseases, the 
concepts of “what can be done does not mean it ought to be 
done” and “short-term and long-term outcomes must out-
weigh the risk of intervention” remains the key factors for a 
universal acceptance as a standard recommendation. The 
perspective of this approach will be discussed in this sym-
posium lecture.
C-207
DOES THE EXTENT OF LYMPH NODE 
CLEARANCE MATTER IN CARCINOMA 
OF PANCREAS?
K. Wada
Teikyo University School of Medicine, Tokyo, Japan
Pancreatic ductal adenocarcinoma (PDAC) still have dismal 
prognosis. The only potential “curative” treatment for PDAC 
is surgical resection, but majority of cases have advanced, 
metastatic disease at diagnosis. Even in patients with “resect-
able” PDAC surgery alone is no longer standard treatment 
according to recent clinical trials, thus R0 resection com-
bined with adjuvant therapy is current standard treatment.
The extent of lymph node clearance has been subject of 
hot discussion in the 1990’s to 2000’s as more than 70% of 
patients with resected PDAC have nodal metastasis. Because 
the presence of nodal metastasis showed poorer prognosis 
achieving a greater lymph node clearance should hypotheti-
cally infl uence survival. Several randomized controlled trials 
and meta-analysis comparing extended versus standard 
lymphadenectomy for PDAC have been conducted to date, 
but none of them showed the advantage for extended lymph-
adenectomy in terms of survival. And increasing morbidity 
and impaired QOL were also noted when performing 
extended lymphadenectomy which may cause intolerability 
or signifi cant delay for systemic adjuvant treatment. Thus, 
prophylactic use of extended lymphadenectomy is of no 
benefi t for patients with PDAC.
As of 2010’s more effective systemic agents are available, 
and also quality of imaging is dramatically improved, surgi-
cal planning can be more individualized in clinical practice 
including the extent of lymph node clearance. Prophylactic 
extended lymphadenectomy should be performed only in the 
setting of clinical research. Based on the fi ne imaging, 
usually thin-sliced, multi-phase contrast enhanced MDCT, 
“R0-directed operation” should be performed for patients 
with PDAC, while minimizing severe postoperative morbid-
ity and keeping QOL for fast delivery of adjuvant 
treatment.
C-208
RADICAL ANTEGRADE MODULAR 
PANCREATOSPLENECTOMY: 
RATIONALE AND RESULTS
P. C. Bornman
Department of Surgery University of Cape Town and 
Groote Schuur Hospital Cape Town RSA
Compared to pancreaticoduodenectomy (PD), relatively few 
distal pancreatectomies (DP) are performed for pancreatic 
cancers mainly due to more advanced disease at time of 
diagnosis. As a consequence DP has not gone through the 
same technical refi nements of PD to achieve R0 resections. 
To this end, Strasburg et al. (1) have devised a modifi ed distal 
pancreatectomy, termed radical antegrade modular pancrea-
tospenectomy (RAMPS) to achieve more R0 resections. The 
operation starts with transaction of the neck followed by an 
ante-grade mobilization of the body and tail of the pancreas 
with en-bloc removal of the lymph nodes draining the pan-
creas body and tail. An important step of the operation is to 
establish the correct posterior dissection plain which should 
be either anterior or behind the adrenal gland depending on 
whether the latter is involved by tumor or not. The purported 
advantages of this operation are; i) better identifi cation of the 
dissection plain and in particular the anterior surface of 
the renal vein and adrenal gland ii) better identifi cation of 
the large vessels which allows early control and safer dissec-
tion iii) providing the option of early planned posterior resec-
tion behind the adrenal gland onto the posterior abdominal 
wall when this is involved iv) improve the chances of a 
complete resection margin and N1 lymph nodes.
Although the results achieved by the Washington group(1) 
in terms of complete resection rate and survival are encour-
aging, there is a paucity of data to allow for a meaningful 
comparison with conventional distal pancreatic operations. 
The potential advantage of RAMPS and the performance of 
this laparoscopically, require further evaluation to determine 
its role in the management of body and tail pancreatic 
cancers.
Reference
1. Strasberg SM et al. Radical antegrade modular pancreato-
splenectomy procedure for adenocarcinoma of the body 
and tail of the pancreas: ability to obtain negative tangen-
tial margins. J Am Coll Surg 2007;204:244–49.
C-209
STRATEGIES TO DOWNSTAGE 
PANCREATIC CANCER
V. Usatoff
Alfred and Western Hospitals, Melbourne, Australia
Long-term survival after the diagnosis of pancreatic cancer 
is only possible in patients who are able to undergo resection 
with clear (R0) margins prior to the development of meta-
static disease. Only 20% of patients with pancreatic cancer 
fi t into this category and this group can expect a median 
survival of 12–24 months. This poor prognosis, despite 
“curative” surgery, even with extended radical procedures, 
supports the premise that pancreatic cancer is a systemic 
disease at diagnosis and consequently systemic treatment 
with chemotherapy is likely to be an important part of the 
management. The survival advantage with chemotherapy is 
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well demonstrated in the adjuvant, post resection setting. In 
patients where resection is not likely without negative 
margins, a neoadjuvant approach to downstage the tumor 
prior to resection has a basis in logic. With only small, single 
centre studies published, there continues to be little convinc-
ing evidence to support this approach. This lack of conclu-
sive evidence is partly due to a lack of agreed upon defi nition 
of resectability and “borderline” resectability. Furthermore, 
CT scanning offers an inadequate assessment of response to 
neoadjuvant treatment with CA19.9 and PET scanning pos-
sibly offering some benefi t in assessing metabolic response. 
Another diffi culty in assessing the evidence, is the large 
number of different chemotherapy regimens (with and 
without radiotherapy) that are utilized. This paper explores 
the potential advantages and disadvantages of a neoadjuvant 
approach, particularly in the borderline resectable cases, with 
an attempt to bring together the available evidence to make 
some workable recommendations.
C-210
PALLIATIVE OPTIONS – STENTING OR 
BYPASS PROCEDURES FOR NON-
RESECTABLE LOCALIZED PANCREATIC 
TUMOR
V. D. Borgaonkar
HPB Services, Department of Surgery, Seth Nandlal Dhoot 
Hospital, Aurangabad, India
Introduction: Almost 85 to 90% of pancreatic cancers 
require palliative procedures for relief of three symptoms 
Obstructive Jaundice, Duodenal Obstruction and Pain.
Methods: Palliative options are Surgical or Endoscopic pro-
cedures. Surgical options are choledocho/cholecysto-enter-
ostomy with palliative or elective gastro-jejunostomy. 
Endoscopic options are biliary stent with or without duode-
nal stenting.
Results: Outcome of the patients was better in patients in 
whom decision of palliative bypass was done intraopera-
tively due to nonresectability, than those who were electively 
posted for palliative bypass procedures. Readmissions for 
reasons like cholangitis were signifi cantly low in surgical 
group. Overall survival rate was superior in surgical group 
as compared to stented group.
Conclusions: Combined surgial biliary and gastric bypass 
achieves effective palliation until death in almost 95% of the 
patients. This remains fi rst line therapy in patients identifi ed 
as having unresectable disease at laparotomy. Cholecysto-
jejunostomy is technically simple to perform as compared to 
choledocho/hepatico-jejunostomy. Intraoperatively patency 
and adequate dilatation of cystic duct must be ensured. 
Results of cholecysto jejunostomy are comparable to cho-
ledocho jejunostomy. Gastric bypass procedures should be 
electively performed in order to avoid future need for treat-
ment of gastric outlet obstruction. Endoscopic biliary stent-
ing procedures are technically demanding and need high end 
equipments. Though initial hospital stay is short, these 
patients need frequent readmissions for treatment of cholan-
gitis. Patient might need simultaneous duodenal stenting 
which is technically more demanding. Surgical options are 
better and should be performed for patients with longer life 
expectancy verses endoscopic options should be reserved for 
patients with shorter life expectancy.
C-211
PAIN RELIEF FOR ADVANCED 
CARCINOMA OF THE PANCREAS
D. Martin
Abstract not available at time of publication.
C-212
EHPBA CONSENSUS CONFERENCE ON 
HCC: RESULTS
P-A. Clavien
Abstract not available at time of publication.
C-213
RISK FACTORS IN RESECTION FOR 
HCC
R. Bryant
Royal Brisbane Hospital, Queensland, Australia
90% of HCC occur in cirrhosis and chronic liver disease. 
Hepatectomy in cirrhosis is associated with elevated morbid-
ity and mortality, primarily due to postoperative hepatic 
insuffi ciency. This risk is associated with the degree of pre-
operative hepatic dysfunction, the volume of liver resected, 
the presence of portal hypertension and the level of hepatitis 
activity. Hepatic function can be estimated with the Child-
Pugh score or indocyanine green retention, with major resec-
tions limited to Child’s A cirrhosis. Estimation of functional 
residual liver volume by liver volumetry is important, with 
the aim to preserve 50% of functional liver volume. Anatomic 
resections are recommended for HCC to reduce recurrence, 
and parenchymal-preserving anatomic techniques can be 
employed to improve the residual volume. Residual volume 
can also be increased by preoperative portal vein emboliza-
tion, and a documented increase in volume post embolization 
demonstrates the regenerative capacity of the liver. Portal 
hypertension contraindicates a major hepatectomy, but a 
minor resection can be considered with grade II varices. 
Specifi c surgical techniques such as the type of vascular 
control employed, low central venous pressure, use of the 
anterior approach and hanging maneuver, and utilization of 
the laparoscopic approach are important considerations. 10% 
of HCC occur in normal livers, and the normal regenerative 
capacity of these livers means that extended hepatectomies 
are usually tolerated.
C-214
THE ROLE OF ANTIVIRAL THERAPY IN 
THE MANAGEMENT OF 
HEPATOCELLULAR CARCINOMA (HCC)
A. G. Testro
Department of Gastroenterology, Austin Health, 
Melbourne, Australia
Chronic viral hepatitis, predominantly chronic hepatitis B 
(HBV) infection, is the leading cause of HCC worldwide. In 
regions where HBV is endemic, such as the Asia-Pacifi c 
region, chronic HBV infection is present in 80–90% 
of patients with HCC. It is known that ongoing hepatic 
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infl ammation produces an environment that favors develop-
ment of HCC, and as such it is no surprise that long-term 
suppression of viral replication with nucleos(t)ide analogues 
such as lamivudine and entecavir is associated with a reduced 
risk of HCC, as well as a reduction in fi brosis progression 
and other cirrhosis-related complications. Likewise, treat-
ment of chronic hepatitis C (HCV) infection with the com-
bination of pegylated-interferon and ribavirin, also results in 
a signifi cantly decreased risk of HCC, particularly in those 
patients who achieve a sustained virological response.
Until recently there was a scarcity of data on the role of 
antiviral therapy post curative treatment of HCC, such as 
those patients who have undergone hepatectomy, where 
cumulative recurrence rates at 5-years of 50–70% have been 
reported. Further surgical management of recurrent disease 
in this population is often limited by impaired liver function 
in the remnant liver. The use of antiviral therapy post hepa-
tectomy is now recommended. This presentation will focus 
on the latest evidence supporting the use of antiviral therapy 
(both for HBV and HCV) as an adjunct for the curative treat-
ment of HCC, in particular the effects of antiviral treatment 
on long-term survival, HCC recurrence, and suitability for 
further attempts at curative therapy.
C-215
ADJUVANT THERAPY FOLLOWING 
RESECTION FOR HCC
V. Lam
Westmead Hospital, Westmead, Australia
Hepatocellular carcinoma (HCC) is common worldwide and 
its incidence is increasing. Even after curative liver resection, 
recurrence is common and is the main cause of death. In this 
meta-analysis, the role of adjuvant therapy after resection of 
HCC was reviewed.
C-216
COMBINATION THERAPY WITH 
SELECTIVE INTERNAL RADIATION AND 
SORAFENIB FOR ADVANCED 
HEPATOCELLULAR CARCINOMA – 
THE AHCC05 TRIAL
P. Chow
Duke-NUS Graduate Medical School, Singapore General 
Hospital, National Cancer Center, Singapore
The Asia-Pacifi c bears the largest portion (70%) of the global 
burden of HCC mainly because of the high incidence of 
chronic viral hepatitis in this part of the world. While surgical 
resection and transplantation are potentially curative in HCC 
less than 20% of patients are amendable to these treatments 
at diagnosis. Survival in inoperable patients with poor liver 
function remains grave. Novel therapeutics are thus directed 
at advanced HCC with preserved liver function and this is 
the group where the biggest impact on survival may be 
achieved.
The Asia-Pacifi c Hepatocellular Carcinoma Trials Group 
protocol 05 (AHCC05) (NCT00712790) phase I/II trial com-
bines an effi cacious loco-regional therapy (selective internal 
radiation therapy (SIRT) with yttrium-90) with a proven sys-
temic agent (sorafenib) in patients with both locally advanced 
and metastatic HCC. The trial closed in June 2009 and 
overall survival in patients compared well with treatment by 
either SIRT or sorafenib alone. Median survival were 20.6 
months in BCLCB and 8.2 months in BCLC C and the posi-
tive results demonstrate proof of principle of this combina-
tion therapy.
The success of the AHCC06 trial has lead to the launch of 
the phase III AHCC06 trial “Randomized Controlled Trial of 
SIR-sphere vs Sorafenib in locally advanced inoperable 
HCC” (NCT01135056).
C-217
NOVEL THERAPIES FOR HCC
J. S. Cebon
Ludwig Institute Oncology Unit, Austin Health, Australia
The systemic management of advanced or metastatic hepa-
tocellular carcinoma has been problematic because of HCC 
is relative insensitivity to commonly used cytotoxic chemo-
therapeutics and because of the constraints resulting from 
co-morbidities, especially impaired liver function and portal 
hypertension. The availability of Sorafenib following the 
successful randomized SHARP trial opened new possibilities 
for treatment by targeting activated tyrosine kinases. Median 
overall survival and time to progression were both increased 
by about three months, and 44% (compared to 33% of 
placebo patients) remained alive at one year. Other TKIs 
such as Sunitinib have not been shown to be as effective and 
a recent Phase III comparison between the two agents was 
abandoned because of this. The challenge, therefore, is to 
identify the best targets which will make it possible to build 
on this early success. It remains unclear which kinases 
mediate the benefi t conferred by sorafenib. Although angio-
genesis & VEGF receptor inhibition may play a key role in 
this response, other angiogenesis inhibitors such as 
Bevacizumab and Lenalinomide have only shown only 
modest clinical impact. Sorafenib has greater activity against 
RAF than sunitinib, so differential effects on MAPK pathway 
inhibition are worth evaluating. Other agents currently under 
evaluation include additional inhibitors of angiogenesis, 
mTOR, the EGF receptor, HGF receptor (c-met), and fi bro-
blast growth factor (FGF) receptor. Cancer Testis antigens 
including MAGEA3 are frequently expressed in HCC and an 
Asia/Pacifi c trial is currently being planned to assess immune 
targeting of HCC. As these agents are systematically evalu-
ated it is anticipated that more effective agents and combina-
tions can be identifi ed to further prolong survival or palliate 
symptoms in patients with HCC.
C-218
HPB FELLOWSHIP: OPTIMUM 
REQUIREMENTS FOR A SUCCESSFUL 
TRAINING PROGRAM IN HPB SURGERY
S. Orloff
Abstract not available at time of publication.
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C-219
SIMULATION TRAINING IN HPB 
SURGERY
J. A. Windsor
Professor and Head of Surgery, University of Auckland; 
Foundation Director, Advanced Clinical Skills Centre, 
University of Auckland; Director and Education Advisor, 
SIMTICS Ltd, (www.simtics.com)
Simulation offers the opportunity for the rehearsal of a wide 
range of skills in a controlled, risk-free environment, allow-
ing for the development of mastery at a pace appropriate to 
the learner and offers a means for objective verifi cation of 
skills (1). The case for using simulation in surgical training 
is compelling and in some jurisdictions required even though 
the evidence for skills transfer after simulation training is 
limited (2). Offsetting the benefi ts are a number of limita-
tions in relation to virtual reality simulation where function-
ality is often sub-optimal, educational benefi ts not well 
established, objective measures diffi cult to interpret, being 
confi ned to technical competencies, profi ciency criteria 
usually not defi ned, intensity and duration of training 
unknown, the relatively high cost and that the simulation 
training is not embedded in curriculum (3). And there is a 
resolute tension where the advantages are greatest for the 
simulation of complex procedures that are only rarely 
encountered and the diffi culty and cost associated with pro-
ducing simulation training for them. It is therefore no sur-
prise that simulation training in HPB surgery remains in its 
infancy. Current models for VR simulation training are not 
sustainable. A new conceptual framework is required if there 
is going to be the cost-effective development of VR simula-
tion in HBP surgery, for both technical and non-technical 
skills acquisition. Approaches of promise will be discussed.
References
(1) Dunkin et al. Surgical simulation: a current review. 
Surgical Endoscopy 2007.
(2) Sturm et al. A systematic review of skills transfer after 
simulation training. Annals of Surgery 2008.
(3) Grantcharov. Is virtual reality simulation an effective 
training method in surgery. Nature Clinical Practice 2008.
C-220
FUTURE PLANNING OF HPB TRAINING 
IN INDIA
R. A. Sastry
Nizam’s Institute of Medical Sciences, Hyderabad, India
An acute shortfall of formally trained HPB surgeons is felt 
in India with increasing recognition of surgically correctible 
HPB diseases by the newer diagnostic modalities and 
increasing awareness. Capacity needs are particularly felt not 
only because of the great health disparities, weak infrastruc-
tures and defi cient resources but lack of adequate training 
environments too. Most of the HPB training has been by way 
of clinical and surgical exposures that are not structured and 
by short CMEs and live operative workshops. Formal train-
ing is limited to only about 40 students in the country in a 
year through courses that cover not just the sub-speciality 
but the entire gamut of gastrointestinal surgery in university-
affi liated post doctoral programs.
IHPBA-India’s initiative to conduct certifi cate courses of 
one week duration to supplement the practical knowledge to 
pre-selected batches of 25 general surgeons with HPB inter-
est, periodically at various recognized high-volume centers 
has yielded interesting results. The programs are residential, 
non formal and the trainees have ample opportunity to inter-
act with the experts throughout the week. The course curricu-
lum is common and the sessions are replete with case snippets 
and video clips to illustrate problems and variations in diag-
nosis, surgical techniques and the follow-up problems. The 
course is fl anked by pre- and post tests. The feedback has 
been excellent.
This initiative provides a practical example of supplement-
ing the capacity building framework by a professional orga-
nization by integrating with the more formal academic centers. 
The evolving public-private partnership seems to be the way 
to go in planning the future HPB training models in India.
C-221
HPB TRAINING IN MAINLAND CHINA
W. Y. Lau
The Chinese University of Hong Kong, Shatin, Hong Kong 
SAR
Surgery has not been well-developed in traditional Chinese 
Medicine. At the end of the 19th century, western medicine 
was introduced into China. Soon hospitals and medical 
schools with general surgical units were established in the 
big cities along the costal region, the Yangtze River, the 
Yellow River and the Pearl River. HPB surgery soon fl our-
ished because of the high prevalence of HPB diseases.
There are many HPB centers in China. However, like other 
specialties/subspecialties, China still uses an apprenticeship 
system in training. The accreditation of HPB surgeons is 
usually single-hospital based and there is no unifi ed training/
examination system for the whole of China. Recognizing the 
problem, the Chinese Medical Doctors Association was 
founded on 9/1/2002. It was organized under the Medical 
Practitioners’ Act 1999 and registered with Ministry of Civil 
Affairs. One of its main duties is to supervise and organize 
postgraduate medical education/assessment of 2.1 million 
medical practitioners in China. This organization is helped 
by the Chinese Medical Association founded in 1915 to do 
this job. The Chinese College of Surgeons was inaugurated 
on 22/9/2007.
Surgical training in China is now going internationally. 
There are 9 training centers in China which have been 
accreditated by the College of Surgeons of Hong Kong and 
the Royal College of Surgeons of Edinburgh for training in 
basic surgery, higher training in general surgery/orthopedics/
urology. There has not yet been any discussion on accredita-
tion of training in HPB surgery, which is a subspecialty after 
general surgery training.
C-222
TRAINING IN HEPATO-BILIARY-
PANCREATIC SURGERY IN JAPAN
M. Yamamoto and T. Tadahiro
Japanese Society of Hepato-Biliary-Pancreatic Surgery, 
Tokyo, Japan
All new doctors after graduation from medical school in 
Japan are required to undergo two years of obligatory initial 
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postgraduate clinical training in internal medicine, emer-
gency medicine, pediatrics and surgery. After this initial 
training, trainees advance to specialty training in a specialty 
of their choice. Those who wish to become a board-certifi ed 
hepato-biliary-pancreatic (HBP) surgeon must undergo 4 or 
5 years of specialty training in HBP surgery, while at the 
same time undergoing training for 5 years towards board 
certifi cation in gastroenterological surgery. To be a board-
certifi ed surgeon in gastroenterology one must demonstrate 
competence in procedures such as routine gastrectomy and 
colectomy. During training in gastroenterological surgery, 
HBP surgical fellows must perform 50 high-level diffi culty 
operations in the fi eld of HBP and submit a video recording 
of the procedures to the board. The video recording is evalu-
ated by 3 board-certifi ed instructors at other institutes. There 
currently are 400 board-certifi ed instructors at 180 board-
certifi ed training institutes in Japan. The fi rst 12 board certi-
fi cations in HBP surgery were awarded in 2011. These 12 
new HBP specialists will go on to train the next generation 
of young HBP surgical fellows.
C-223
HPB TRAINING IN KOREA
S. W. Kim
Department of Surgery Seoul National University College 
of Medicine, Seoul, Korea
Since the HPB surgery is very complicated and rapidly pro-
gressed, it requires CME system as well as a strict and effi -
cient training system. In Korea, to be a hepato-biliary 
surgeon, he or she has to take subspecialty fellowship train-
ing courses after 4 year resident training in the hospitals 
where the HPB training system is available. Korean Surgical 
Society has planned the subspecialty board system for the 
last few years and submitted it to Korean Academy of 
Medical Science this year. The aim/objectives of training and 
the standard and curriculum for the training are documented. 
In Korea, some hospitals have good conditions for HPB 
training in terms of the hospital volume and number of 
trainer. Most of the big hospitals have 2 separate units: 
Hepatic surgery including transplantation unit and pancrea-
tobiliary surgery unit. Rotation system let trainee to complete 
the course where available. Survey study for current status 
of HPB training system in each hospital has been carried out 
and will be reported and HPB training systems in a few big 
hospitals will be introduced during my talk.
C-224
THE ANZHPBA TRAINING PROGRAM 
– TWO YEARS ON
C. Christophi
Abstract not available at time of publication.
C-225
NEUROENDOCRINE TUMORS (NET) OF 
PANCREAS
P. Jagannath
Department of Surgical Oncology, Lilavati Hospital & 
Research Centre, Mumbai, India
Neuroendocrine tumors are now called neuroendocrine neo-
plasias (NEN) and WHO classifi cation 2010 of gastroentero-
pancreatic NET includes histopathological grading (G1, G2, 
G3), location of tumors, functional status, nodal involvement 
and metastasis. Tumors are classifi ed from T1–T4 on basis 
of size, confi nement to pancreas and adjacent organ or large 
vessel invasion.
Insulinoma and Glucogonoma are the most common func-
tional pancreatic NENs that are usually small and tumor 
localization if often a challenge. In contrast non-functioning 
pancreatic NENs present as mass lesions diagnosed inciden-
tally or with pressure symptoms.
Treatment depends mainly on localization and functional 
status. Contrast enhanced MRI and endoscopic ultrasound 
are useful for localizing small functional tumors. DOTATOC 
PET scan has emerged as a useful imaging modality for 
NENs.
Histopathological grade is an important determinant in 
planning management. Well differentiated G1 and G2 NENs 
are classically treated by surgery. Small and localized func-
tioning NENs can be treated with enucleation and pancreas 
preserving resections while the usually large non functioning 
tumors need radical resections such as pancreatoduodenec-
tomy or a spleen preserving distal pancreatectomy depending 
on tumor location. NENs with liver metastasis need a tailored 
approach. A resection of the primary and debulking of metas-
tasis should be strongly considered. RFA or trans arterial 
chemo embolization (TACE) are options to treat residual 
liver metastasis.
G1 and G2 tumors can also treated by peptide receptor 
tagged radiotherapy (PRRT) using lutetium 177 if they have 
positive receptors on Somatostatin Scintigraphy. Sandostatin 
LAR is used for non resectable G2 tumors while poorly 
differentiated G3 tumors are treated with Cytotoxic 
chemotherapy.
C-226
LOCALIZATION OF NET OF THE 
PANCREAS
B. N. J. Thomson
Peter MacCallum Cancer Centre, Melbourne; Royal 
Melbourne Hospital, Melbourne, Australia
Localization of neuroendocrine tumors of the pancreas can 
be diffi cult, particularly for functioning symptomatic tumors 
which cannot be localized using conventional techniques. 
Ultrasound examination of the pancreas is frequently limited 
by overlying bowel gas and body habitus. Computed tomog-
raphy (CT) scanning may show a hypervascular lesions but 
only if an adequate arterial pancreatic phase is performed and 
in tumors larger than 8 mm in diameter. Magnetic resonance 
imaging of the pancreas has similar sensitivity to CT scan-
ning. Venous sampling has been used for isolating the posi-
tion of pancreatic insulinoma however the precise localization 
remains diffi cult. There are a number of surgical techniques 
that can be utilized such as trans-illumination of the duode-
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num for gastrinoma and intra-operative ultrasound for detec-
tion of intra-pancreatic tumors.
The majority of NETs have somatostatin receptors on the 
cell surface of which there are 5 subclasses. These can be 
targeted for imaging with somatostatin receptor scintigraphy 
using various somatostatin analogues (i.e. 111Indium octreo-
tide). Such imaging can be combined with CT scanning to 
provide anatomical. Recent advances in Positron Emission 
Tomography tracers have allowed excellent imaging for 
gastro-intestinal and pancreatic NETs. CT PET using gal-
lium-68-DOTA allows the best detection of both small pan-
creatic NETs as well as nodal and distant metastatic disease.
C-227
SURGICAL TREATMENT FOR 
PANCREATIC NEUROENDOCRINE 
TUMORS
D. G. Chhabra
Department of Surgical Oncology. Dr. L.H. Hiranandani 
Hospital (Powai), Mumbai, India
Pancreatic neuroendocrine tumors (PNETs) are no longer a 
rare entity. Their complex biological behavior, indolent 
nature, and small numbers have precluded optimal therapeu-
tic options. These neoplasms can present either as non-func-
tional tumors or as functional entities related to clinical 
syndromes of hormonal excess. Functional tumors are often 
small and diffi cult to localize. Endoscopic ultrasound and 
specialized nuclear scans aid identifi cation of these tumors. 
Tumor size, location, and malignant potential determine the 
type of resection varying from a simple enucleation to a 
formal pancreatectomy. Non functional tumors present as 
large lesions with mass effect and radical pancreatic resec-
tions (pancreatoduodenectomy, central/distal pancreatec-
tomy, with or without vascular reconstruction) and/or en bloc 
removal of adjacent organs is necessary. Surgical excision is 
the only curative treatment esp. for well-differentiated 
PNETs. The surgical goals are to: 1. prolong survival by 
resecting the primary and any nodal or hepatic metastases, 
2. control symptoms related to hormonal secretion, 3. prevent 
or treat local complications. Patients with resectable, early-
stage tumors are usually managed surgically. In addition, 
cytoreductive surgery may be appropriate even in metastatic 
disease, particularly if the metastases are confi ned to the 
liver. Patients with limited liver metastases who undergo 
complete or near-complete resection of metastases have 
demonstrated prolonged survival. Major liver resections, 
radiofrequency ablation and liver transplantation are options 
for treating neuroendocrine liver metastases. The prognosis 
of patients with unresected PNET is poor.
C-228
THE MEDICAL THERAPY OF 
GASTROINTESTINAL 
NEUROENDOCRINE TUMORS
M. Michael
Peter MacCallum Cancer Centre, East Melbourne, 
Australia
Gastrointestinal Neuroendocrine tumors (GNETs) are rare 
malignancies but whose incidence is increasing, possibly 
refl ecting aggressive diagnostic procedures, greater aware-
ness and ?environmental factors. Their prognosis is based 
upon disease extent, primary site and histological grade (dif-
ferentiation and proliferative index as measured by Ki67). 
GNET histological grading based on biopsy can be associ-
ated with sampling error from tumoral heterogeneity. 
To better characterize disease biology and individualize 
therapy imaging based on somatostatin-receptor expression 
(Octreotide-SPECT/CT or Gallium-DOTA-PET/CT) and 
tumoral glucose metabolism (FDG-PET/CT), are now 
routine in our centre as part of the workup. Patients are hence 
characterized into 3 distinct biological groups:
(1) Those with advanced well-differentiated Somatostatin 
receptor-expressing (Octreotide avid) tumors. Offered 
therapy somatostatin analogue, regardless of symptoms. 
The supporting results of the randomized Phase III 
PROMID and RADIANT-II trials will be presented. 
Patients with progressive disease can be offered radioac-
tive peptide receptor therapy often with radiosensitizing 
chemotherapy. Other treatment options include chemo-
therapy, generally Streptozotocin-or Temozolamide-
based regimens. Phase III trials have also demonstrated 
the utility of the m-TOR inhibitor Everolimus and the 
multitargeted tyrosine kinase inhibitor Suntinib in this 
setting.
(2) Patients with advanced poorly differentiated disease 
(FDG-avid, non-Octreotide avid) are treated with che-
motherapy similar to small cell lung cancer.
(3) Patients with mixed disease biology, are considered for 
sequential chemotherapy followed by radioactive peptide 
receptor therapy.
Management is multidisciplinary involving several 
subspecialties.
Conclusions: The medical management of GNETs is 
complex but evolving with the ability now to individualize 
therapy and the introduction of novel biological agents. 
Multidisciplinary consultation is optimal.
C-229
PANCREAS TRANSPLANTATION – AN 
OVERVIEW
H. Pleass
Westmead Hospital, Westmead, Australia
Type 1 diabetes mellitus is a chronic condition often leading 
to disabling complications including retinopathy, neuropathy 
and cardiovascular disease which can be modifi ed by inten-
sive treatment with insulin. Such treatment, however, is asso-
ciated with a restrictive lifestyle and risk of hypoglycemic 
morbidity and mortality.
Pancreas transplantation is a highly specialized procedure 
which has evolved both in terms of the surgical technique, 
patient selection and assessment and is currently the only 
proven option to achieve long-term insulin independence, 
resulting in an improvement or stabilization of those diabetic 
related complications. The hazards of pancreas transplanta-
tion as a major operation are well known. Balancing the risks 
of a surgical procedure, with the benefi ts of restoring normo-
glycemia remains an important task for the pancreas trans-
plant surgeon.
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C-230
REVERSAL OF TYPE 1 DIABETES BY 
ISLET TRANSPLANTATION
T. W. Kay
St. Vincent’s Institute, Fitzroy, 3065, Victoria, Australia
Introduction: Type 1 diabetes, an autoimmune disease in 
which the pancreatic beta cells are destroyed places an enor-
mous burden on individuals and their families, as well as on 
the healthcare system. Diabetes is currently treated with mul-
tiple daily insulin injections but this is imperfect. Our even-
tual aim is to treat the underlying mechanisms that lead to 
the disease in at risk and affected individuals. Treatment 
without insulin injections will require restoration of insulin 
production as well as correction of autoimmunity. Both are 
being trialled at present. Islet transplantation is being carried 
out in patients in whom insulin therapy has failed especially 
those with severe hypoglycemia not corrected by conven-
tional means such as insulin infusion pumps or long-acting 
insulin. 
Methods: Islets are isolated from the pancreas of organ 
donors and transplanted into the liver via portal 
cannulation.
Results: We have carried out over 30 islet transplants in the 
last 3 years into people with severe hypoglycemia. In virtu-
ally all cases hypoglycemia is corrected even when insulin 
is still required. Approx half the patients no longer require 
insulin, one has been insulin independent for over 3 years. 
Side-effects have been infusion and anti-coagulation related 
and immunosuppression has been well-tolerated. Weight loss 
has been observed in virtually all recipients and the mecha-
nisms of this studied. 
Conclusion: Islet transplantation effectively restores insulin 
production but has the major problems of insuffi cient donors 
and the need for immunosuppression to prevent rejection.
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XENOTRANSPLANTATION OF 
PANCREATIC ISLET CELLS – DREAM 
OR REALITY?
M. S. Sandrin
The University of Melbourne, Department of Surgery, 
Austin Health/Northern Health, Heidelberg, Victoria, 
Australia
Xenotransplantation is now a possibility in Australia after the 
recent lifting of the fi ve-year moratorium. Of all the animal 
species, the pig is the most suitable donor for a variety of 
reasons. In particular, pigs can be modifi ed by genetic engi-
neering to be less immunogenic and more resistant to immune 
destruction.
Xenotransplantation of pig islets to humans offers a solu-
tion to the chronic shortage of human islets from deceased 
donors. Clinical pig-to-human transplantation is limited by 
the complexity of the xenograft response however this is 
progressively being resolved. Collectively, data from our 
laboratory and others demonstrate that xenograft protection 
by local secretion of immunomodulatory molecules is fea-
sible and effective. However, the strategy requires refi ne-
ment and improvement since in most instances graft 
modifi cation results in prolongation but not indefi nite 
survival.
These refi nements as well as the current state of genetic 
modifi cations and preclinical pig-to primate and clinical pig-
to-human trials will be reviewed.
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CRITICAL SUCCESS FACTORS FOR 
SURGEONS LEADING TRANSPLANT OR 
OTHER PROGRAMS
C. W. Pinson
Abstract not available at time of publication.
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SMALL FOR SIZE SYNDROME IN LT
C. M. Lo
Abstract not available at time of publication.
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MANAGING THE VASCULAR 
COMPLICATIONS OF LT
A. S. Soin
Abstract not available at time of publication.
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BILIARY STRICTURES AFTER LIVER 
TRANSPLANTATION – ANASTOMOTIC 
AND NON ANASTOMOTIC
S. Orloff
Abstract not available at time of publication.
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BILIARY COMPLICATIONS IN LIVER 
TRANSPLANTATION: HOW I DEAL 
WITH THEM
F. A. Alvarez, J. Iniesta and E. de Santibañes
Sección de Cirugía Hepatobiliopancreática, Hospital 
Italiano de Buenos Aires-Argentina
Introduction: Biliary complications after liver transplanta-
tion include biliary stones, bile leaks and biliary strictures. 
With an incidence of approximately 30%, biliary complica-
tions are the greatest cause of morbidity after adult living-
donor liver transplantation (LDLT). Although data about the 
incidence and management of biliary complications after 
deceased-donor liver transplantation (DDLT) are well 
defi ned, those pertaining LDLT are confl icting.
Description of Contents: Duct-to-duct biliary reconstruc-
tion is favored over hepatico-jejunostomy for LDLT in many 
centers to prevent ascending cholangitis and to facilitate 
endoscopic access to the bile ducts. Although endoscopic 
treatment is accepted as a fi rst-line therapy to treat biliary 
complications after liver transplantation, endoscopic treat-
ment of anastomotic biliary strictures is less successful in 
patients after LDLT. This is likely attributable to biliary 
anatomy that is challenging to the endoscopists. In contrast 
most biliary leaks are usually treated with success at endos-
copy after LDLT or DDLT. Complications after liver trans-
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plantation mainly consist of anastomotic biliary strictures 
and/or biliary leaks, with signifi cant more incidences of both 
complications in LDLT recipients. Partial graft, a pediatric 
recipient and a Roux-en-Y biliary anastomosis are indepen-
dent predictors of biliary strictures. When conservative man-
agement with endoscopy or percutaneus treatment has failed 
surgery is indicated, and biliary reconstructions, segmental 
resections or even re-transplantation may be required.
Conclusions: Biliary complications are signifi cantly more 
frequent after LDLT compared with DDLT, and they are less 
amenable to endoscopic treatment. Although most biliary 
complications after LDLT can be successfully treated by 
non-surgical approaches, management of multiple biliary 
anastomoses and non-anastomotic strictures continues to be 
a challenge. Surgery should be reserved for patients who 
have failed conservative treatment.
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DIFFERENTIAL DIAGNOSIS AND 
PREOPERATIVE EVALUATION
J. W. Chen
Abstract not available at time of publication.
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ASSESSING THE RISK OF 
MALIGNANCY: OBSERVATION OR 
SURGICAL INTERVENTION
I. Frigerio
Casa Di Cura Pederzoli, Verona, Italy
Intraductal Papillary Mucinous Neoplasms (IPMNs) are 
nowadays the most frequent cystic neoplasm of the pancreas, 
even in asymptomatic patients, in which they represent an 
incidental fi nding. In our experience, IPMNs are one of the 
most common indication for pancreatic resection. During the 
consensus held in Sendai in 2005, a group of surgeons, gas-
troenterologists and pathologists edited the fi rst guidelines in 
the management of IPMNs. Before 2005 all patients with a 
diagnosis of IPNM were considered potentially at risk for 
develop a malignancy and therefore surgery was always pro-
posed. After the Sendai meeting two different approaches 
have been defi ned when considering MD-IPMN (together 
with the mixed form) or BD-IPMN. By considering epide-
miology, pathological fi nding, improvements in radiology 
and new genetical aspects of IPMNs we try to defi ne how to 
manage these patients.
Main Duct-IPMN: Patients affected by IPMN involving 
the main duct or the mixed form should always be candidate 
to resection because of the high prevalence of in situ and 
invasive carcinoma found in the resected specimens (70%). 
Noteworthy is that in MD-IPMNs malignancy can be present 
regardless the presence or absence of symptoms and so the 
radiological aspect of these lesions gives the indication for 
surgery. The surgical management of main duct IPMNs rep-
resents a challenge for the surgeon. The segmental dilatation 
of the main duct showed in the preoperative studies may 
occur both proximally and distally to the tumor, because of 
mucus overproduction, making more diffi cult the localiza-
tion of the neoplasia. A typical resection (pancreaticodu-
odenectomy, left pancreatectomy, total pancreatectomy, 
according to the site and extension of the disease) with lymph 
node dissection must be performed. Because IPMN extends 
along the pancreatic duct and it can do so without macro-
scopic tumor, it is important to exclude residual tumor with 
frozen section. In case of de-epithelialization, adenoma or 
borderline tumor at surgical margin the optimal surgical 
strategy remains controversial: we usually extend the resec-
tion a few centimeters to obtain a new margin, trying to 
obtain a negative resection margin. In our experience with 
140 patients affected by main duct IPMN who underwent 
surgical resection, the rate of negative margins in the surgical 
specimen was 58.5%, and the results of the intraoperative 
frozen section analysis modifi ed the surgical plan, leading to 
an extension of the resection or to total pancreatectomy in 
29 patients (20.7%). Recurrence in the pancreatic remnant 
may develop even if the transection margin is negative and 
even in patients with noninvasive disease. Some authors 
have reported that for malignant IPMNs the frequency of 
recurrence (local recurrence or distant metastases) is similar 
whether or not total pancreatectomy was performed. Finally, 
in patients with MD-IPMN undergoing pylorus-preserving 
pancreaticoduodenectomy, pancreaticogastrostomy can be 
preferred instead of pancreaticojejunostomy because it 
allows direct access to the pancreatic stump by endoscopy 
during follow-up, giving the possibility to sample of pancre-
atic juice for cytological examination.
Branch-Duct IPMN: Behavior of BD-IPMNs is different 
because the prevalence of malignancy is quite lower (25%) 
than MD-IPMN and it is predictable on the basis of symp-
toms, size and morphological criteria. For this reasons a strict 
follow up is suggested for patients with BD-IPMN smaller 
than 3 cm, with no nodules nor duct dilatation (which would 
imply a combined IPMN). Follow up consists in MRCP 
repeated 6 months after the fi rst diagnosis and then yearly 
together with Ca19.9 dosage, unless there is an increase in 
size, the development of nodules or the onset of symptoms. 
We like to stress the fact that this non-operative approach 
should be carried out in experienced centers and data from 
large series is needed to validate this approach. When surgery 
is indicated a typical resection should be performed for 
branch duct IPMNs. For asymptomatic patients with small 
single lesion (<3 cm) of the neck of the pancreas, without 
any suspicion for malignancy, a middle pancreatectomy can 
be considered. In the case of multifocal disease, a total pan-
createctomy or an extended standard resection would ensure 
a radical treatment; however, a more selective approach can 
be considered with segmental resection of the biggest lesion 
(or of the lesion “suspected” for malignancy) and non-oper-
atively management with strict follow-up of the remnant 
BD-IPMN. Indications for surgery in multifocal BD-IPMN 
follow the same rule as uni-focal BD-IPMN: symptomatic 
patients and suspicion of malignancy.
Combined IPMNs: In which category the mixed form of 
IPMNs harbor is still to be defi ned: whether they originate 
from MD-IPMN or arise as a combined form itself. It does 
not change the fact that their biological behavior is similar 
to that of MD-IPMN and therefore their treatment follows 
the same rules as the MD-IPMN do: high risk of malignant 
degeneration and, for all surgically fi t patients, indication for 
surgery.
After resection, strict follow-up should be done. Patients 
affected by malignant IPMN present an obvious higher risk 
of recurrence, but neoplastic recurrence can arise even in the 
presence of a benign tumor with negative resection margins, 
particularly for main duct IPMN. It is important to detect a 
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“recurrence” or the development of a new disease in the 
remnant since another resection shall be considered. We 
identify in a recent study based on a multivariate analysis, 
three independent factors associated with poor prognosis in 
invasive IPMN carcinoma: Ca19.9 value higher than 37 U/
mL (adjusted for jaundice), familiar history of pancreatic 
cancer and a lymph node ratio (LNR) >0.2. These three 
factors are associated with a 5-years survival of 44.2%, 
16.7% and 11% respectively. In conclusion, it is still diffi cult 
to defi ne the impact on the clinical practice of these prog-
nostic factors. Only familial history and Ca19.9 can be 
known preoperatively and therefore have a role in the deci-
sion making for example in those patients, like BD-IPMN, 
where surgery may not be the fi rst option.
At this time the strategy we follow is that early surgery of 
high risk lesions and early detection of signs of malignancy 
or recurrence may be benefi cial for prognosis in these 
patients.
C-239
EUS-GUIDED THERAPY FOR CYSTIC 
TUMORS OF THE PANCREAS
D. W. Seo
Department of Gastroenterology, Asan Medical Center, 
University of Ulsan Medical College, Seoul, Korea
EUS-guided intervention has been recently used for the treat-
ment of pancreatic cystic tumors (PCT). Preliminary reports 
showed the safety and feasibility of EUS-guided PCT treat-
ment. Treatment responses varied among studies as previous 
studies involved small number of patients and short-term 
follow-up.
Our group conducted a series of studies to evaluate the 
technical feasibility, safety and therapeutic effi cacy of EUS-
guided PCT ablation. At fi rst, we conducted a pilot study and 
selected 14 patients with PCT received EUS-guided ethanol 
lavage and paclitaxel injection (EUS-EP) and observed for 6 
months. Complete resolution (CR) of PCT was observed in 
11 patents and partial resolution (PR) in 2 patients. Next step 
study was focused on septated PCT and we observed 60% 
of CR and 20% of PR. Encouraged by above results, we 
conducted a long-term follow-up study after EUS-EP of 
PCT. Fifty-one patients were enrolled for EUS-EP by the 
following inclusion criteria; 1) uni- or oligolocular cyst, 2) 
indeterminate tumors for which EUS-FNA was required, and 
3) PCTs showing size growth during the observation period. 
Under EUS-guidance, cyst fl uid aspiration, ethanol lavage 
and injection of paclitaxel were performed. Twenty PCT 
were oligolocular. Mean CEA level was 463 ng/mL (1–8190). 
The median follow-up was 20.6 months. Mean volume of 
PCT decreased from 14.09 mL to 3.31 mL. CR was observed 
in 28 patients, PR in 6 patients, and a cyst persisted in 12 
patients. Splenic vein thrombosis as procedure-related com-
plication occurred in 1 patient. EUS-EP appears to be a safe 
and effective method for treating PCT.
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OPERATIVE TECHNIQUES FOR CYSTIC 
TUMORS OF THE PANCREAS
B. Debanshu
M N Budhrani Cancer Institute and Research Centre, 
Pune, India
Introduction and Background: The benefi t of maintaining 
exocrine function of the pancreas is the reason why less 
radical resections of the pancreas have come into vogue, 
especially when the chance of malignancy is low. Enucleation 
maybe attempted when CT scan, EUS or IOUS show a high 
probability of the lesion being benign and there is no involve-
ment of the main pancreatic duct or adjacent organs. 
Remaining outside the pseudocapsule is mandatory. 
Harmonic scalpel, tissue coagulation devices, hemoclips 
etcetera ensures a successful enucleation rate of 90%, but 
upto 50% of patients may develop self limiting leaks. For 
cystic tumors in the neck or body, with duct involvement, 
central pancreatectomy can be done. The duct is suture 
ligated in the stapled head and a duct to mucosa anastomosis 
is done in the tail. Distal spleen preserving pancreatectomies 
by techniques like Warshaw have shown no difference in 
complication rates as compared to spleen sacrifi cing tech-
niques. Laparoscopic distal pancreatectomy is performed in 
the right lateral decubitus position as there is natural gravity 
retraction of viscera.
Methods: Electronic data was reviewed using PubMed as 
the search engine using the meta-tags, “cystic tumors”, “pan-
creas” and “operative techniques”. Conclusions were also 
drawn from printed literature, case reports, patient series and 
institutional published data.
Conclusions: Non standardized resections for cystic lesions 
of the pancreas should be considered provided there is no 
oncological compromise.
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FOLLOW UP AND MANAGEMENT OF 
RECURRENT DISEASE
S. V. Shrikhande
Tata Memorial Centre, Mumbai, India
Pancreatic cystic tumors are detected due to greater aware-
ness and superior imaging. Their spectrum is vast but 
common tumors are serous cystadenomas, mucinous cystad-
enomas (MCN) and cystadenocarcinomas, IPMN’s and solid 
papillary epithelial neoplasms of the pancreas (SPEN). 
While serous cystadenomas can be observed without offering 
defi nitive surgery, the others are best treated by complete 
surgical resection. Margin negative resections are crucial for 
long term disease free survival. Equally important is the 
degree of invasiveness. When MCN is completely resected 
followed by adequate histopathologic examination, absence 
of invasion predicts a curative operation and detailed follow 
up is unnecessary. Invasive cystadenocarcinoma often 
behaves like pancreatic ductal adenocarcinoma and recur-
rences are known and detailed follow up every 4–6 months 
is necessary. However, some reports suggest that all MCN’s 
should be considered as mucinous cystadenocarcinomas of 
low grade malignant potential since assessment of benign, 
borderline, or malignant categories is often impossible. In 
IPMN’s, disease extent is carefully assessed and pancreatic 
resections performed accordingly. It is important to differen-
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tiate tumor free margins from de-epithelialized margins on 
frozen section during surgery. Recurrences are known with 
de-epithelialized margins. Also, it is important to differenti-
ate invasive IPMN from non-invasive IPMN. Invasive 
IPMN’s can recur and large SPEN’s are likely to be malig-
nant and in both follow up is essential. Triphasic CECT 
examination is the preferred follow up investigation. Locally 
recurrent disease is best treated by re-resection. In metastatic 
disease, approach is unclear. Chemotherapy might be benefi -
cial but high level evidence supporting its use is still lacking.
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ECHINOCOCCUS ALVEOLARIS – 
CHANGING EPIDEMIOLOGICAL 
PATTERNS AND MANAGEMENT 
STRATEGIES (1)
G. A. Mantion1,2, H. Wen3, S. Bresson Hadni1,2, 
D. A. Vuitton1,2 and M. Gillet2
1WHO Collaborating Center for Prevention and Treatment 
of Human Echinococcosis, France; 2University Hospital 
Besançon, France; 3Medical University of Xinjang, Urumqi, 
China
Alveolar echinococcosis, due to the development of larval 
stage of the cestode Echinococcus multilocularis, is located 
in the liver in 97% of the cases. The progression is very slow 
and the course of the disease is silent for many years. Larval 
development behaves like a slow growing liver cancer with 
progressive invasion of the liver parenchyma, vessels and 
biliary ducts. In addition, the marked granulomatosis sur-
rounding the larva followed by a very strong reactive fi bro-
sis, also contribute to the severity of the disease. Progressive 
extension to adjacent organs and distant metastases by hae-
matogenous spreading can also be observed. Purely extra 
hepatic alveolar echinococcosis is exceptional, but physi-
cians in endemic area should be warned of these particular 
forms of disease. This may avoid delay to diagnosis. 
Important changes in diagnosis circumtances have occured 
during the past twenty years. By the past, clinical presenta-
tion was similar to a liver cancer: progressively getting worse 
jaundice due to involvement of the hilum, huge, hard and 
irregular hepatomegaly resembling to a liver cancer, chronic 
Budd Chiari syndrome due to hepatic veins involvement. 
Currently, due to the extensive use of abdominal ultrasonog-
raphy, earlier diagnosis of alveolar echinococcosis at an 
asymptomatic stage is common. Alveolar echinococcosis 
may also be revealed by a complication: cholangitis episodes 
due to communication between the parasitic mass and the 
lumen of a biliary duct, or to pigmental stones accumulating 
above a parasitic biliary stenosis, liver abscess related to 
centro-parasitic necrosis, hematemesis due to oesophagal 
varices in case of portal vein involvement. Metastatic locali-
zation, mainly in the lungs, may also be the revealing 
manifestation in 5 % of the cases.
Alveolar echinococcosis is characterized by a long asymp-
tomatic period, but without any treatment, mortality reaches 
80% within 10 years of diagnosis. Due to the lack of fast-
acting and totally effi cie nt chemotherapy, partial radical 
hepatic resection is the only chance of cure for patients. 
These resections concern now 30%–40% of the patients ans 
may include complex vascular and biliary reconstruction 
procedures. Liver transplantation may also be indicated in 
very selected patients (about 5%) with life-threatening com-
plications after failure of the other treatments. More recently 
innovative surgical techniques were applicated for end stage 
AE patients such as living donor liver transplantation (2) and 
ex vivo liver resection and liver auto transplantion (3) that 
widen the potential of radical cure by surgical approach in 
very selected patients.Interventional radiology or endoscopy 
are effi cient to drain liver abcesses and or infected and 
obstructed bile ducts, as palliative procedures or as a bridge 
to radical resection. In all cases, parasitostatic benzimidazole 
therapy, using especially albendazole continuously, is man-
datory for at least two years after radical resection and for 
life in inoperable patients. This new and aggressive approach 
will improve life expectancy of AE patients at nearly the 
same level as general population (4).
References:
1. Expert consensus for the diagnosis and treatment of cystic 
and alveolar echinococcosis in humans, Acta Tropica 
2009.
2. Moray G. Transpl Proc 2009.
3. Wen H. Chinese Med J 2011.
4. Torgerson P. J Hepatol 2008.
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CHEMOTHERAPY ALONE AS 
DEFINITIVE TREATMENT OF HYDATID 
DISEASE:
H. Wen
Abstract not available at time of publication.
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PERCUTANEOUS MANAGEMENT (PAIR) 
VERSUS SURGERY FOR HYDATID 
DISEASE
M. Smith
Alfred Hospital, Victoria, Australia
Hydatid disease of the liver is a common benign infestation 
of the liver that affects the global population in a heterogene-
ous distribution. 
Optimal care of hepatic hydatidosis usually requires a 
considered combination of medical and interventional tech-
niques. This combination will frequently involves either sur-
gical drainage or resection; or a Percutaneous Aspiration, 
Injection and Re-aspiration (PAIR) procedure.
Despite these approaches having been developed over a 
number of years little comparative data exists perhaps refl ect-
ing the differences in expertise and incidental distribution of 
hydatidosis. Each approach has its own set of indications and 
contraindications which render the clinical decision-making 
somewhat complex.
In this discussion I will cover the fundamental technical 
details of these approaches and current evidence will be 
examined to try and elucidate some clinical guidance with 
reference to appropriate therapy in a given clinical setting.
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SURGICAL APPROACHES TO COMPLEX 
HYDATID DISEASE OF THE LIVER
S. O. Javed
Sher-i- Kashmir Institute Medical Sciences, Srinagar, 
Kashmir, India
Hydatid disease is a parasitic disease of worldwide distribu-
tion. Seventy fi ve percent of hydatid cysts are found in liver. 
It can involve adjacent structures or organs by developing 
fi stulous tracts and dissemination of daughter cysts into the 
biliary tree, pleura, bronchi, or peritoneum. The incidence of 
complicated hydatid cysts is reported to be as high as 60% 
among patients diagnosed and treated for liver hydatid 
disease. Treatment of liver hydatid disease continues to be a 
matter of debate, and till date no clear guidelines are avail-
able. That, medical therapy alone is ineffective and unreli-
able is the common belief. Operative therapies vary from 
complete resection (e.g., total pericystectomy or hepatec-
tomy) to minimal invasive procedures (e.g., percutaneous 
aspiration of cysts). Lately, reports have been published on 
laparoscopic approaches to the treatment of hepatic hydatid 
cysts. The choice of therapy is dictated by factors like, the 
general condition of the patient, number and localization of 
the cysts, surgeon’s expertise, and quality of hospital at 
which the surgery is performed including the possibility of 
intensive postoperative care. The current presentation is 
aimed at analyzing the clinical presentation, operative strat-
egy and long-term outcome of patients treated for compli-
cated liver hydatid cysts at our center.
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LAPAROSCOPIC TECHNIQUES FOR 
HYDATID DISEASE OF THE LIVER
J.-H. Zhang
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